{
  "doc_id": "bilag-til-medicinradets-anbefaling-vedr-sotorasib-til-nsclc-med-kras-g12c-vers-1-0-xx",
  "created_date": "unknown_year",
  "country": "DK",
  "source_type": "hta_submission",
  "chunks": [
    {
      "heading": "",
      "text": "lin lin -Dr. Dr. sotorasib",
      "start_page": 1,
      "end_page": 2
    },
    {
      "heading": "Medicinal Medicinal Products",
      "text": "With With Amgen'Sotorasib Sotorasib (Lumykras) comment comment on:",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "the the review",
      "text": "grade grade 3+ 100 100 (20.6%) SELECT-1 SELECT-1 (30%) 100. 100.",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "survival. survival.",
      "text": "fit fit (see AIC/BIC) distributions distributions (and and Exponentiel) cancer cancer register: •arms. arms. • arm. arm.",
      "start_page": 3,
      "end_page": 4
    },
    {
      "heading": "estimates. estimates.",
      "text": "of of +the the patient'medicine. medicine.",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "the the applicant'analysis. analysis.",
      "text": "medical medical council'of of applicants' case, case, Amgen'Medical Medical Board'550, 550,000/Medicine Medicine Council'000 000 DKK/G12C-muted G12C-muted NSCLC- line. line.",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "Yours faithfully,",
      "text": "Amgros Amgros I/T T +F F +45 88713008 Medicin@amgros.dk",
      "start_page": 4,
      "end_page": 5
    },
    {
      "heading": "DBS, SNI",
      "text": "120 120 mg/X X (sotorasib) Lumykras Lumykras (sotorasib). ... ... ... ... [...] ... ... ... ... . . . . ... ... . ... . .. ... . . ... ... ... .",
      "start_page": 5,
      "end_page": 11
    },
    {
      "heading": "Contact information",
      "text": "authorization authorization hol",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "Denmark",
      "text": "Active Active substance(s) Pharmaceutical form (s) assessment assessment (approved approved therapeutic",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "indications",
      "text": "n Nicholas Sroczynski",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "Lead, Lead, Denmark",
      "text": "nsroczyn@Manager Manager jburmest@LUMYKRAS LUMYKRAS Sotorasib",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "Amgen Amgen Denmark",
      "text": "960mg 960mg (120mg 120mg tablets) LUMYKRAS LUMYKRAS (sotorasib) cancer cancer (_MEDTERM4_) with less than",
      "start_page": 12,
      "end_page": 13
    },
    {
      "heading": "Hospital?",
      "text": "Combination therapy and",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "medication",
      "text": "Packaging types, sizes/n",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "units, and concentrations",
      "text": "to to d/107 107 (1) 107 107 (3) (c) TFEU. TFEU.",
      "start_page": 13,
      "end_page": 17
    },
    {
      "heading": "of of tables",
      "text": "prior prior anti-SELect-1. SELect-1. ... . . . ... ... ... ... . ... . ... ... . . . . ... . .. ... . ... ... ... ... [...] . Adjustment Adjustment • Adjustment Adjustment ... ...89. 89. Goodness-Patients Patients (ATT)",
      "start_page": 18,
      "end_page": 21
    },
    {
      "heading": "of of figures",
      "text": "... ... ... ... . . . ... ... ... ... . ... . ... . ... ... . . Mutant Mutant ... __MEDTERM0_ __MEDTERM0_ ... Flatiron Flatiron KRA's Mutant ...",
      "start_page": 21,
      "end_page": 23
    },
    {
      "heading": "4. Summary",
      "text": "customers. customers.",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "Population",
      "text": "sequence sequence (NGS) currently currently exist).",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "Intervention",
      "text": "novel, novel, first-Use Use (CHMP) cancer cancer (_MEDTERM1_) mg mg (mg mg tablets) administered. administered.",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "Comparator",
      "text": "75 75 mg/weeks. weeks.",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "Clinical comparison",
      "text": "a a second- of of head-__medterm6___ __medterm6___ . events events (TRAE) (20% vs 30%) AEs AEs (9% vs 14.5%). of of life(8, 9). safety_related safety_related agents",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "Health economic model",
      "text": "question. question.",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "economic economic evaluation",
      "text": "ratio ratio (ICER) a a willingness-ICER ICER were: (i) ratio ratio (HR) treatment treatment discrimination; (ii) of of docetaxel; (iii) to to loss; (iv) factor factor (HR).",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "Disease Disease information",
      "text": "4 4 (1) (b) of Regulation (EU) No 575/following following criteria: approximately approximately 10% and and 26% disease disease (16). 1. 1.",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "Lung Cancer",
      "text": "Adenocarcinoma Adenocarcinoma Others",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "Molecular Molecular altars",
      "text": "heterogeneity heterogeneity (17, 18), subtype subtype (19).",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "in in NSCLC",
      "text": "in in active/guanosine guanosine tri/diphosphate (GTP/GDP) (30). the the KRA'estimated estimated 80% substitution substitution (_MEDTERM0_ mutation) 12. 12.",
      "start_page": 27,
      "end_page": 28
    },
    {
      "heading": "and and stagnating",
      "text": "imaging imaging (e.g., tomography tomography [CT]/tomgraphy tomgraphy [PET]-CT scan). disease disease (34). trials trials (35). including including (_MED_MED__MED_IREME_MED,",
      "start_page": 28,
      "end_page": 28
    },
    {
      "heading": "Clinical Clinical presentation",
      "text": "challenging challenging (37). dyspnea dyspnea (shortness of breath), atelectasis (partial/complete lung collapse), effusion effusion (and and lungs) (38).",
      "start_page": 28,
      "end_page": 28
    },
    {
      "heading": "KRAS G12C_mutated KRAS G12C_mutated NSCLC",
      "text": "for for 2L+, inhibitor inhibitor (ICI) chemotherapy chemotherapy (24.49).",
      "start_page": 28,
      "end_page": 28
    },
    {
      "heading": "in in Denmark",
      "text": "NSCLCpatients NSCLCpatients (5). otherwise otherwise stated) __MEDTERM0_MENT __MEDTERM0_MENT (Danish registry analysis) treatment treatment (mean) metastases metastases (%) PS1, PS1, PS<Gender Gender (% female) baseline baseline (% IIIB [vs IV]) history history (% yes) X Key: oncology oncology group; status. status. Note: systemic systemic treatment; systemic systemic therapy; systems systems treatment; *for for X_TIL",
      "start_page": 28,
      "end_page": 29
    },
    {
      "heading": "5 5 Epidemiology",
      "text": "Registry Registry (DLCR) 1623 1623 patients(4). non-square non-square __medterm4_] patients (Data on file(5)).",
      "start_page": 29,
      "end_page": 30
    },
    {
      "heading": "this this application",
      "text": "Sotorasib (LUMYKRASTM) Agency Agency (EMA)",
      "start_page": 30,
      "end_page": 30
    },
    {
      "heading": "treatment treatment options",
      "text": "DLCG DLCG (6), clinical experts (2, 3) basket basket (Table 60).",
      "start_page": 30,
      "end_page": 31
    },
    {
      "heading": "comparators comparators (s)",
      "text": "by by DLCG(6) clinical clinical experts(2, 3).",
      "start_page": 32,
      "end_page": 32
    },
    {
      "heading": "comparator comparator (docetaxel)",
      "text": "75 75 mg/weeks. weeks.",
      "start_page": 32,
      "end_page": 32
    },
    {
      "heading": "Subject",
      "text": "Generic name (ATC-code) Docetaxel (L01CD02) 75 75 mg/infusion. infusion.",
      "start_page": 32,
      "end_page": 32
    },
    {
      "heading": "Treatment:",
      "text": "count count < 500 cells/60 60 mg/mg mg /required. required.",
      "start_page": 32,
      "end_page": 32
    },
    {
      "heading": "5.3 Intervention",
      "text": "107 107 (3) (c) C C - 6. 6.",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "Subject",
      "text": "Generic name (ATC-code) Sotorasib (L01XX73) 960mg 960mg (120mg 120mg tablets) Oral Oral tablets",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "other other medications",
      "text": "Treatment duration: tests tests (total total bilirubin) Disease Disease / therapy. therapy.",
      "start_page": 33,
      "end_page": 34
    },
    {
      "heading": "relevant relevant studies",
      "text": "review review (SLR) 107 107 (3) (c) A A - comparators. comparators.",
      "start_page": 34,
      "end_page": 35
    },
    {
      "heading": "relevant relevant studies",
      "text": "B B - study study (journal, journal, year) (completion completion date) 08. 08.2018",
      "start_page": 35,
      "end_page": 35
    },
    {
      "heading": "and and safety",
      "text": "of of head-2. 2., months months (7.9, NE) (on on file) of of therapy",
      "start_page": 35,
      "end_page": 36
    },
    {
      "heading": "X X X",
      "text": "K K - MAIC.",
      "start_page": 36,
      "end_page": 36
    },
    {
      "heading": "100 100 study",
      "text": "D D - study. study.",
      "start_page": 36,
      "end_page": 36
    },
    {
      "heading": "100 100 results",
      "text": "__MEDTERM0_ __MEDTERM0_ (CI) months months (5.1- (73) 8.2 months) Median __MEDTERM1_ (ci) months months (73) 10.0-NE months) 9 9 (7.1%) (73)",
      "start_page": 36,
      "end_page": 37
    },
    {
      "heading": "TRAEs - n (%)",
      "text": "TRAEs grade 3+ - n (%) 26 26 (20.6%) (73) 126 126 11(8.7%), (73)",
      "start_page": 37,
      "end_page": 37
    },
    {
      "heading": "AEs-n (%)",
      "text": "AEs grade 3+n (%) 77 77 (61%) (73) EORTC QLQ-C30",
      "start_page": 37,
      "end_page": 37
    },
    {
      "heading": "survival survival (PFS)",
      "text": "8 8 (95% CI 5.1-82) months (Figure 2). 52. 52.2% (95% 6-60. 6-60.9) 16. 16.3% (95% 4-28. 4-28.2) patients patients (56.5%) 13 13 (10.5%) patients patients (33.1%) 25 25 (20.2%) 7 7 (5.6%) 5. 5.1%) disease. disease.",
      "start_page": 37,
      "end_page": 37
    },
    {
      "heading": "survival survival (OS)",
      "text": "5 5 (95% CI 10.0-NE) months (Figure 3). 75. 75.5% (95% 8-82. 8-82.2) 51. 51.4% (95% 9-60. 9-60.1) 59 59 (46.8%) patients patients (53.2%) 56 56 (44.4%) 9 9 (7.1%) included (71).",
      "start_page": 37,
      "end_page": 37
    },
    {
      "heading": "safety safety profile",
      "text": "events events (TREAs) patients patients (69.8%).",
      "start_page": 38,
      "end_page": 38
    },
    {
      "heading": "life life (HRQoL)",
      "text": "health health status/change change (were were > 5 patients) 9 9 (cycle 3) to -5.3 (cycle 11) (see Error! found. found.).",
      "start_page": 38,
      "end_page": 38
    },
    {
      "heading": "EORTC EORTC QLQ-",
      "text": "107 107 (3) (c) Parties. Parties.",
      "start_page": 38,
      "end_page": 39
    },
    {
      "heading": "SELECT-1 SELECT-1 study",
      "text": "2016 2016 (72). D D - study. study.",
      "start_page": 39,
      "end_page": 39
    },
    {
      "heading": "SELECT-1 SELECT-1 results",
      "text": "Results Results (IQR) Placebo Placebo + 8 8 (1.4-5.5) months (72) Bo Bo + 9 9 (3.8-20.1) months (72) AEs AEs (%) Placebo+ 37 37 (14.5%) (72), AEs grade 3+ (%) Placeb + 115 115 (45.0%) (72). NA NA Key: NA, not available; __MIDTERM1__, overall survival; _MEDTERM0_, progression-free survival; outcomes. outcomes.",
      "start_page": 39,
      "end_page": 39
    },
    {
      "heading": "survival survival (PFS)",
      "text": "date date (June 7, 2016), 8 8 (5-4. 5-4.5) months (Figure 4) (72). placebo placebo + docetaxel (treatment treatment comparison) and __medterm0__+ docetaxel. Key: HR, Hazard ratio; survival. survival.",
      "start_page": 39,
      "end_page": 40
    },
    {
      "heading": "survival survival (OS)",
      "text": "date date (June 7, 2016), months months (8-20. 8-20.1) events events (Figure 5). placebo placebo + docetaxel (treatment treatment comparison) docexole. docexole. Key: HR, Hazard ratio; survival. survival.",
      "start_page": 40,
      "end_page": 41
    },
    {
      "heading": "safety safety profile",
      "text": "affected affected 10% diarrhoea diarrhoea (89 events, 35%), fatigue (79 events, 31%), alopecia (64 events, 25%), and nausea (62 events, 24%). anemia anemia (11 events, 4%), fatal (10 events,.4%), neutropenia (10 events; and (7 events, 3%). 76 patients (30%) hospitalization hospitalization (72). events events (45%), pregnancy, pregnancy, 32% docetaxel. docetaxel.",
      "start_page": 41,
      "end_page": 41
    },
    {
      "heading": "life life (HRQoL)",
      "text": "docetaxel. docetaxel.",
      "start_page": 41,
      "end_page": 41
    },
    {
      "heading": "and and safety",
      "text": "sources sources (74).",
      "start_page": 41,
      "end_page": 42
    },
    {
      "heading": "MAIC MAIC overview",
      "text": "study study (75). in in (n = 126) the the Commission'107 107 (3) (c) removal. removal. Variable'process. process.",
      "start_page": 42,
      "end_page": 43
    },
    {
      "heading": "Population Population characteristics",
      "text": "charts charts (SELECT-1) N = 126 N = 256 Age (mean) Gender Gender (% female) 50% 43% Brain metastases (%) 21% NRb ECOG (% PS 0) 70% 59% Race (% white) 82%c 95% % KRAS-G12C 100% 42%d Anti-PD-(L) prior prior line(s) 91% 0% lines lines (% with 1/2/3 prior lines) 43%/35%/22% 100%/0% baseline baseline (% IIIB [vs IV]) 97% 96% Histology (% Non-squamous) 99% 95% Smoking status (% ever smoker) 93% 92% mutations mutations (_MEDTERM2___L_REV1",
      "start_page": 43,
      "end_page": 44
    },
    {
      "heading": "MAIC MAIC approach",
      "text": "shall shall apply: (i) transferable transferable securities; (ii) financial financial instruments; (iii) in in securities; or (iv) foreign foreign currency; (v) foreign foreign currencies; (vi) trading trading purposes; (vii) treatment. treatment.",
      "start_page": 44,
      "end_page": 45
    },
    {
      "heading": "Category Covariate",
      "text": "ECOG ECOG (0, 1) * metastases metastases (Y, N) baseline baseline (Y; N) * expression expression (<5%, >5%) following following mutations/alterations: Age Age * status status (of of smoking) * metastasies metastasies (Y and N) metastasese metastasese (Y), N) metastasis metastasis (or or more) therapies therapies (1, 2, 3) date date (<3 3 - 6 months, > K K - MAIC.",
      "start_page": 45,
      "end_page": 46
    },
    {
      "heading": "MAIC MAIC Results",
      "text": "risks. risks.",
      "start_page": 46,
      "end_page": 47
    },
    {
      "heading": "1 1 OScurve",
      "text": "sotorasib sotorasib (in blue) SELECT-1 SELECT-1 (in yellow) in in Error! found. found., 100 100 (in Blue) SELECT-1 SELECT-1 (yellow) Error Error ! found. found.; results. results.",
      "start_page": 47,
      "end_page": 47
    },
    {
      "heading": "A B",
      "text": "Key: KM, Kaplan-Meier; indirect indirect comparison; survival. survival. A: curve, curve, B: curve. curve. Note: of of weights",
      "start_page": 48,
      "end_page": 48
    },
    {
      "heading": "2 2 PFScurve",
      "text": "sotorasib sotorasib (in blue) SELECT-1 SELECT-1 (in yellow). Error! 100 100 (in Blue) vs: docecent-1 docecent-1 (In yellow). in in Error!",
      "start_page": 48,
      "end_page": 48
    },
    {
      "heading": "and and __MIDTERM1__results",
      "text": "included included (i) important important (SET 1) and (ii) adjustment adjustment (Set 2). MAIC MAIC analyses; in in error! HR_page. HR_page.",
      "start_page": 48,
      "end_page": 48
    },
    {
      "heading": "vs. vs. docetaxel",
      "text": "limits limits (MAIC), sotorasib",
      "start_page": 49,
      "end_page": 49
    },
    {
      "heading": "the the primary",
      "text": "at at DMC(7).",
      "start_page": 49,
      "end_page": 49
    },
    {
      "heading": "comparator comparator docetaxel",
      "text": "at at DMC(7). in in Error! found. found., Error Error ! estimated estimated hazard",
      "start_page": 49,
      "end_page": 49
    },
    {
      "heading": "analysis analysis (X).",
      "text": "results. results.",
      "start_page": 49,
      "end_page": 49
    },
    {
      "heading": "2 2 Safety",
      "text": "grade grade 3+ CodeBre100. CodeBre100.",
      "start_page": 49,
      "end_page": 49
    },
    {
      "heading": "adverse adverse events",
      "text": "months months (range: 0.2-17.8) for sotorasib (73), months months ( range: 0.1-27.4) for docetaxel (72) (4 4 months). soorasib soorasib (8.7%) and docetaxel (14.5%), treatments. treatments. (0.8) 2 2 (1.6) 1 (0.8) 1 (0.5) 1 (2) 2 2 (0.6) 1 (0.8) 1 (0.6).",
      "start_page": 49,
      "end_page": 51
    },
    {
      "heading": "and and docetaxel",
      "text": "_MEDERM2___. _MEDERM2___.",
      "start_page": 51,
      "end_page": 51
    },
    {
      "heading": "8.1 Model",
      "text": "107 107 (1) 3. 3.5% outcomes. outcomes.",
      "start_page": 52,
      "end_page": 53
    },
    {
      "heading": "were were obtained",
      "text": "tariff tariff set(86) and the EQ-clinical clinical practice",
      "start_page": 53,
      "end_page": 54
    },
    {
      "heading": "Patient Patient population",
      "text": "SELECT-1. SELECT-1.",
      "start_page": 54,
      "end_page": 54
    },
    {
      "heading": "Table 19.",
      "text": "documentation documentation / etc. etc. (including source) Age Age (mean) older. older. (2, 3.5) (see Table 1) Gender (% female) 50.0% 50.0%) practices practices (2, 3, 5) (See Table 1) Weight (kg) be be similar(2, 3) area area (m2) be be comparable(2,3)",
      "start_page": 54,
      "end_page": 54
    },
    {
      "heading": "2 2 Sotorasib",
      "text": "Sotorasib (LUMYKRASTM) the the EMA",
      "start_page": 54,
      "end_page": 54
    },
    {
      "heading": "Table 20. Intervention",
      "text": "clinical clinical (including source) (number/practice practice (including sources source) if known) mg mg (mg mg tablets) duration duration / toxicity toxicity treatment: • models. models.",
      "start_page": 55,
      "end_page": 55
    },
    {
      "heading": "3 3 Comparators",
      "text": "75 75 mg/weeks. weeks.",
      "start_page": 55,
      "end_page": 55
    },
    {
      "heading": "Table 21. Comparator",
      "text": "clinical clinical (including source) (number/practice practice (including sources) source) 75 75 mg/duration duration / toxicity toxicity treatment: the the models",
      "start_page": 55,
      "end_page": 55
    },
    {
      "heading": "effectiveness effectiveness outcomes",
      "text": "2. 2., 3. 3.5",
      "start_page": 55,
      "end_page": 55
    },
    {
      "heading": "reaction reaction outcomes",
      "text": "of of ≥ 0.5% arms arms (sotorasib and docetaxel) cut cut (87). the the SELECT-1(72).",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "Table 22.",
      "text": "Sotorasiba Sotorasiba Docetaxelb",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "5. 5.6% 0.0%",
      "text": "Neutropenia 0.8% 1.6% Note: cut-off cut-off (87) to to treatment(72)",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "relative relative effectiveness",
      "text": "direct direct head-data, data, goodness-guidance guidance (TSD 14) (88). anti anti PD-(L)results. results.",
      "start_page": 56,
      "end_page": 57
    },
    {
      "heading": "MAIC MAIC results",
      "text": "included included (i) important important (SET 1) and (ii) adjustment adjustment (Set 2). in in Error! X-unit X-unit X;",
      "start_page": 57,
      "end_page": 57
    },
    {
      "heading": "Overall Overall survival",
      "text": "sotorasib sotorasib (in blue) SELECT-1 SELECT-1 (in yellow) in in Error! 100 100 (in Blue) SELECT-1 SELECT-1 (i Yellow) Error Error ! survival. survival.",
      "start_page": 57,
      "end_page": 57
    },
    {
      "heading": "A B",
      "text": "Key: KM, Kaplan-Meier; indiect indiect comparison; survival. survival. A: adjusted, B: 14 14 (88). fitting fitting (limited limited model) R R (0. 0.3).",
      "start_page": 57,
      "end_page": 58
    },
    {
      "heading": "Statistical goodness-of-fit",
      "text": "Glossary-criterion criterion (AIC), criteria criteria (BIC) models models (Table 23). 107 107 (1) the the goodness-sotorasib. sotorasib.",
      "start_page": 58,
      "end_page": 61
    },
    {
      "heading": "observed observed data",
      "text": "below below (Error! found. found.). well well (Error! notfound. notfound.).",
      "start_page": 61,
      "end_page": 61
    },
    {
      "heading": "X",
      "text": "Key: KM, Kaplan-Meier; indirect indirect comparison; survival. survival.",
      "start_page": 61,
      "end_page": 61
    },
    {
      "heading": "XX",
      "text": "91. 91.3% 91.0% 92.9% 95.8% 94.7% 95.5% 76. 76.0% 75.6% 77.7% 76.9% 78.0% 77.4% 57. 57.8% 57.7% 57.9% 55.7% 56.0% 56.1% 85. 85.8% 85.5% 88.3% 89.1% 89.2% 89.3% 63. 63.3% 62.7% 65.5% 65.7% 62.7% 61.0% 61.6% 40. 40.0% 39.9% 39.9% 38.2% 37.0% 38.1% 38.1% Key: Exp, exponential; GG, Generalized gamma; survival. survival.",
      "start_page": 61,
      "end_page": 62
    },
    {
      "heading": "curve curve selection",
      "text": "the the goodness-data. data.",
      "start_page": 62,
      "end_page": 62
    },
    {
      "heading": "long-term long-term extrapolations",
      "text": "fitting fitting (restricted) in in Error! found. found..",
      "start_page": 62,
      "end_page": 62
    },
    {
      "heading": "X",
      "text": "approximately approximately 5% presented presented (and and Weibull) and and was",
      "start_page": 62,
      "end_page": 62
    },
    {
      "heading": "5-years 5-years (10-years 10-years (rate, rate, duration",
      "text": "107 107 (1) Treaty. Treaty.",
      "start_page": 63,
      "end_page": 63
    },
    {
      "heading": "Progression-free Progression-free survival",
      "text": "Error! sotorasib sotorasib (in blue) SELECT-1 SELECT-1 (in yellow). Error! KM KM .100 100 (in Blue) vs: Select-1 Select-1 (yellow). For the __MIDTERMM0]relative relative survival: same. same.",
      "start_page": 63,
      "end_page": 63
    },
    {
      "heading": "A B",
      "text": "Key: KM, Kaplan-Meier; indirect indirect comparison; survival. survival. A: adjuvanted time-14 14 (88). jointly jointly (restricted restricted models) R R (0. 0.3) distribution distribution (Table 24).",
      "start_page": 63,
      "end_page": 63
    },
    {
      "heading": "Statistical goodness-of-fit",
      "text": "Goodness-produced produced (unrestricted and restricted) models models (Table 24). Schoe Schoe Key: ha ha -residua residua -direct direct comparison; direct direct compare; MAIC MAIC spsion- General General Business",
      "start_page": 64,
      "end_page": 65
    },
    {
      "heading": "base-case base-case MAIC",
      "text": "Key: indirect indirect comparison; extrapolation. extrapolation.",
      "start_page": 66,
      "end_page": 66
    },
    {
      "heading": "observed observed data",
      "text": "below below (Error! found. found.). well well (Errror! notfound. notfound.).",
      "start_page": 66,
      "end_page": 66
    },
    {
      "heading": "X",
      "text": "Key: KM, Kaplan-Meier; indirect indirect comparison; survival. survival.",
      "start_page": 67,
      "end_page": 67
    },
    {
      "heading": "curve curve selection",
      "text": "107 107 (1) Treaty. Treaty.",
      "start_page": 67,
      "end_page": 68
    },
    {
      "heading": "long-term long-term extrapolations",
      "text": "found. found.",
      "start_page": 68,
      "end_page": 68
    },
    {
      "heading": "survival survival outcomes",
      "text": "analyses analyses (no MAIC), HR HR (was was unclear), as as follows: • distribution distribution • model model (best-fitting best-fitting model)",
      "start_page": 68,
      "end_page": 68
    },
    {
      "heading": "1 1 Sotorasib",
      "text": "100 100 (75) discrimination discrimination (TTD) and PFS (progression. progression.",
      "start_page": 68,
      "end_page": 69
    },
    {
      "heading": "of of X) PFScurve. PFScurve.",
      "text": "CodeBreaK CodeBreaK 100: curve curve (Error! found. found.). below. below.",
      "start_page": 69,
      "end_page": 69
    },
    {
      "heading": "X",
      "text": "For For example: • assume assume TTD=model model (than than PFS).",
      "start_page": 69,
      "end_page": 69
    },
    {
      "heading": "2 2 Docetaxel",
      "text": "docetaxel. docetaxel.",
      "start_page": 69,
      "end_page": 70
    },
    {
      "heading": "X",
      "text": "Key: PFS, progression-free survival; interruption. interruption.",
      "start_page": 70,
      "end_page": 70
    },
    {
      "heading": "data data • summarized:",
      "text": "data. data.",
      "start_page": 70,
      "end_page": 70
    },
    {
      "heading": "values values (HSUV)",
      "text": "the the EQ-The The EQ-5-visit visit (~ of of sotorasib).",
      "start_page": 70,
      "end_page": 70
    },
    {
      "heading": "100 100 EQ-5D-5L",
      "text": "tariff tariff (Error! found. found.).",
      "start_page": 70,
      "end_page": 71
    },
    {
      "heading": "X",
      "text": "Key: Danish EQ-5D-5L index (86). Note: reported reported EQ-5-cut. cut.",
      "start_page": 71,
      "end_page": 71
    },
    {
      "heading": "X",
      "text": "Key: Danish EQ-5D-5L index (86) Note: reported reported EQ-5-cut. cut.",
      "start_page": 71,
      "end_page": 71
    },
    {
      "heading": "measures measures analysis",
      "text": "found. found.. scores scores (Error! Ref or! notfound. notfound..",
      "start_page": 71,
      "end_page": 71
    },
    {
      "heading": "the the Denmark",
      "text": "threshold threshold (0.080), visits visits (the the 95% Cis). the the EQ-4. 4.",
      "start_page": 72,
      "end_page": 72
    },
    {
      "heading": "case case (health state utilities)",
      "text": "Danish Danish EQ-5D-5L value set(86) (Error! found. found.), guidelines. guidelines.",
      "start_page": 72,
      "end_page": 72
    },
    {
      "heading": "death death utilities",
      "text": "Danish Danish EQ-set set (86) in in Error! found. found..",
      "start_page": 72,
      "end_page": 72
    },
    {
      "heading": "significant significant (X (Error! found. found.).",
      "text": "analyses. analyses.",
      "start_page": 73,
      "end_page": 73
    },
    {
      "heading": "modality modality disutility",
      "text": "Mean Mean (95% CI)* TA484 TA484 [assumption](90) 047 047 (0. 0.077) Nafees 2008(91) 073 073 (0. 0.110) Naphees 2008(92) 050 050 (0. 0.060) 484 484 [assumption] (82, 90, 91) TA484 TA484 (assumption](90) 0090 0090 (0. 0.120) 050 050 (0. 0.006) 347, 347, 520; 550 550 (0. 0.774) Doyle 2008 (8) Febre neutropenia.",
      "start_page": 73,
      "end_page": 74
    },
    {
      "heading": "resource resource use",
      "text": "dk dk (94). 100 100 (73.95.96).",
      "start_page": 74,
      "end_page": 75
    },
    {
      "heading": "Administration Administration costs",
      "text": "3 3 weeks(92).",
      "start_page": 75,
      "end_page": 75
    },
    {
      "heading": "management management costs",
      "text": "A A summary",
      "start_page": 75,
      "end_page": 75
    },
    {
      "heading": "Hb 31",
      "text": "L+D (DIFFMAS) Liver Liver (ALT) 24 Livers (AST) 24",
      "start_page": 76,
      "end_page": 76
    },
    {
      "heading": "Table 29.",
      "text": "unit unit (DKK) 2021, 04MA98: years, Diagnosis: DC349: lung cancer UNS(98). 2022, 30PR06: complicated, Diagnosis: dc349; uns uns Procedure: scanning scanning chest(98) cycle cycle • Progression-free",
      "start_page": 76,
      "end_page": 76
    },
    {
      "heading": "treatment treatment cost",
      "text": "NSCLCpatients NSCLCpatients (2, 6). experimental experimental treatment(2). analysis. analysis.",
      "start_page": 76,
      "end_page": 76
    },
    {
      "heading": "Biomarks Biomarks testing",
      "text": "clinical clinical experts(2, 3). model. model.",
      "start_page": 76,
      "end_page": 76
    },
    {
      "heading": "resource resource use",
      "text": "DID, DID, WW: UNGi-Twww-Tah-Ta-Tay-TAt-T Away-Tab-Tough-Tube-Dut-Tace-Taw-Tuck-Tact-Tawn-Trad-Trand-Oat. Diagnosis: DD7228: 2021, 2021, 06MA11: Bidiag. Bidiag., Diagnosis: 114, 114, Diagnos: DDG 2021, DDKK) 2021, 2021, 16MA98: MDC16 1-Day-daygroup, Pat.",
      "start_page": 77,
      "end_page": 77
    },
    {
      "heading": "transport transport cost",
      "text": "DMC DMC guidelines(99) (see Table 32). g. g., Resource Resource (DKK) Medicinal Medicinal products",
      "start_page": 77,
      "end_page": 78
    },
    {
      "heading": "administration with sotorasib",
      "text": "of of benzoletaxel(92) minutes. minutes. assumet",
      "start_page": 78,
      "end_page": 78
    },
    {
      "heading": "consultation",
      "text": "mins mins . assumet",
      "start_page": 78,
      "end_page": 78
    },
    {
      "heading": "Base-case Base-case overview",
      "text": "assessments. assessments.",
      "start_page": 78,
      "end_page": 78
    },
    {
      "heading": "TTD",
      "text": "Docetaxel: MAIC MAIC Adjusted: •low low effective",
      "start_page": 78,
      "end_page": 78
    },
    {
      "heading": "Importation· (SET 1) samples size.",
      "text": "located. located. Key: 2L, second-line; medications medications council; of of life; IV, intravenous; indirect indirect comparison; NSCLC, non-small-cell lung cancer; _MEDTERM1_, progression-free survival; __MEDTERM2_, overall survival; analysis analysis set; treatment treatment interruption; adverse adverse event",
      "start_page": 79,
      "end_page": 79
    },
    {
      "heading": "Base-case Base-case results",
      "text": "in in Error! found. found.. ratio ratio (ICER) of X NOK/a a willingness-QAly. QAly. XX",
      "start_page": 80,
      "end_page": 80
    },
    {
      "heading": "X X",
      "text": "Key: AE, adverse event; cost-effect cost-effect ratio; LY, life-years; monetary monetary benefit; WTP, willingness-to-pay; years. years.",
      "start_page": 80,
      "end_page": 80
    },
    {
      "heading": "sensitivity sensitivity analyses",
      "text": "in in Error! found. found.. were were (i) discontinuation, discontinuation, (ii) docetaxel, docetaxel, (iii) sotoraseb, sotoraseb, (iv) and and (v) disturbance. disturbance.",
      "start_page": 80,
      "end_page": 80
    },
    {
      "heading": "X",
      "text": "Key: Admin, administration; AE, adverse event; HR, hazard ratio; IV, intravenous; __MEDTERM0_, progression-intensity; TTD, time-to-treatment discontinuation.",
      "start_page": 81,
      "end_page": 81
    },
    {
      "heading": "Scenario Scenario analysis",
      "text": "distribution, distribution, log-__medterm1__. __medterm1__. -ibution. ibution. urvival; receive receive 100% dosage. dosage. Key: AE, adverse event; caused. caused.",
      "start_page": 81,
      "end_page": 82
    },
    {
      "heading": "X X X",
      "text": "X",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "X X X",
      "text": "X",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "X X X",
      "text": "X",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "X X X",
      "text": "X",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "X X X",
      "text": "X",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "X X X",
      "text": "X",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "X X X",
      "text": "X",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "X X X",
      "text": "X",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "sensitivity sensitivity analyses",
      "text": "in in Error!",
      "start_page": 83,
      "end_page": 83
    },
    {
      "heading": "X X X",
      "text": "Key: cost-effectiveness cost-effectiveness ratio; Incr., incremental; year. year. Error! curve curve (Error! Reference",
      "start_page": 83,
      "end_page": 83
    },
    {
      "heading": "found. found.), a a X% the the DKK",
      "text": "threshold. threshold.",
      "start_page": 83,
      "end_page": 83
    },
    {
      "heading": "X",
      "text": "Key: life life year; o-pay. o-pay.",
      "start_page": 84,
      "end_page": 84
    },
    {
      "heading": "X",
      "text": "Key: life life year; WTP, willingness-to-pay.",
      "start_page": 85,
      "end_page": 85
    },
    {
      "heading": "impact impact analysis",
      "text": "model model (BIM) Denmark Denmark . economy. economy.",
      "start_page": 85,
      "end_page": 85
    },
    {
      "heading": "market market uptake",
      "text": "of of 5%, physician. physician.",
      "start_page": 85,
      "end_page": 86
    },
    {
      "heading": "Budget Budget impact",
      "text": "as as default",
      "start_page": 86,
      "end_page": 86
    },
    {
      "heading": "Scenario Scenario analysis",
      "text": "two two scenarios: - year. year. - in in Error! Error Error ! found. found..",
      "start_page": 86,
      "end_page": 86
    },
    {
      "heading": "submitted submitted documentation",
      "text": "injury. injury.",
      "start_page": 87,
      "end_page": 87
    },
    {
      "heading": "Clinical outcomes",
      "text": "measures, measures, PFS",
      "start_page": 87,
      "end_page": 87
    },
    {
      "heading": "monotherapy monotherapy (X]), in in median",
      "text": "PFS(7). monotherapy monotherapy (X), median median __medterm1___(7). docetaxel. docetaxel.",
      "start_page": 88,
      "end_page": 88
    },
    {
      "heading": "Strengths",
      "text": "practice practice (1. 1.5) compatible. compatible.",
      "start_page": 88,
      "end_page": 88
    },
    {
      "heading": "Limitations",
      "text": "the the Commission'107 107 (3) (c) 108 108 (3) 108 108 (1) 108 108 (2) Agreement. Agreement.",
      "start_page": 88,
      "end_page": 88
    },
    {
      "heading": "Health economics",
      "text": "docetaxel docetaxel EUR/4 4 (1) of Regulation (EU) No 575/the the willness-scenario. scenario.",
      "start_page": 88,
      "end_page": 89
    },
    {
      "heading": "Conclusion",
      "text": "NSCLC NSCLC patient'mutation. mutation.",
      "start_page": 89,
      "end_page": 90
    },
    {
      "heading": "12. References",
      "text": "HOUSEHOLD HOUSEHOLD [Available Available from: caregiovers/lung cancer-101/treatment options/targeted-therapy. Last updated: 16 April,. cancer cancer (_MEDTERM2__) in Europe: Res. Res. 2019;28(7):2010 2010 statement: Trials. Trials. 2010;11(1):amount amount (in EUR) Collaboration Collaboration (1) Reviews Reviews & Dissection (CRD; York, UK) Excellence Excellence (NICE), Meta-Analysiss Meta-Analysiss (66), Trials Trials (CONSORT) and statements (66-70).",
      "start_page": 92,
      "end_page": 98
    },
    {
      "heading": "Search Strategies",
      "text": "economy economy operator'principle. principle.",
      "start_page": 98,
      "end_page": 98
    },
    {
      "heading": "Embase • original search",
      "text": "107 107 (1) Reviews Reviews (Cochrone Revi # lung lung cancer/ cancer cancer / 2 lung Cancer/ 5 5 (carcinom$ 6 6 lung$.2 2 .",
      "start_page": 99,
      "end_page": 102
    },
    {
      "heading": "Embase - 2021 update",
      "text": "($$$*[t] $$$#$$%$$=$$£$$€$$ #$$ $$ $ $$##$ $#$# $$*$$&$$_$$\"$$~$$x$$+$$^$${$$1$$2$$3$$5$$0$$6$$4 or $$4 and $6$5 $$7$$9$$and and 6) crossover procedure/ or double-blind procedure/single-blind single-blind proceeding/ (random$ or or factorial$ or crossover$ or Crossover $ or cross-over$, adj adj blind$) or (singl$ adj blank$ or assigg$ or allocat$ 11 11 (animal$ not human$).14 14 (2020 Sep* or 2020 Oct* or 20 Nov* or 2020. Dec* to to ed=mized mized ver$ $ o nteer$ Jan*). Treaty Treaty (81 81 EC) EC EC (81 81 (1) EC) Treaty. Treaty.",
      "start_page": 102,
      "end_page": 106
    },
    {
      "heading": "• Reference lists",
      "text": "relevant relevant SLRs/scanned. scanned.",
      "start_page": 106,
      "end_page": 106
    },
    {
      "heading": "Single-arm Single-arm Trials",
      "text": "Justice Justice (as as \"First First Instance'), Auditors Auditors (hereinafter \"the General Court'), Bank Bank (\"the Court') Authority Authority (\"the Administrative Court'), Regulation Regulation (EU) No 1071/Union Union (\"the EEA Agreement'), thereof. thereof.",
      "start_page": 106,
      "end_page": 107
    },
    {
      "heading": "to to yr=\"2014 -Current' 71 463",
      "text": "colon colon cancer/ rectum rectum cancer/or colorectal tumor/ 6 6 ((colorect$ or rectal$ or rectum$ or colon$ or sigma$ or segmo$ or rectosigm$ or bowl$ or or anus) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or adenocarcinoma$ or metastas$ or meta-sta$ or sarcoma$or adenom$or lesion$)).ti,ab.",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "ras ras oncogene/ 9909",
      "text": "13 13 epidemiology/14 14 incidence/or accident.ti;15 15 prevalence/overall overall survival/or (su su long$ survival* or survival anal$).free free survival/ or (procession 18 (rate rate ORR_).mp. 19 (21 21 or/Case Case study/pay. pay.",
      "start_page": 108,
      "end_page": 109
    },
    {
      "heading": "to to yr=\"2014 -Current' 29 081",
      "text": "colon colon cancer/ rectum rectum cancer/or colorectal tumor/6 6 ((colorect$ or rectal$ or rectum$ or colon$ or sigma$ or segmo$ or rectosigm$ or bowl$ or or anus) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or carcinoma$ or adenocarcinoma$ or metastas$ or meta-sta$ or sarcoma$or adenom$or lesion$)).ti,ab.",
      "start_page": 109,
      "end_page": 109
    },
    {
      "heading": "ras ras oncogene/ 12 293",
      "text": "((or or k-ki-ras or c-Kirsten Kirsten RAS) adj5 (mutation$ or mutant$ or or gene$ or translocation$ or oncogene$ or fusion$ or expression$ or over?expression$ or amplification$ or inversion$ or deletion$)).13 13 epidemiology/14 14 incidence/15 15 prevalence/to to yr=\"2014 -Current.$ (in in DARE; records were established] colon colon cancer/ or ectosigm$ or or anus) adj3 (cancer$ or neoplas$ or oncolog$ or malignant$ or tumo$ or or adenocarcinoma$ or meta$ or meta-sta$ or sarcoma$ or adenom$or lesion$) to to ry=\"2009 -Curiant\" [in in DARE; or or absented] ras ras oncogene/ 11 ((language language [was was established] to to (editorial or review) [CLHTA, CLHTA,CLCMR; records were removed] 32 systematic review/or \"systematic review (topic)\"/or syste analysis/ or \"meta analysis (topic).\"from from 34",
      "start_page": 109,
      "end_page": 112
    },
    {
      "heading": "• Embase ~ updated search: 10 March 2021",
      "text": "$$$$£$$ $$ $ $$ £ $ $ $ £ £ / $ @ £ or $ ~ ~ or • or ~ $ { ~ 0 $ , $ ^ ~ 1 ~ language language c-survi survi val).ki-31465 ki-31465 AS) adj5 on$ or on$or ival* to to (or or \"review\" or or tombstone) 32 systematic review/ or \"systematic review (topic)\"/ meta-511387 meta-511387 analysis/ analysis analysis (topic).\"mp.",
      "start_page": 112,
      "end_page": 114
    },
    {
      "heading": "to to yr=\"2019 -Current' 15154",
      "text": "colon colon cancer/ rectum rectum cancer/or colorectal tumor/199364 6 ((colorect$ or rectal$ or rectum$ or colon$ or sigma$ or segmo$ or rectosigm$ or bowl$ or or anus) adj3 (cancer$ or neoplas$ or oncoog$ or malignan$ or tumo?r$ or carcinoma$ or adenocarcinoma$ or metastas$ or meta-sta$ or sarcoma$or adenom$or lesion$)).ti,ab.",
      "start_page": 114,
      "end_page": 114
    },
    {
      "heading": "ras ras oncogene/ 12466",
      "text": "21 ((or or k-ki-ras or c-Kirsten Kirsten RAS) adj5 (mutation$ or mutant$ or or gene$ or translocation$ or arrangement$ or oncogene$ or fusion$ or expression$ or over?expression$ or amplification$ or inversion$ or deletion$)).",
      "start_page": 114,
      "end_page": 116
    },
    {
      "heading": "Cochrane updated search: 10 March 2021",
      "text": "[ascinoma, ascinoma, Non-Small-Cell retail, Lung/ 2 (lung lung cancer).to to yr=\"2019 -Current\" [in in DARE; records were established] colon colon cancer/ or ecctum cancer/cancer cancer / or colorectal tumor/6 ((colorect$ or rectum$ or colon$ or sigma$ or signo$ or rectosign$ or or anus) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or or adenocarcinoma$ or metasta$ or sarco$ or salom$ or lesion$)). language language [was was established] to to (editorial or review) [CLHTA, CLHTA,CLCMR; records were retarded] 32 systematic review/or \"systematic review (topic)\"/or systema analysis/ or \"meta analysis (topic).32 32 val* mp mp survival* or 105477 val).25533 25533 MR; or or Meta-33812",
      "start_page": 116,
      "end_page": 117
    },
    {
      "heading": "34 34 65",
      "text": "• with with __MEDTERM0_- and and comparison; risk risk factor; regard, regard, • Indeterminate risk (Twisting) • risk risk (an an anti-PD-(L) outcomes outcomes • Overall survival (_MEDERTM9__2) § • Progression-free survival (PFS_)§ • therapy therapy (__MIDTERM 10_2)",
      "start_page": 118,
      "end_page": 119
    },
    {
      "heading": "Safety and tolerability:",
      "text": "• AEs AEs . • SAES SAES • Tolerability: discrimination discrimination (any reason), discrimination (due to AEs) Phase II • trials trials • only only • trials trials ■ Studies with < publications publications (inclusion. inclusion.) papers papers • Exclu Exclu (experimental/studio studio observational) 1) SLR Update: trials trials (to cover KRASm)",
      "start_page": 119,
      "end_page": 120
    },
    {
      "heading": "2. SLR Screen:",
      "text": "2019 2019 (to cover KRASm) comparator comparator arm) out animal/SCLCry SCLCry (systematic systematic reviews* Country Not restricted",
      "start_page": 120,
      "end_page": 121
    },
    {
      "heading": "the the SLRs",
      "text": "irrelevant irrelevant RCT'subgroup. subgroup.",
      "start_page": 121,
      "end_page": 121
    },
    {
      "heading": "excluded excluded RCTs",
      "text": "† patient patient (Table Table 3). mutation mutation (Table Table 4). countries. countries.",
      "start_page": 122,
      "end_page": 122
    },
    {
      "heading": "reliability reliability criteria",
      "text": "mg mg 1) have have 1) Patients aged ≥ 18 1) had had 1°: _PFS 2015/101) students (previous previous year; 2°: Hungary, Hungary, (n=86) previous previous years; added added >were were 2) daily daily + antiepileptic antiepileptic (n=30) 2018 2018 (104) mg mg 1) Patients of (1) Patients with 1) knowledge knowledge 1°: 1 1 patient' patients with 1) People with 1) 1 1 °: _ ---MEDERM6T01395758 2o: Still Still [...] (n=45) 2020 2020 (105) 21 21 days) mg mg 1) Patients with 1) 21 21 days), (n =45) 2020. 2020. (105] mg mg (1) Patients with1) ___medTERM64-_astatic ___medTERM64-_astatic (stage IV) __ARMM64__as __ARMM64__as (n=270) Phaseing 3 (still night IV) platinum-based platinum-based - MEDTERM464__astatic MEDTERM464__astatic (Stage IV) 2011. 2011. platinum-treatment treatment (a non-mechano Supper's honour) Patients with e/with with 1°: OSe/untreaated brain 2°: of of study; NC. NC. (n=254) any any (same schedule) docetaxel-containing 3) With WHO (n=156) __MEDTERM4_150 __MEDTERM4_150 1) to to 1) Patients aged ≥ 18 1) tumor tumor 1°: EML4-__MEDTER EML4-__MEDTER [...] 2 2 (2) of Regulation (EU) No 182/the the Commission'powers powers (p. p. 1). 107 107 (1) 2020 2020 (110) 150 150 1) had had 1) unstable unstable 1°: satisfied satisfied mg/NC01798485 NC01798485 2°: NCT02008227 NCT02008227 2°: and and (n=425) A A NCT082272°: __MIDTERM65_, [N=4255] an an ---met_assis met_assis mg/excluded excluded (n=179) 2015 2015 (114) mg mg 1) had had 1) clinically clinically 1°: __ENTERTM66_ STY (orally orally + received 1 •NCT01244191 NCT01244191 2°: sugar-canned sugar-canned sugar-cake-and-sugar-cane syrup-to-poor sugar-in-the-market sugar- content content (n) median, (%) n (%) Name Name (n = = n=== n] n [N=103) n n (%) p p (%) NCT ID, (n), n (%) i i n) median; n (%) y y (all all , n % PD-L1 KRAS (n (%) c c (%) Nct) u u . __MEDTERM35_u __MEDTERM35_u (36) Current: 0 (0) 0 (0) - - - KRASm: 11 (100) (n=11) (50 responsibility83) Forms: 11 KRASSmG12C: 4 (36), NCT01229150; (100) Excluded CTEP: 2 2 __MIDTERM7__+ 66 14 (47) Current: 9 (30) - -- KRASMm: 30 (100) comparators __MEDARM3_ (58-82) Shapes: 21 (70) KRASFmG2C: 8 (27) (n=30) ___MEDTERM7_ ___MEDTERM7_ + 64 18 (35) Curent: 3 (6) -- -- n° workers. workers.",
      "start_page": 123,
      "end_page": 135
    },
    {
      "heading": "Local adaptation",
      "text": "studies studies • December December 2019: 4 14 PD-[L]1 therapies) brain brain metastases; antitumour antitumour Secondary: pk, __MEDTERM67_03; whole. whole. (b ≥ 3: 20 (100) N N CHT: 20 (100), metastatic solid BEV: 10 (50) tumors; standard of Nivolumab_: 1 (5) or or TKI: 19 (95) inappropriate; __medterm15_: 1 (5), ≥ 20 years old; ECOG ErlotinibS: 10-50) PS ≤ 2; no significant __medterm17__= 13 (65) comorbidityes. __midterm18__-: 1 (20) __MIDTERM66__^expansion: MEDTERMM66__ MEDTERMM66__ (IIIb or IV); v1. v1.0; the the following: _EGFRUTE (__MEDARM50_ __MEDARM50_ inhibitor); KRASm; Kingdom Kingdom - Median Median (Range), Endpoints/n n (%) and and 1:16 (29.6) NR NR Primary: ___MEDTERM20_ ___MEDTERM20_ 2: 38 (70.4) KRASAm subtype; __MEDARM66___ SECONDARY: or or recurrent; Regulation Regulation (EU) No 1239/Union Union (p. p. 671). risk, risk, risk/benefit/risk/risk-of-security risk/loss/losses of risk/risk_risk/loss_risk_capital_risks/risks_risk &amp; equity_risk=risk/107 107 (3) (c) concomitant concomitant Primary: dose finding nt: Oct sorafenibSurgery: 1 (0 - 4) (NSCLCuncontrolled NSCLCuncontrolled Secondary: 16 16 Radiation: 1 (0.4) with KRASm); conditioning; 2013 2013 CHT: 2.5 (0-6) Targeted Targeted therapy: v1. v1.1; permanently permanently (0.2) PS 0 - 107 107 (1) Union Union (TFEU) __MIDTERM38_3 __MIDTERM38_3 (0 - 11) or or 1; active active Primary: Cohort Cohort A: NR NR Primary: pembrolizumabCohort pembrolizumabCohort B: 68% with with ≥ 1% KRASm KRASm non- and non-SAEs (__midTERM66_United __midTERM66_United Kingdom: ___MEDERTSB68_IN ___MEDERTSB68_IN Crombet; Autophagy Autophagy Inhibitions: n n (%) NR NR Primary: NR NR ed: Oct 153 CHT: 25 25 (73.5) 22 22 (78.6) All __ENTERTM66__; ≥ 2 LOTs, Secondary: 92 92 (60.1) PK PK Hormonestheapy: soorasib. soorasib.",
      "start_page": 135,
      "end_page": 153
    },
    {
      "heading": "Local adaptation:",
      "text": "future. future.",
      "start_page": 153,
      "end_page": 154
    },
    {
      "heading": "local local adaptation",
      "text": "Ø Ø +00 00 medicieraadet@Proprietary Proprietary - of of 1) Patients 18 1) Mixed 1°: had had 2°: and and non",
      "start_page": 154,
      "end_page": 156
    },
    {
      "heading": "Quality assessment",
      "text": "methodology. methodology.",
      "start_page": 156,
      "end_page": 156
    },
    {
      "heading": "Unpublished data",
      "text": "to to EMA/Page Page 150/Ø Ø +00 00 medicraadet@B B - Table 39: Trial Trial name: Publications Publications • 1 1 (to to 5). • response response • rate rate (1. 1.1; 5 5 weeks) • Overall survival • Progress-free survival ■ secondary secondary endpoints: • Safety • 0. 0.",
      "start_page": 156,
      "end_page": 159
    },
    {
      "heading": "Table 40: SELECT-1 • Study Characteristics",
      "text": "Ø Ø +00 00 medicraadet@Compar Compar Medicinsråe: criteria criteria rator(eria eria s) Proprietary Proprietary - NCT NCT number: NCT01933932 Main inclusion: • procedures procedures • older older • ___ ___ (IIIB-IV) • laboratory laboratory • radiological radiological disease",
      "start_page": 159,
      "end_page": 160
    },
    {
      "heading": "Main exclusion:",
      "text": "• surgery. surgery. • Received >therapy therapy (first-line first-line regimen) reliable. reliable. • 75 75 mg/factor factor (G-CSF) G-CSF G-CSF (pegfilgrastim) toxicity. toxicity.",
      "start_page": 160,
      "end_page": 161
    },
    {
      "heading": "Health economic model?",
      "text": "Proprietary Proprietary - NCT NCT number: overall overall survival: placebo + months months (progression-free progression-free survival: Placebo + months months (03-11. 03-11.1) Outcome Outcome Variables: 1. 1.1",
      "start_page": 161,
      "end_page": 161
    },
    {
      "heading": "Secondary Outcome Variables:",
      "text": "Index Index (ASBI) Scale Scale (LCSS) The The LCSS",
      "start_page": 161,
      "end_page": 161
    },
    {
      "heading": "Safety:",
      "text": "• Advise events • urinalysis urinalysis • Vital signs • ECHO/MUGA • Ophthalmological examination",
      "start_page": 161,
      "end_page": 161
    },
    {
      "heading": "Exploratory Outcome Variables:",
      "text": "• levels levels • results results • discrimination discrimination • kras mutation subtype(s) • polymorphismsms polymorphismsms • Ø Ø +00 00 medicineraadet@medicintraadet.dk (de de 155/diciner diciner me: Proprietary Proprietary - 80 80 (__MIDTERM5__ __MIDTERM5__ events).an an intention-interval interval (CI), Kaplan-Meier Kaplan-Meier (KM) represented. represented. • randomization randomization (< 65 vs. = 65) • Smoking status (non-smokers non-smokers (never smoker) ● disease disease (vs. vs. Metastatic) II II (D1532C00016) effect. effect.",
      "start_page": 161,
      "end_page": 163
    },
    {
      "heading": "information information None",
      "text": "• assets assets (CodeBreak-1) criteria criteria • Adults (age ≥ 18 years) • Adults (age > 18 years), • locally locally • Histologically/metastatic metastatic (stage IIIB - or or IV) NSCLC Metastatic ( stage IIIB-IV) ___MEDTERM 2_ECOG/1 1 • ADOG/ or or • to to KRA'Ø Ø +00 00 medicieradet@Proprietary Proprietary - C C - a a (CodeBreak 100) N = 126 Age (mean) Gender Gender (% female) 50% Brain metastases (%) 21% ECOG (% PS 1 [vs PS 0]) 70% Race (% white) 82%c % KRAS-G12C 100% Anti-PD-(L) prior prior line(s) 91% lines lines (% with 1/2/3 senior lines).",
      "start_page": 163,
      "end_page": 164
    },
    {
      "heading": "across across studies",
      "text": "studies. studies.",
      "start_page": 164,
      "end_page": 164
    },
    {
      "heading": "for for treatment",
      "text": "2. 2.",
      "start_page": 164,
      "end_page": 164
    },
    {
      "heading": "outcome outcome measures",
      "text": "2 2 (7) Regulation. Regulation.",
      "start_page": 164,
      "end_page": 166
    },
    {
      "heading": "Results per study",
      "text": "following following data: http://europa.eu.int/comm/dgl/index_en.htm",
      "start_page": 166,
      "end_page": 167
    },
    {
      "heading": "X",
      "text": "0 0 (NA NA * ary ary - Ø Ø +NA NA *cut-off cut-off 2021(7 in 3) March NA *Cut-off Cut-off 2022(7in3) March NA*data data file(75) March March NA",
      "start_page": 167,
      "end_page": 167
    },
    {
      "heading": "X",
      "text": "Page 161/237 adet@Am Am , tary tary - Ø Ø +medicierra medicierra aadet@x X X",
      "start_page": 167,
      "end_page": 168
    },
    {
      "heading": "X",
      "text": "Proprietary Proprietary - Ø Ø +medicinsra medicinsra aadet@Page Page 163/Proprietive Proprietive - Copenhagen Copenhagen Ø+medikra medikra aadet@@medici inraade",
      "start_page": 169,
      "end_page": 170
    },
    {
      "heading": "Page 164/237",
      "text": "Proprietary Proprietary - Ø Ø +mediciera mediciera aadet@@medici inraade",
      "start_page": 170,
      "end_page": 171
    },
    {
      "heading": "Page 165/237",
      "text": "N N = analysis analysis set; n = Proprietary Proprietary - observed observed data; SD = Ø Ø +deviation deviation aadet@medici n inraade",
      "start_page": 171,
      "end_page": 172
    },
    {
      "heading": "Page 166/237",
      "text": "NCE01933932) __medterm0_medrm0_ __medterm0_medrm0_ (___medtermo__dsk ___medtermo__dsk + o o + N(%) 9 9 (5. 5.9) SELECT-1 SELECT-1 (NCT019 Lect-1 (NCT0193332) 9 9 (5. 5.9) 8 8 (2 2 . A A , CT-1 CT-1 (T T ABSI: asib asib (tary tary - co co CodeBreak-100)* n=126 Grade 3+ vn Ø +nly nly arator(s) Docetaxel + NA NA NA",
      "start_page": 172,
      "end_page": 176
    },
    {
      "heading": "adverse adverse events",
      "text": "waywaywaywayswaywaywardwaywaythroughwaywayhomewaywaymarketwaywayspacewaywaywellwaywayourwaywaygroundwaywayallwaywayholewaywayotherwaywaybywayway waywaywaywayswaywaywardwaywaythroughwaywayhomewaywaymarketwaywayspacewaywaywellwaywayourwaywaygroundwaywayallwaywayholewaywayotherwaywaybywayway (54.8) 16 16 (12.7) 12 12 (9.5) 6 6 (4.8) 5 5 (4.0) 5 5 (4.5) 0 0 (0) 2 2 (1.6) 3 3 (2.4) 0 0 (0) disorder disorder 0+ 4 4 (3.2) Footnote: reported reported . hard hard - U U CodeBreak-100)* Grade 3+ vn +Docetaxel Docetaxel + p n= Any Grade edicinraadet@o o (SELECT-1) Grade 3 + de de 171/Proprietary Proprietary - 8 8 (6.3) 0 (0) Heache 11 (8.7) 0 (0) Myalgia 8 (6.3) 0 (0) Footnote: in in >10% 48 48 (3 3 6), 8 8 (63) 0 (0) th. th.",
      "start_page": 176,
      "end_page": 181
    },
    {
      "heading": "from from SELECT-1",
      "text": "Ø Ø +mediciera mediciera aadet@@Page Page 175/Proprietary Proprietary - Use Use Only",
      "start_page": 181,
      "end_page": 182
    },
    {
      "heading": "X X X",
      "text": "grade grade 3+ economic economic analysis? Grade 3+ CodeBreak 100 16% (61%- 35. 35.5% events events & SELECT-1 45%) 100 100 -5.8% (8.7%- NA 40% no no & Select-1 14.5%) AEs AEs ((14.5%-- NA 40) AUS AUS ((13.5%-",
      "start_page": 182,
      "end_page": 182
    },
    {
      "heading": "Appendix G - Extrapolation",
      "text": "of of time-to-event data.",
      "start_page": 182,
      "end_page": 182
    },
    {
      "heading": "X *population population (N =126)",
      "text": "Page 176/Ø Ø +36 36 00medicinsraadet@medicinraadet.dk",
      "start_page": 182,
      "end_page": 182
    },
    {
      "heading": "X",
      "text": "*Proprietary Proprietary - population population (N =123) ndix H - I I - Ø Ø +medicinera medicinera aade@@Side Side 177/Proprietary Proprietary - J J - all all data/parameters. parameters.",
      "start_page": 183,
      "end_page": 184
    },
    {
      "heading": "X X X",
      "text": "Ø Ø +00 00 medicraadet@values values alysis",
      "start_page": 184,
      "end_page": 184
    },
    {
      "heading": "Page 178/237",
      "text": "et.dk",
      "start_page": 184,
      "end_page": 184
    },
    {
      "heading": "X",
      "text": "Steamfae Steamfae Ergevej",
      "start_page": 185,
      "end_page": 185
    },
    {
      "heading": "X",
      "text": "Pr. Pr.",
      "start_page": 185,
      "end_page": 185
    },
    {
      "heading": "X",
      "text": "roprietary roprietary - F",
      "start_page": 185,
      "end_page": 185
    },
    {
      "heading": "X",
      "text": "benhavn Ø + For Internal U",
      "start_page": 185,
      "end_page": 185
    },
    {
      "heading": "X",
      "text": "me me nly",
      "start_page": 185,
      "end_page": 185
    },
    {
      "heading": "X X",
      "text": "edicinraadet@de de 179/237 medicinadet.dm",
      "start_page": 185,
      "end_page": 185
    },
    {
      "heading": "X",
      "text": "Steamfae Steamfae Ergevej",
      "start_page": 186,
      "end_page": 186
    },
    {
      "heading": "X",
      "text": "Pr. Pr.",
      "start_page": 186,
      "end_page": 186
    },
    {
      "heading": "X",
      "text": "roprietary roprietary - F",
      "start_page": 186,
      "end_page": 186
    },
    {
      "heading": "X",
      "text": "benhavn Ø + For Internal U",
      "start_page": 186,
      "end_page": 186
    },
    {
      "heading": "X",
      "text": "me me nly",
      "start_page": 186,
      "end_page": 186
    },
    {
      "heading": "X X",
      "text": "edicinraadet@de de 180/237 medicinadet.dm",
      "start_page": 186,
      "end_page": 186
    },
    {
      "heading": "X",
      "text": "Proprietary Proprietary - Use Use Only",
      "start_page": 187,
      "end_page": 187
    },
    {
      "heading": "X X X",
      "text": "Ø Ø +00 00 medicraadet@et. et.dk",
      "start_page": 187,
      "end_page": 187
    },
    {
      "heading": "Page 181/237",
      "text": "Amgen Proprietary - Use Use Only",
      "start_page": 188,
      "end_page": 188
    },
    {
      "heading": "Data Data sources",
      "text": "interest. interest.",
      "start_page": 188,
      "end_page": 188
    },
    {
      "heading": "data data sources",
      "text": "the the Commission'2 2 (1) Regulation. Regulation.",
      "start_page": 188,
      "end_page": 189
    },
    {
      "heading": "Endpoint",
      "text": "assessed assessed PFS; __MIDTERM1__",
      "start_page": 189,
      "end_page": 189
    },
    {
      "heading": "endpoints",
      "text": "PFS_ PFS_ Key: oncology oncology group; protein protein kinase; lung lung cancer; response response rate; ~MEDTERM2_, overall survival; }MEDTERMI_, progression-free survival; factor factor receptor; __MIDTERM3_ __MIDTERM3_ (Stage IIIB",
      "start_page": 189,
      "end_page": 189
    },
    {
      "heading": "investigators investigators in",
      "text": "Ø Ø +00 00 medicieradet@Proprietary Proprietary - Gender Gender (% female) 50% 43% Brain metastases (%) 21% status status (ECOG or WHO; 70% 59% % PS 1 [vs PS 0]) Race (% white) 82%d 95% % KRAS G12Cmutated 100% 42%b Anti-PD-(L) prior prior line(s) 91% 0% lines lines (% with 1/2/3 43%/35%/22% 100%/0%/0% senior lines) baseline baseline 96% 96% Histology (% Non-squamous) 99% 95% Smoking status (% ever smoker) 93%e 92% mutations mutations (_MEDTERM2__, 3% BRAF, BRAF, ROS-1) baseline baseline (< 5% 48%",
      "start_page": 189,
      "end_page": 190
    },
    {
      "heading": "indirect indirect comparisons",
      "text": "included included 57% Page Page 184/Ø Ø +of of therapy; conservative. conservative.",
      "start_page": 190,
      "end_page": 191
    },
    {
      "heading": "of of weights",
      "text": "concerned. concerned.",
      "start_page": 191,
      "end_page": 191
    },
    {
      "heading": "rescaled rescaled weights",
      "text": "following following formula: size size (ESS). unstable. unstable.",
      "start_page": 191,
      "end_page": 191
    },
    {
      "heading": "sample sample size",
      "text": "the the ESS:",
      "start_page": 191,
      "end_page": 191
    },
    {
      "heading": "incorporating incorporating weights",
      "text": "107 107 (1) groups groups <5% and ≥ 5% only; physicians. physicians.",
      "start_page": 191,
      "end_page": 192
    },
    {
      "heading": "in in MAIC",
      "text": "2 2 (3. 3.1) used. used.",
      "start_page": 192,
      "end_page": 192
    },
    {
      "heading": "2 2 • available available covariates",
      "text": "case. case.",
      "start_page": 192,
      "end_page": 192
    },
    {
      "heading": "X X X",
      "text": "survival. survival.. only. only. a: Investigator, b: Page Page 186/Ø Ø +00 00 medicierraadet@Proprietary Proprietary - Use Use Only",
      "start_page": 192,
      "end_page": 193
    },
    {
      "heading": "SET SET 2",
      "text": "N N = 256 N = ECOG ECOG (% PS) 1 [Age Age (mean) baseline baseline (%) Smoking status (% ever ever smoker) level level (<5% vs ≥ 5%) Gender (% female) x Histology (% Non- x x squalous) Ø Ø +medicine medicine aadet@ n n = Side Side 187/237 @Proprietary Proprietary - Race Race (% white)",
      "start_page": 193,
      "end_page": 194
    },
    {
      "heading": "Overall Overall survival",
      "text": "Hi5G2g Hi5G2g rightway!H2Aright rightowowowing.Hash-of-and and log-log-loggistic. Goodness-of‐Fit Fit (unrestricted and restricted) 58. 58. _OSGoodness-matched matched (fit fit .fit fit - Jointfit 58.",
      "start_page": 194,
      "end_page": 195
    },
    {
      "heading": "Page 189/237",
      "text": "Proprietary Proprietary - Use Use Only",
      "start_page": 195,
      "end_page": 196
    },
    {
      "heading": "SET SET 2",
      "text": "Key: indirect indirect comparison; survival. survival.",
      "start_page": 196,
      "end_page": 196
    },
    {
      "heading": "SET SET 2",
      "text": "Key: indirect indirect comparison; Ø Ø +medicera medicera aadet@@medici inraade",
      "start_page": 196,
      "end_page": 196
    },
    {
      "heading": "Page 190/237",
      "text": "Proprietary Proprietary - in in Error! found. found..",
      "start_page": 196,
      "end_page": 197
    },
    {
      "heading": "X",
      "text": "Key: Doc, docetaxel; KM, Kaplan-Meier; indirect indirect comparison; OS, overall survival; Sot, sotorasib.",
      "start_page": 197,
      "end_page": 197
    },
    {
      "heading": "Progression-free Progression-free survival",
      "text": "14. 14.",
      "start_page": 197,
      "end_page": 198
    },
    {
      "heading": "SET SET 2",
      "text": "Key: indirect indirect comparison; survival. survival.",
      "start_page": 198,
      "end_page": 198
    },
    {
      "heading": "SET SET 2",
      "text": "Key: indirect indirect comparison; Ø Ø +medicinera medicinera aadet@@medici inraade",
      "start_page": 198,
      "end_page": 198
    },
    {
      "heading": "Page 192/237",
      "text": "Proprietary Proprietary - Use Use Only",
      "start_page": 198,
      "end_page": 199
    },
    {
      "heading": "SET SET 2",
      "text": "Key: indirect indirect comparison; in in Error! found. found..",
      "start_page": 199,
      "end_page": 199
    },
    {
      "heading": "X",
      "text": "Key: Doc, docetaxel; KM, Kaplan·Meier; indirect indirect comparison; __MEDTERM0_, progress",
      "start_page": 199,
      "end_page": 199
    },
    {
      "heading": "MAIC MAIC analysis",
      "text": "2 2 (1) of Regulation (EU) No 575/2013. • overlap overlap (_MEDTERM0_, anti-prior prior lines) data data (% patients. patients. • metastases metastases (brain brain metases) was was 21% years. years.",
      "start_page": 199,
      "end_page": 201
    },
    {
      "heading": "score score analysis",
      "text": "25,9$$$===%== %==#==[%=%&%= ###=###[*]##_[[[-[-][- [-]#[- ]#[[ -][[S][ -[-T][A]][ [-[B]]] _ [- [S] , [- (S] - [T] - ...[- and [- S] - [...] - [- ] - [[- T] -[S ] -[G] -",
      "start_page": 201,
      "end_page": 202
    },
    {
      "heading": "Index Index date",
      "text": "as as follows: • received received ≥ 2 but ≤ theory theory on/selected. selected. • lines lines on/2020. 2020.",
      "start_page": 202,
      "end_page": 202
    },
    {
      "heading": "Analysis Analysis sets",
      "text": "were were considered: Page Page 196/Ø Ø +00 00 mediceraadet@Proprietary Proprietary - time time on/CodeBreak. CodeBreak.",
      "start_page": 202,
      "end_page": 203
    },
    {
      "heading": "expert expert elicitation",
      "text": "presented presented (Table 61). Page 197/Ø Ø +36 36 00medicinraadet@Proprietary Proprietary - Use Use Only",
      "start_page": 203,
      "end_page": 204
    },
    {
      "heading": "Covariate Include (Y/N) Adjustment",
      "text": "baseline baseline (Y; N) were were lower; expression expression (<1%, 1-49%, <50%) No PD- anti anti PD-(L)with with anti-sheet. sheet.",
      "start_page": 204,
      "end_page": 204
    },
    {
      "heading": "Page 198/237",
      "text": "Ø Ø +36 36 00medicinraadet@Proprietary Proprietary - Use Use Only",
      "start_page": 204,
      "end_page": 205
    },
    {
      "heading": "patient patient disposition",
      "text": "presented presented (Error! found. found.).",
      "start_page": 205,
      "end_page": 205
    },
    {
      "heading": "baseline baseline characteristics",
      "text": "mutant mutant (Error! Figure Figure 20).",
      "start_page": 205,
      "end_page": 205
    },
    {
      "heading": "X X X",
      "text": "Ø Ø +36 36 00medicinraadet@idea idea 199/237 et.dm",
      "start_page": 205,
      "end_page": 205
    },
    {
      "heading": "X",
      "text": "etary etary - Ø Ø + Use Use Only",
      "start_page": 206,
      "end_page": 206
    },
    {
      "heading": "X",
      "text": "+y y dicinraad",
      "start_page": 206,
      "end_page": 206
    },
    {
      "heading": "X",
      "text": "it@medicra aadet.dk",
      "start_page": 206,
      "end_page": 206
    },
    {
      "heading": "X",
      "text": "idea idea 200/237 et.dk",
      "start_page": 206,
      "end_page": 206
    },
    {
      "heading": "X",
      "text": "etary etary - Use Use Only",
      "start_page": 207,
      "end_page": 207
    },
    {
      "heading": "X",
      "text": "avn Ø +with with y",
      "start_page": 207,
      "end_page": 207
    },
    {
      "heading": "X",
      "text": "dicinraad",
      "start_page": 207,
      "end_page": 207
    },
    {
      "heading": "X",
      "text": "it@medicra aadet.dk",
      "start_page": 207,
      "end_page": 207
    },
    {
      "heading": "X",
      "text": "idea idea 201/237 et.dk",
      "start_page": 207,
      "end_page": 207
    },
    {
      "heading": "X",
      "text": "etary etary - Use Use Only",
      "start_page": 208,
      "end_page": 208
    },
    {
      "heading": "X",
      "text": "avn Ø +y y dicinraad",
      "start_page": 208,
      "end_page": 208
    },
    {
      "heading": "X",
      "text": "it@medicra aadet.dk",
      "start_page": 208,
      "end_page": 208
    },
    {
      "heading": "X",
      "text": "idea idea 202/Proprietary Proprietary - Use Use Only",
      "start_page": 208,
      "end_page": 209
    },
    {
      "heading": "KRAS KRAS mutant",
      "text": "Key: mass mass index; DUR, duration; Oncology Oncology Group; ETHN, metastatic; PREV, previous Note: for for binary/of of > 10% Ø Ø +00 00 medikraad",
      "start_page": 209,
      "end_page": 209
    },
    {
      "heading": "X X",
      "text": ", ethnicity; GRP, group; for for det@Page Page 203/Proprietary Proprietary - Use Use Only",
      "start_page": 209,
      "end_page": 210
    },
    {
      "heading": "Flatiron Flatiron KRAS-G12C",
      "text": "Key: mass mass index; DUR, duration; Oncology Oncology Group; ETHN, ethnicity; GRP, group; __MEDTERM0_, metastatic; PREV, previous Note: for for binary/of of > 10% considered impaired",
      "start_page": 210,
      "end_page": 210
    },
    {
      "heading": "analysis analysis methods",
      "text": "analysis. analysis.",
      "start_page": 210,
      "end_page": 210
    },
    {
      "heading": "CodeBreak CodeBreak 100",
      "text": "107 107 (3) (c) Treaty. Treaty.",
      "start_page": 210,
      "end_page": 211
    },
    {
      "heading": "in in Flatiron",
      "text": "__MEDTERM0_ __MEDTERM0_ (rw_MEDTERM0__) report. report.",
      "start_page": 211,
      "end_page": 211
    },
    {
      "heading": "Covariates",
      "text": "physicians physicians (76). interviewed interviewed (oncsists oncsists interviewed): • Baseline ECOG (0 or 1) • metastases metastases (Y; N) • baseline baseline (Y); N) Ø Ø +00 00 medicraadet@idea idea 205/Proprietary Proprietary - Only Only • date date (<6 6 months) • baseline baseline • Liver function (ALT, AST) at baseline",
      "start_page": 211,
      "end_page": 212
    },
    {
      "heading": "Analysis Analysis methods",
      "text": "problem. problem.",
      "start_page": 212,
      "end_page": 212
    },
    {
      "heading": "Analysis set",
      "text": "criteria criteria included: • __MEDTERM0_A __MEDTERM0_A • an an anti-PD(L)anti anti PD-(L),lines, lines, • Baseline ECOG ≤ other other non-time time on/the the patient's decision.",
      "start_page": 212,
      "end_page": 213
    },
    {
      "heading": "Statistical Statistical methods",
      "text": "as as follows: weight. weight.",
      "start_page": 213,
      "end_page": 213
    },
    {
      "heading": "model model development",
      "text": "AIC AIC (to be limited) information. information.",
      "start_page": 213,
      "end_page": 213
    },
    {
      "heading": "Balance diagnostics",
      "text": "following following criteria:",
      "start_page": 213,
      "end_page": 214
    },
    {
      "heading": "adjustment adjustment method",
      "text": "applied applied (136, 137). weight weight scores: treated treated (sotorasib) equivalent. equivalent.",
      "start_page": 214,
      "end_page": 214
    },
    {
      "heading": "Effective sample size",
      "text": "size size (ESS). as as follows: ESS = . Ø Ø +mediciner mediciner Vervad@endraformik.",
      "start_page": 214,
      "end_page": 215
    },
    {
      "heading": "Missing values",
      "text": "information information (n=7), presented presented (Table 62). (g/l) 1 (0.8) BMI (kg/m2) n (%) 11 (0.0.8) n (%) 85 (37.8) 1 (0.8) 1 (0.8) n % n (%) 12 (5.3) 1 (0.3) n (%) 7 (3.3) 1 (0.1) 3 (2.4) Smoking history",
      "start_page": 215,
      "end_page": 216
    },
    {
      "heading": "Efficacy Efficacy results",
      "text": "weighting weighting (Figure 23), balanced. balanced.",
      "start_page": 216,
      "end_page": 216
    },
    {
      "heading": "Key: None",
      "text": "Weighting Weighting Key: Side Side 210/Ø Ø +36 36 00medicinraadet@Proprietary Proprietary - good good (Figure Figure 25). as as •outliers",
      "start_page": 216,
      "end_page": 217
    },
    {
      "heading": "Key: None",
      "text": "Weighting Weighting Key: Page Page 211/Ø Ø +00 00 medikraadet@Proprietary Proprietary - 26. 26.",
      "start_page": 217,
      "end_page": 218
    },
    {
      "heading": "Analysis Analysis Set",
      "text": "Key: differences differences >0.1; p-value p-value < Page Page 212/Ø Ø +00 00 medicineraadet@Proprietary Proprietary - limited limited (99.5% v. v.",
      "start_page": 218,
      "end_page": 219
    },
    {
      "heading": "sample sample size",
      "text": "mutation mutation (any type) 206 206 (adjuvanted adjuvanted (Table 63). 85 85 (unaided) Sotorasib Sotorasib KRA'Adjusted Adjusted (ATT) 104.8 119",
      "start_page": 219,
      "end_page": 219
    },
    {
      "heading": "G12C",
      "text": "Adjusted Adjusted (ATT) 119 119 Key: the the treated",
      "start_page": 219,
      "end_page": 219
    },
    {
      "heading": "analysis analysis results",
      "text": "Flatiron Flatiron KRA",
      "start_page": 219,
      "end_page": 219
    },
    {
      "heading": "mutation. mutation.",
      "text": "(Figure Figure 29), Model 2 (Figure Figure 31) 3 3 (Figure Figure 33). Ø Ø +00 00 medicierraadet@ely ely ed) ide ide 213/Proprietary Proprietary - Use Use Only",
      "start_page": 219,
      "end_page": 220
    },
    {
      "heading": "Flatiron Flatiron KRAS G12C",
      "text": "Key: mass mass index; DUR, duration; Oncology Oncology Group; ETHN, ethnicity; GRP, group; __MEDTERM0_, metastatic; PREV, previous Note: for for binary/of of > 10% considered impaired",
      "start_page": 220,
      "end_page": 220
    },
    {
      "heading": "KRAS KRAS Mutant",
      "text": "Key: mass mass index; DUR, duration; Oncology Oncology Group; ETHN, ethnicity; GRP, group; __MEDTERM0_, metastatic; PREV, previous Note: for for binary/of of > 10% Ø Ø +www. www.medic",
      "start_page": 220,
      "end_page": 220
    },
    {
      "heading": "Page 214/237",
      "text": "Proprietary Proprietary - Use Use Only",
      "start_page": 220,
      "end_page": 221
    },
    {
      "heading": "Flatiron Flatiron KRAS G12C",
      "text": "Key: mass mass index; DUR, duration; Oncology Oncology Group; ETHN, ethnicity; GRP, group; __MEDTERM0_, metastatic; PREV, previous Note: for for binary/of of > 10% Mutant Mutant Key: Body Mass Index; DU, Duration; Cooperation Cooperation Unit; ETHN, ethnicity; GRP, group",
      "start_page": 221,
      "end_page": 221
    },
    {
      "heading": "Page 215/237",
      "text": "Proprietary Proprietary - Use Use Only",
      "start_page": 221,
      "end_page": 222
    },
    {
      "heading": "Flatiron Flatiron KRAS G12C",
      "text": "Key: mass mass index; DUR, duration; Oncology Oncology Group; ETHN, ethnicity; GRP, group; __MEDTERM0_, metastatic; PREV, previous Note: for for binary/of of > 10% Mutant Mutant Key: Body Mass Index; DU, Duration; Cooperation Cooperation Unit; ETHN, ethnicity; GRP, group",
      "start_page": 222,
      "end_page": 222
    },
    {
      "heading": "Page 216/237",
      "text": "Proprietary Proprietary - Use Use Only",
      "start_page": 222,
      "end_page": 223
    },
    {
      "heading": "using using Flatiron",
      "text": "MAC MAC analysis: (i) anti anti PD-(L)landscapes landscapes (ii) adjustment. adjustment.",
      "start_page": 223,
      "end_page": 223
    },
    {
      "heading": "Flatiron Flatiron database",
      "text": "2 2 (1) of Regulation (EU) No 182/the the Commission'Regulation. Regulation.",
      "start_page": 223,
      "end_page": 224
    },
    {
      "heading": "analysis analysis results",
      "text": "important important , default default (altars altars (or or ROS-1)), the following •price price , selection selection procedure: baseline. baseline.",
      "start_page": 224,
      "end_page": 224
    },
    {
      "heading": "ECOG: 1 74.27% 70.59% 70.46%",
      "text": "Gain of metastasic_property: Yes 28.16% 20.89% 92. 92.72% 97.48% 97.88% Presence of __MEDTERM0_/_MEDTERM1_/BRAF/8. 8.25% 3.36% 3.43% Age (categories) 43. 43.20% 52.10% 50.82% 33. 33.98% 39.50% 41.02% ≥ 22. 22.82% 8.40% 8.15% Ø Ø +00 00 medicraadet@ide ide 218/Proprietary Proprietary - Prior Prior PD-(L) 1 immunotherapy: Yes 73.30% platinum-based platinum-based chemotherapy: Yes 84.47% 89.08 Alminaft; Ø Ø +00 00 medicraadet@Gro Gro -for for cant",
      "start_page": 224,
      "end_page": 226
    },
    {
      "heading": "comparator comparator cohort",
      "text": "chemotherapy chemotherapy (from 31.07% to 23.04% main main •KRA mutant^ analysis), ramucirumab ramucirumab (fro 21.84% to 34.20% in the KRA's mutant",
      "start_page": 226,
      "end_page": 226
    },
    {
      "heading": "(N = 206) (N= 120.57)",
      "text": "31. 31.07% 23. 23.04% Chemotherapie monotherapy (including docetaxel) 61 29.61% 26. 26.94% 21. 21.84% 34. 34.20% 10. 10.19% 10. 10.09% 7. 7.28% 5. 5.73%",
      "start_page": 226,
      "end_page": 226
    },
    {
      "heading": "(N = 85) (N= 133.11)",
      "text": "29. 29.41% 17. 17.90% Chemotherapy monotherapy (excluding docetaxel) 24 28.24% 22. 22.85% 21. 21.18% 48. 48.21% 12. 12.94% 6. 6.43% 8. 8.24% 4. 4.61% Ø Ø +00 00 medicieraadet@ide ide 220/Proprietary Proprietary - Use Use Only",
      "start_page": 226,
      "end_page": 227
    },
    {
      "heading": "2 2 Results",
      "text": "p. p.G12C",
      "start_page": 227,
      "end_page": 227
    },
    {
      "heading": "HR (95% CI) G12C G12C only",
      "text": "Cohort.",
      "start_page": 227,
      "end_page": 227
    },
    {
      "heading": "Overall Overall survival",
      "text": "14 14 (88). fitting fitting (restricted restricted models) R R (0. 0.3) between between .of of goodness-distribution distribution (Table 67). States. States.",
      "start_page": 227,
      "end_page": 228
    },
    {
      "heading": "X",
      "text": "valid. valid.",
      "start_page": 228,
      "end_page": 229
    },
    {
      "heading": "and and Control",
      "text": "Key: survival. survival.",
      "start_page": 229,
      "end_page": 229
    },
    {
      "heading": "and and Control",
      "text": "Key: Ø Ø +dicinraad dicinraad det@w. w.medic",
      "start_page": 229,
      "end_page": 229
    },
    {
      "heading": "Page 223/237",
      "text": "Proprietary Proprietary - Use Use Only",
      "start_page": 229,
      "end_page": 230
    },
    {
      "heading": "and and Control",
      "text": "Key: fitted fitted (restrictive model) dataset. dataset.",
      "start_page": 230,
      "end_page": 230
    },
    {
      "heading": "Progression-free Progression-free survival",
      "text": "14 14 (88) fitting fitting (restricted restricted model) R R (0. 0.3) and and log-of of goodness-of-fit statistics (finished finished models) carrier carrier (Table 68). data. data.",
      "start_page": 230,
      "end_page": 231
    },
    {
      "heading": "X",
      "text": "plots plots (plot plot (Figure 38). plot plot (Figure 39). Control Control Key: survival. survival.",
      "start_page": 231,
      "end_page": 232
    },
    {
      "heading": "and and Control",
      "text": "Key: survival. survival.",
      "start_page": 232,
      "end_page": 232
    },
    {
      "heading": "and and Control",
      "text": "Key: Ø Ø +dicinraad dicinraad det@w. w.medic",
      "start_page": 232,
      "end_page": 232
    },
    {
      "heading": "Page 226/237",
      "text": "Proprietary Proprietary - monotherapy monotherapy (Flutiron Flutiron real-worth",
      "start_page": 232,
      "end_page": 233
    },
    {
      "heading": "at at X) indicating indicating that",
      "text": "treatment. treatment.",
      "start_page": 233,
      "end_page": 233
    },
    {
      "heading": "X",
      "text": "Ø Ø +36 36 00medicinraadet@idea idea 227/Proprietary Proprietary - Use Use Only",
      "start_page": 233,
      "end_page": 234
    },
    {
      "heading": "X",
      "text": "Key: treated treated Note: each each arm",
      "start_page": 234,
      "end_page": 234
    },
    {
      "heading": "Progression-free Progression-free survival",
      "text": "KRAS KRAS mutant~ in in Error! and and Error! found found . Cox Cox proportion",
      "start_page": 234,
      "end_page": 234
    },
    {
      "heading": "and and X) adjustment, adjustment, indicatin",
      "text": "PFS PFS (ATT ATT weighting).Ø Ø +00 00 medicierraadet@Side Side 228/Proprietary Proprietary - Use Use Only",
      "start_page": 234,
      "end_page": 235
    },
    {
      "heading": "X",
      "text": "Key: treated treated Note: Ø Ø +arm arm det@Side Side 229/Proprietary Proprietary - Use Use Only",
      "start_page": 235,
      "end_page": 236
    },
    {
      "heading": "Overall Overall survival",
      "text": "explorery explorery •p.G12C-only • in in Error! and and Error! notfound. notfound., mutant mutant • Cox Cox proportion",
      "start_page": 236,
      "end_page": 236
    },
    {
      "heading": "sotorasib sotorasib productions",
      "text": "treatment. treatment.",
      "start_page": 236,
      "end_page": 236
    },
    {
      "heading": "X",
      "text": "Ø Ø +00 00 medicieraadet@Side Side 230/Proprietary Proprietary - Use Use Only",
      "start_page": 236,
      "end_page": 237
    },
    {
      "heading": "X",
      "text": "Key: treated treated Note: each each arm",
      "start_page": 237,
      "end_page": 237
    },
    {
      "heading": "Progression-free Progression-free survival",
      "text": "the the .in in Error! and and Error! main main •KRAS mutant^ Cox Cox proportion",
      "start_page": 237,
      "end_page": 237
    },
    {
      "heading": "sotorasib sotorasib produce",
      "text": "PFS PFS (statistically statistically significant).Ø Ø +Page Page 231/Proprietary Proprietary - Use Use Only",
      "start_page": 237,
      "end_page": 238
    },
    {
      "heading": "X",
      "text": "Key: treated treated Note: Ø Ø +arm arm det@Side Side 232/Proprietary Proprietary - Use Use Only",
      "start_page": 238,
      "end_page": 239
    },
    {
      "heading": "estimate estimate EQ-values values using",
      "text": "trial trial (as as monotherapy), measures measures (PROMs): EORTC QLQ-",
      "start_page": 239,
      "end_page": 239
    },
    {
      "heading": "PGIS, PGIS, EQ-are are required",
      "text": "economic economic modelling; subgroups. subgroups.",
      "start_page": 239,
      "end_page": 239
    },
    {
      "heading": "Study 20170543 (CodeBreak 100)",
      "text": "and and safety/as as monotherapy",
      "start_page": 239,
      "end_page": 239
    },
    {
      "heading": "PROM assessments",
      "text": "this this study: PIGIS, PIGIS, EQ-",
      "start_page": 239,
      "end_page": 239
    },
    {
      "heading": "PRO-CTCAE. PRO-CTCAE.",
      "text": "cycle cycle (cycle length: 21 days) visit. visit.",
      "start_page": 239,
      "end_page": 239
    },
    {
      "heading": "EQ-5D-5L",
      "text": "5 5 dimensions: activities, activities, pain/discomfort, and anxiety/of of responses: problems. problems.",
      "start_page": 239,
      "end_page": 239
    },
    {
      "heading": "Score Score (VAS): The last EQ-on on a",
      "text": "as as \"can can imaginable' as as \"can can imagine'.• of of ...Ø Ø +00 00 medicraadet@idea idea 233/Proprietary Proprietary - difference difference (MID) patients patients (139,",
      "start_page": 239,
      "end_page": 240
    },
    {
      "heading": "utility utility scores",
      "text": "The EQ-values values (or or tariffs) each each dimension",
      "start_page": 240,
      "end_page": 240
    },
    {
      "heading": "EQ-5D-5L Denmark Index",
      "text": "Denmark Denmark EQ-5D-5L value set(86). 1 1 (full health) to -0.757 (worse than death). Denmark Denmark index; MID MID (UK Index: 0.08) MID. MID.",
      "start_page": 240,
      "end_page": 240
    },
    {
      "heading": "of of interest",
      "text": "status status (pre- and",
      "start_page": 240,
      "end_page": 240
    },
    {
      "heading": "post-progress response), tumour response (cycle cycle 3), status, status,",
      "text": "as as follows:",
      "start_page": 240,
      "end_page": 240
    },
    {
      "heading": "Progression status",
      "text": "definition. definition.",
      "start_page": 240,
      "end_page": 240
    },
    {
      "heading": "used. used. EQ-5D-5L ratings were",
      "text": "of of EQ-missing. missing.",
      "start_page": 240,
      "end_page": 240
    },
    {
      "heading": "ECOG score",
      "text": "of of EQ-5D-5L assessment within",
      "start_page": 240,
      "end_page": 240
    },
    {
      "heading": "coded coded as",
      "text": "Missing.",
      "start_page": 240,
      "end_page": 240
    },
    {
      "heading": "Treatment status",
      "text": "used. used. EQ-as as on- as as follows: Ø Ø +00 00 medicraadet@ide ide 234/Proprietary Proprietary - Only Only • date date • interruption interruption date",
      "start_page": 240,
      "end_page": 241
    },
    {
      "heading": "Time to death",
      "text": "date. date. EQ-as as follows: • date date - date date ≤30 • 31 31 ≤ Death date- PRO assessmentdate ≤90 • 91 91 ≤ Death Date - date date ≤183 • ≥date date - date date ≥date date -PRO assessment date≥missing missing (i.e. censored) and",
      "start_page": 241,
      "end_page": 241
    },
    {
      "heading": "Advertise events - Anemia",
      "text": "EQ-of of EQ-5-several, several, mild/as as follows: • Severe: event event (emergent or about) assessment assessment • Mild/moderate: events events (empergent or ongoing) an an .EQ-5L assessment ● Absent: incident incident (extragent or only) an an eq-5D/5L assessment",
      "start_page": 241,
      "end_page": 241
    },
    {
      "heading": "Statistical methodology",
      "text": "the the EQ-index index (dimensions dimensions complete) measures measures (MMRMs): subsequent subsequent EQ/0. 0.",
      "start_page": 241,
      "end_page": 242
    },
    {
      "heading": "descriptive descriptive statistics",
      "text": "for for EQ-Follow-Up Follow-Up (complete complete assessment). box box plots(141) missing missing EQ-5-analyses. analyses.",
      "start_page": 242,
      "end_page": 242
    },
    {
      "heading": "baseline baseline MMRM",
      "text": "visit visit (categorical) effect effect (repeated by subject). squares squares (LS) and and 95% confidence intervals (CIs) presented. presented.",
      "start_page": 242,
      "end_page": 242
    },
    {
      "heading": "values values MMRM",
      "text": "random. random.(143), studies. studies.(143, 144) visit visit (and and follow-up) matrix. matrix.",
      "start_page": 242,
      "end_page": 242
    },
    {
      "heading": "Subject population",
      "text": "the the EQ-5-values values (see main body). Ø Ø +00 00 medikraadet@ide ide 236/23/Proprietary Proprietary - subsequent subsequent EQ/MMRMs. MMRMs.",
      "start_page": 242,
      "end_page": 243
    },
    {
      "heading": "Completion rates",
      "text": "the the EQ-70. 70.97% below below 50% least least 70% 23. 23.",
      "start_page": 243,
      "end_page": 243
    },
    {
      "heading": "Table 69. EQ-time time points",
      "text": "40 mg/17. 17.74% 73.33% 18. 18.55% 79.31% 29. 29.84% 75.51% 25. 25.81% 72.73% 7. 7.4% 73.37% 18. 18.51% 79.32% 14. 14.52% 78.26% 25. 25.13%",
      "start_page": 243,
      "end_page": 243
    },
    {
      "heading": "heading heading DBS, SNI",
      "text": "Row 1:\nin in #28.09.2022;Row 2:\n•Medical Council •Row 3:\nProvider • AverageRow 4:\n• Medicinal product • Lumykras (sotorasib)Row 5:\nRequested indication • with with __MEDTERM0_-mutation",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "heading heading DBS, SNI",
      "text": "Row 1:\n•Row 2:\nFalse/Strengthening • AIP·Currently negotiated • RowRow 3:\n• SAIP~RowRow 4:\n■Row 5:\n• Lumykras •120 mg/stk^240 stk. •13 13 • 13 13 •XXxxX",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "heading heading DBS, SNI",
      "text": "Row 1:\n Row 2:\nXX",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "heading heading DBS, SNI",
      "text": "Row 1:\nXxxXXX_XX XX",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "heading heading DBS, SNI (from previous page)",
      "text": "Row 1:\nepi epi 2: XX29/XX ECRXX",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "heading heading DBS, SNI (from previous page)",
      "text": "Row 1:\n•Row 2:\nPick up/dosing • Packing price • Number of packs/year • RowRow 3:\n•SAIP·Row 4:\n■Row 5:\nLumykras (sotorasib) •120 mg/stk. •XXxxXXX",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "heading heading DBS, SNI (from previous page)",
      "text": "Row 1:\nRowRow 2:\npacks/year",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "heading heading DBS, SNI (from previous page)",
      "text": "Row 1:\nLumykrasRow 2:\n(sotorasib)",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "heading heading DBS, SNI (column column 1)",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nXXRXX XXRXX orXX",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "heading heading DBS, SNI (column column 1)",
      "text": "Row 1:\n•Row 2:\nPick up/dosing • RowRow 3:\n▪Row 4:\nLumykras (sotorasib) • 120 mg/tk•240 stk.•Row 5:\n• single single •Row 6:\nday-to-day (8°Row 7:\ntk) ■Row 8:\nDocetaxel (Kabi) ~ 80 mg/75 75 mg/days days •",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "heading heading DBS, SNI (column column 2)",
      "text": "Row 1:\nXXXRow 2:\nRowRow 3:\nXXxxXXxxRow 4:\nXX_XX",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "heading heading DBS, SNI (column column 2)",
      "text": "Row 1:\n•Row 2:\n• RowRow 3:\n• SAIPRow 4:\n•Row 5:\n• XX",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "heading heading DBS, SNI (column column 3)",
      "text": "Row 1:\nXRow 2:\nXRow 3:\nXXxxRow 4:\nXXX",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "heading heading DBS, SNI (column column 3)",
      "text": "Row 1:\n•Row 2:\n• An paknin·AnRow 3:\n• Paknin-Row 4:\n■Row 5:\n~Row 6:\nX^12; •",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "heading heading DBS, SNI (column column 4)",
      "text": "Row 1:\nXXRow 2:\nXX Raw 3: XX",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "heading heading DBS, SNI (column column 4)",
      "text": "Row 1:\n Row 2:\nNtalRow 3:\nreg/yRow 4:\n Row 5:\n Row 6:\n Row 7:\n,18",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "heading heading DBS, SNI (column column 5)",
      "text": "Row 1:\nXXXRow 2:\nXRow 3:\nXXxxXXx",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "heading heading DBS, SNI (column column 5)",
      "text": "Row 1:\n•Row 2:\n• RowRow 3:\nyear • Raw 4: • RowRow 5:\n■Row 6:\n•XX~",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "heading heading DBS, SNI (column column 6)",
      "text": "Row 1:\n Row 2:\nmeanpRow 3:\nRowRow 4:\n Row 5:\n Row 6:\n Row 7:\nXXRow 8:",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "heading heading DBS, SNI (column column 7)",
      "text": "Row 1:\n Row 2:\nPriceRow 3:\n Row 4:\nX",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "heading heading Amgen Amgen Denmark",
      "text": "Row 1:\nContact information •Row 2:\nName • Nicholas Sroczynski",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "heading heading Amgen Amgen Denmark",
      "text": "Row 1:\nJannick Burmester",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "heading heading Amgen Amgen Denmark (column 1)",
      "text": "Row 1:\nRow",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "heading heading Amgen Amgen Denmark (column 2)",
      "text": "Row 1:\n▪Row 2:\nNicholas Sroczynski",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "heading heading Amgen Amgen Denmark (column 2)",
      "text": "Row 1:\nJannick Burmester",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "heading heading  units, and concentrations (from previous page)",
      "text": "Row 1:\nAbbreviation term·Definition",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "heading heading  units, and concentrations (column column 8)",
      "text": "Row 1:\n• Define",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "heading heading 5 5 Epidemiology",
      "text": "Row 1:\nBaseline characteristics...DanishRow 2:\n__KRAS G12CRow 3:\n•patients",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "heading heading 5 5 Epidemiology",
      "text": "Row 1:\nAnalysis Set...N°event. event.. ..Median OS, Months^6-month __medterm0_,...RowRow 2:\n•95% CI) •% (95% CI) =% (95%CI)Row 3:\n·",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "heading heading 5 5 Epidemiology",
      "text": "Row 1:\nAnalysis Set...N°event. event.. ..Median OS, Months^6-month __medterm0_,...RowRow 2:\n•95% CI) •% (95% CI) =% (95%CI)Row 3:\n·",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "heading heading 5 5 Epidemiology",
      "text": "two. two...",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "heading heading treatment treatment options",
      "text": "Row 1:\nYear-to-date 2022°2023°2024°2025°2026",
      "start_page": 30,
      "end_page": 30
    },
    {
      "heading": "heading heading treatment:",
      "text": "Row 1:\nSubject·Description",
      "start_page": 32,
      "end_page": 32
    },
    {
      "heading": "heading heading other other medications",
      "text": "Row 1:\nSubject·Description",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "heading heading and and safety",
      "text": "Row 1:\nReference: RowRow 2:\n(journal, year)",
      "start_page": 35,
      "end_page": 35
    },
    {
      "heading": "100 100 results",
      "text": "Row 1:\n\"N·mOSRow 2:\nPatient subgroups•Row 3:\n\"(_OS_) '\"months (95% CI)Row 4:\n\"",
      "start_page": 36,
      "end_page": 36
    },
    {
      "heading": "100 100 results",
      "text": "Row 1:\nOutcome-Study arm...N..Result-Reference.",
      "start_page": 36,
      "end_page": 36
    },
    {
      "heading": "SELECT-1 SELECT-1 results",
      "text": "Row 1:\n•Outcome •Student arm •N·Result (IQR) •References •",
      "start_page": 39,
      "end_page": 39
    },
    {
      "heading": "heading heading MAIC MAIC overview",
      "text": "Row 1:\nElement...Sotorasib (CodeBreak 100)..Docetaxel (SELECT-1)Row 2:\nBlinding...\"Open label..Double-blindedRow 3:\nInclusion criteria.. ..patients patients (> 18 years) patients patients (>18 years)",
      "start_page": 42,
      "end_page": 42
    },
    {
      "heading": "heading heading Population Population characteristics",
      "text": "Row 1:\nRowRow 2:\nReceived Received > drug drug regiment",
      "start_page": 43,
      "end_page": 43
    },
    {
      "heading": "heading heading MAIC MAIC approach",
      "text": "Row-right- right-way- right stock- holder-right, right- right square- right stone- right. right.N= 256Row 2:\nAge (mean) RowRow 3:\nGender (% feale) Gender#43%Row 4:\nBrain metastases (%) +21% /NRbRow 5:\nECOG (% PS 1 [vs PS 0]) ] •70% ♫59%Row 6:\nRace (% white) ^82%RowRow 7:\n% KRAS-G12C+100% .42%Row 8:\nAnti-PD-(L) line line lines)",
      "start_page": 44,
      "end_page": 44
    },
    {
      "heading": "heading heading Category Covariate",
      "text": "RowRowway RowRowway 1: Category ♪CovariateRow 2:\nECOG ECOG (0, 1) *Row 3:\nmetastases metastases (Y, N)Row 4:\n#baseline baseline (Y; N) *Row 5:\n•expression expression (<5%, >5%)Row 6:\nfollowing following mutations/alterations: ROS-1 ROS-1 (Y), N) Now 7: Sonewhat importerAge *Row 8:\nSmoking status (of of smoking) * Raw 9:",
      "start_page": 45,
      "end_page": 45
    },
    {
      "heading": "heading heading Category Covariate (column 1)",
      "text": "Row 1:\nCategoryRow 2:\nRowRow 3:\nRowRow 4:\nother other MAIC",
      "start_page": 45,
      "end_page": 45
    },
    {
      "heading": "heading heading MAIC MAIC Results",
      "text": "Row 1:\nCovariates...important important (Set1) •variables variables (Set2)Row 2:\nECOG (% PS 1 [vs PS 0]) •X • XRow 3:\nAge (mean) ~XRow 4:\nbaseline baseline (% IIIB [ivs IV]) ■X ~Row 5:\nSmoking status (% ever smoker) \\X ^XRow 6:\nlevel level }XRow 7:\nGender (% female) ♫XRow 8:\nHistology (% Non-squamous) ►XRow 9:\nRace (% white) /*XRow 10:\nKey: Oncology Oncology Group; status. status.",
      "start_page": 46,
      "end_page": 46
    },
    {
      "heading": "heading heading MAIC MAIC Results",
      "text": "Row 1:\nX°X",
      "start_page": 46,
      "end_page": 46
    },
    {
      "heading": "heading heading MAIC MAIC Results",
      "text": "Row 1:\nRowRow 2:\nCovariatesSELECT-1•CodeBreak 100·CodeBreak 100-Row 3:\nAge (mean) RowRow 4:\nECOG (% PS 1 [vs PS 0]) 59% · 70% · 59%Row 5:\nbaseline baseline (% IIIB (vs IV]) 96% *96% •96%Row 6:\nSmoking status (% ever smoker) 92% b^92%Row 7:\nKey: Oncology Oncology Group; PD-(L1), death-ligand death-ligand 1; status. status. Note: 2 2 percent",
      "start_page": 46,
      "end_page": 46
    },
    {
      "heading": "heading heading XXX XX",
      "text": "Row 1:\nXXRow 2:\nX A B",
      "start_page": 48,
      "end_page": 48
    },
    {
      "heading": "heading heading XXX XX",
      "text": "Row 1:\nXXRow 2:\nA B",
      "start_page": 48,
      "end_page": 48
    },
    {
      "heading": "heading heading XXX XX",
      "text": "Row 1:\nX° X° x° X' X'X' X",
      "start_page": 48,
      "end_page": 48
    },
    {
      "heading": "heading heading adverse adverse events",
      "text": "Row 1:\nX· X* X * X *Row 2:\nX^ X * x *Row 3:\nX ■ X * ~ X ~ ~",
      "start_page": 49,
      "end_page": 49
    },
    {
      "heading": "heading heading adverse adverse events (from previous page)",
      "text": "Row 1:\nTreatment n (%) • treatment treatment •References",
      "start_page": 50,
      "end_page": 50
    },
    {
      "heading": "heading heading adverse adverse events (from previous page)",
      "text": "Row 1:\nAdvertise events... Sotorasib (CodeBreak-100)*·Docetaxel + placebo (SELECT-1)**",
      "start_page": 50,
      "end_page": 50
    },
    {
      "heading": "heading heading adverse adverse events (column column 1)",
      "text": "Row 1:\nTreatment N",
      "start_page": 50,
      "end_page": 50
    },
    {
      "heading": "heading heading adverse adverse events (column column 1)",
      "text": "Row 1:\nRow",
      "start_page": 50,
      "end_page": 50
    },
    {
      "heading": "heading heading adverse adverse events (column column 2)",
      "text": "Row 1:\n•n (%) •",
      "start_page": 50,
      "end_page": 50
    },
    {
      "heading": "heading heading adverse adverse events (column column 2)",
      "text": "Row 1:\nSotorasib (CodeBreak-100)*·Docetaxel + placebo (SELECT-1)**",
      "start_page": 50,
      "end_page": 50
    },
    {
      "heading": "Table 19.",
      "text": "Row 1:\nPatient population...Clinical documentation /•model. model.. ..RowRow 2:\n\"etc. etc...\" \"Including source\"Row 3:\nImportant baseline \"Row 4:\ncharacteristics·",
      "start_page": 54,
      "end_page": 54
    },
    {
      "heading": "Table 21. Comparator",
      "text": "Row 1:\nIntervention·Clinical documentation·model model \"RowRow 2:\n\"(including source') '; (number/practice practice (RowRow 3:\n\"Row 4:\n'source) '; 'if known)Row 5:\n\"",
      "start_page": 55,
      "end_page": 55
    },
    {
      "heading": "Table 21. Comparator",
      "text": "Row 1:\nmodel. model...RowRow 2:\n•(including source) • (number/value including • practice (including source)Row 3:\n•Row 4:\n•source) ■Row 5:\n▪",
      "start_page": 55,
      "end_page": 55
    },
    {
      "heading": "Table 22.",
      "text": "Row 1:\noutcome outcome Sotorasiba·Docetaxelb",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "heading heading A B",
      "text": "Row 1:\nX •Row 2:\nX ~X ~ X ■Row 3:\nX ^X \\X __X } ~Row 4:\nX ·X • X £X −Row 5:\n~x ~ x ~ ~ * X ►Row 6:\nKey: CI, confidence interval; sample sample size; HR, hazard ratio; indirect indirect comparison; mth, months; OS, overall survival; ~MEDTERM1___, progression-freevival.",
      "start_page": 57,
      "end_page": 57
    },
    {
      "heading": "heading heading A B",
      "text": "Row 1:\nXXRow 2:\nA B",
      "start_page": 57,
      "end_page": 57
    },
    {
      "heading": "heading heading Statistical goodness-of-fit",
      "text": "2 2 ...8 8 •8 8 !RowRow 4:\nGompertz",
      "start_page": 58,
      "end_page": 58
    },
    {
      "heading": "heading heading XX",
      "text": "Row 1:\nXX •Row 2:\n•Exp • Gompertz • Weibull •GG • Log-logistic •Log-normalRow 3:\nSotorasib • Raw 4: 2 months • 91.3% •91.0% • 92.9% • 95.8% •94.7% •95.5%Row 5:\n6 months ~76.0% *75.6% •77.7% ■76.9% −78.0%",
      "start_page": 61,
      "end_page": 61
    },
    {
      "heading": "heading heading 5-years 5-years (10-years 10-years (rate, rate, duration",
      "text": "Row 1:\nDoceteknavel •Row 2:\n2 months • 85.8% •85.5% • 88.3% •89.1% • 89.2% • 79.3%Row 3:\n6 months ~63.3% ~62.7% ~65.5% ~60.7% • 62.0% • 61.6%Row 4:\n12 months ■ 40.0% *39.9% • 39.9% ~38.2% ~37.0% / 38.1%Row 5:\nKey: Exp, exponential; GG, Generalized gamma; survival. survival.",
      "start_page": 62,
      "end_page": 62
    },
    {
      "heading": "heading heading 5-years 5-years (10-years 10-years (rate, rate, duration",
      "text": "Row 1:\nXX",
      "start_page": 62,
      "end_page": 62
    },
    {
      "heading": "heading heading Statistical goodness-of-fit",
      "text": "Row 1:\nXXRow 2:\nA B",
      "start_page": 63,
      "end_page": 63
    },
    {
      "heading": "heading heading  Statistical goodness-of-fit (from previous page)",
      "text": "Indepenent fit • fit fit (restricted)Joint fit (stricted),Joint fit (rested)",
      "start_page": 64,
      "end_page": 64
    },
    {
      "heading": "heading heading curve curve selection",
      "text": "",
      "start_page": 67,
      "end_page": 67
    },
    {
      "heading": "the the Denmark",
      "text": "Row 1:\nXX",
      "start_page": 72,
      "end_page": 72
    },
    {
      "heading": "the the Denmark",
      "text": "Row 1:\nXX°-Row 2:\nX°-X°-x°-ax-X'-X-X",
      "start_page": 72,
      "end_page": 72
    },
    {
      "heading": "heading heading mode mode discipline",
      "text": "Row 1:\nXX°-Row 2:\nX°-X°-x°-ax-X'-X-X",
      "start_page": 73,
      "end_page": 73
    },
    {
      "heading": "heading heading mode mode discipline",
      "text": "Row 1:\nX· X* X* x* X * X*",
      "start_page": 73,
      "end_page": 73
    },
    {
      "heading": "heading heading mode mode discipline",
      "text": "Row 1:\nX· X* X* x* X * X*",
      "start_page": 73,
      "end_page": 73
    },
    {
      "heading": "heading heading resource resource use",
      "text": "Row 1:\nAdvertise event...Mean (95% CI)*..Source",
      "start_page": 74,
      "end_page": 74
    },
    {
      "heading": "heading heading management management costs",
      "text": "Row 1:\nUnit·Unit *Reference *apply apply *RowRow 2:\n•[DKK) •dose •monthRow 3:\n•Row 4:\n•intensity •(DKK]dRow 5:\n•",
      "start_page": 75,
      "end_page": 75
    },
    {
      "heading": "heading heading management management costs",
      "text": "Row 1:\nDrug...Cost (DKK)•Source",
      "start_page": 75,
      "end_page": 75
    },
    {
      "heading": "heading heading management management costs",
      "text": "Row 1:\n•Row 2:\n• Unit cost • Raw 3: Blood sample • SourceRow 4:\n• R. R. 5: • Roll 6: ■",
      "start_page": 75,
      "end_page": 75
    },
    {
      "heading": "Table 29.",
      "text": "Row 1:\n•Row 2:\nUnits • unit unit (DKK) • SourceRow 3:\n•",
      "start_page": 76,
      "end_page": 76
    },
    {
      "heading": "Table 29.",
      "text": "Row 1:\n•Row 2:\n• Health states • Raw 3: ■Row 4:\n• First cycle • Progression-free •Row 5:\nUnits • Accountance-free• Subsequential cycles • Post-progressRow 6:\n● Frequency per cycle) •(frequency per cycle), • défrequency per bicycle)",
      "start_page": 76,
      "end_page": 76
    },
    {
      "heading": "heading heading transport transport cost",
      "text": "Row 1:\n•Row 2:\nAdvertise event • Cost (DKK) • Source a",
      "start_page": 77,
      "end_page": 77
    },
    {
      "heading": "heading heading transport transport cost",
      "text": "Row 1:\n•Unit cost •Row 2:\nResource •SourceRow 3:\n•(DKK) •",
      "start_page": 77,
      "end_page": 77
    },
    {
      "heading": "heading heading importance· (SET 1) samples size.",
      "text": "Row 1:\n\"Time usage\"Row 2:\n\"Resource\"\"SourceRow 3:\n\"(mins.) \"",
      "start_page": 78,
      "end_page": 78
    },
    {
      "heading": "heading heading importance· (SET 1) samples size.",
      "text": "Row 1:\nCategory...Base-case analysis.. ..Rational",
      "start_page": 78,
      "end_page": 78
    },
    {
      "heading": "heading heading sensitivity sensitivity analyses",
      "text": "Row 1:\nXX°--Row 2:\n-- --Row 3:\n-- X°-X°-x°-",
      "start_page": 80,
      "end_page": 80
    },
    {
      "heading": "heading heading Scenario Scenario analysis",
      "text": "Row 1:\nNo. •Scenario •Base-case Assumption • Rationale",
      "start_page": 81,
      "end_page": 81
    },
    {
      "heading": "heading heading Scenario Scenario analysis (column 1)",
      "text": "Row 1:\nNo. •Scenario •Base-case Assumption •",
      "start_page": 81,
      "end_page": 81
    },
    {
      "heading": "heading heading Scenario Scenario analysis (column 2)",
      "text": "Row 1:\n Row 2:",
      "start_page": 81,
      "end_page": 81
    },
    {
      "heading": "heading heading Scenario Scenario analysis (column 3)",
      "text": "Row 1:\n• Rationale",
      "start_page": 81,
      "end_page": 81
    },
    {
      "heading": "heading heading XXX XX",
      "text": "Row 1:\nXX°-Row 2:\nX°-X°-x-X-X",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "heading heading XXX XX",
      "text": "Row 1:\nX",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "heading heading XXX XX",
      "text": "Row 1:\nX",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "heading heading XXX XX",
      "text": "Row 1:\nX",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "heading heading XXX XX",
      "text": "",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "heading heading XXX XX",
      "text": "",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "heading heading XXX XX",
      "text": "Row 1:\nX· X* X* x* X * X*",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "heading heading XXX XX",
      "text": "Row 1:\nX",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "heading heading XXX XX",
      "text": "Row 1:\nX",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "heading heading XXX XX",
      "text": "Row 1:\nX",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "heading heading XXX XX",
      "text": "Row 1:\nX",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "heading heading XXX XX",
      "text": "",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "heading heading XXX XX",
      "text": "",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "heading heading found. found.), a a X% the the DKK",
      "text": "Row 1:\nXX°-Row 2:\nX°-X°-x°-Z-X-X'-",
      "start_page": 83,
      "end_page": 83
    },
    {
      "heading": "heading heading Scenario Scenario analysis",
      "text": "Row 1:\n• Year 1· Year 2· Year 3· Year 4· RowRow 2:\n■",
      "start_page": 86,
      "end_page": 86
    },
    {
      "heading": "heading heading Scenario Scenario analysis",
      "text": "Row 1:\n• Year 1· Year 2· Year 3· Year 4· RowRow 2:\n■",
      "start_page": 86,
      "end_page": 86
    },
    {
      "heading": "heading heading Scenario Scenario analysis",
      "text": "Row 1:\nX°Row 2:\n... X° X°X° X* X°",
      "start_page": 86,
      "end_page": 86
    },
    {
      "heading": "heading heading monotherapy monotherapy (X]), in in median",
      "text": "Row 1:\nXX°-Row 2:\nX°-X°-x-X-X",
      "start_page": 87,
      "end_page": 87
    },
    {
      "heading": "heading heading monotherapy monotherapy (X]), in in median",
      "text": "Row 1:\nXX°-Row 2:\nX°-X°-x-X-X",
      "start_page": 87,
      "end_page": 87
    },
    {
      "heading": "heading heading  Conclusion (from previous page)",
      "text": "Row 1:\n• Xxxxrow 2: • xdex",
      "start_page": 90,
      "end_page": 90
    },
    {
      "heading": "heading heading Conclusion (column column 1)",
      "text": "Row 1:\n• XxRow 2:\n• x",
      "start_page": 90,
      "end_page": 90
    },
    {
      "heading": "heading heading Conclusion (column column 2)",
      "text": "Row 1:\nxxxRow 2:\nxxx",
      "start_page": 90,
      "end_page": 90
    },
    {
      "heading": "heading heading  Conclusion (column column 3)",
      "text": "Row 1:\nxxxRow 2:\nx",
      "start_page": 90,
      "end_page": 90
    },
    {
      "heading": "heading heading Conclusion (column column 4)",
      "text": "Row 1:\nxxRow 2:\nxx",
      "start_page": 90,
      "end_page": 90
    },
    {
      "heading": "heading heading  Embase • original search",
      "text": "Row1Right Row1Right 1: \"Searches' means 11:Row 2:\n1;lung lung cancer/=9821Row 3:\n2 lairlung cancer/ ab. ab.•14730Row 4:\n3·_nsclc_.ti-,RowRow 5:\nRowRow 6:\n5*carcinom$ or cancer$ or neoplas$).ti,ab.",
      "start_page": 99,
      "end_page": 99
    },
    {
      "heading": "heading heading  Embase • original search (column 1)",
      "text": "Row 1:\n Row 2:\n1Row 3:\n2Row 4:\n3Row 5:\n4Row 6:\n5Row 7:\n6Row 8:\n7Row 9:\n8Row 10:\n9Row 11:\n10Row 12:\n11Row 13:\n12Row 14:\n13Row 15:\n14Row 16:\n15Row 17:\n16Row 18:\n17Row 19:\n18",
      "start_page": 99,
      "end_page": 99
    },
    {
      "heading": "heading heading  Embase • original search (column 9)",
      "text": "Row 1:\nResultsRow 2:\n98821Row 3:\n14730Row 4:\n81646Row 5:\n102425Row 6:\n3177270Row 7:\n933416Row 8:\n156582Row 9:\n690342Row 10:\n2272961Row 11:\n2372831Row 12:\n4395903Row 13:\n2158432Row 14:\n16155Row 15:\n6524Row 16:\n9631Row 17:\n2485Row 18:\n3950Row 19:\n6435",
      "start_page": 99,
      "end_page": 99
    },
    {
      "heading": "heading heading  Embase original search (from previous page)",
      "text": "Row$1 =&gt;== &gt;&lt;= &lt; ==& #&gt: $13\"R77$1:==#Searches•ResultsRow 2:\n1 ^lung lung cancer/=52621Row 3:\n2·lung cancer/ ab. ab.",
      "start_page": 100,
      "end_page": 100
    },
    {
      "heading": "heading heading  Embase original search (column column 1)",
      "text": "Row 1:\n#Row 2:\n1Row 3:\n2Row 4:\n3Row 5:\n4Row 6:\n5Row 7:\n6Row 8:\n7Row 9:\n8Row 10:\n9Row 11:\n10Row 12:\n11Row 13:\n12Row 14:\n13Row 15:\n14",
      "start_page": 100,
      "end_page": 100
    },
    {
      "heading": "heading heading  Embase original search (from previous page)",
      "text": "to to 1: # hoseSearches -ResultsRow 2:\n1;lung lung cancer/RowRow 3:\n2;lung cancer/ ti, ti,ab: 3559Row 4:\n3___nsclc.ti-,ab.",
      "start_page": 101,
      "end_page": 101
    },
    {
      "heading": "heading heading  Embase original search (column column 1)",
      "text": "Row 1:\n#Row 2:\n1Row 3:\n2Row 4:\n3Row 5:\n4Row 6:\n5Row 7:\n6Row 8:\n7Row 9:\n8Row 10:\n9Row 11:\n10Row 12:\n11Row 13:\n12Row 14:\n13Row 15:\n14Row 16:\n15Row 17:\n16Row 18:\n17Row 19:\n18",
      "start_page": 101,
      "end_page": 101
    },
    {
      "heading": "heading heading  Embase original search (column column 6)",
      "text": "Row 1:\nResultsRow 2:\n4213Row 3:\n3559Row 4:\n9389Row 5:\n11599Row 6:\n169791Row 7:\n51312Row 8:\n13703Row 9:\n137Row 10:\n1118684Row 11:\n1118699Row 12:\n2072Row 13:\n1117419Row 14:\n9466Row 15:\n4281Row 16:\n4213Row 17:\n3559 Raw 18: 9389 row 19: 115999",
      "start_page": 101,
      "end_page": 101
    },
    {
      "heading": "heading heading  Embase - 2021 update",
      "text": "Row 1:\n19°8312Row 3:\n21°or or (and and 20) 13703Row 4:\n22°crossover procedure/ or double-blind procedure/controlled controlled trial/or single-blind proceeding/.137Row 5:\n23°(random$or facto$or crossover$or Cross-over$ or placebo$or (doubl$adj blind$) or (singl$dj blind $) or assign$or allocat$or volunteer$).ti,ab.",
      "start_page": 102,
      "end_page": 102
    },
    {
      "heading": "heading heading  Embase - 2021 update",
      "text": "Row 1:\n•Searches •ResultsRow 2:\n1 •lung lung cancer/ •105188Row 3:\n2 •lung cancer/ ab. ab. *14842Row 4:\n3 •__MEDTERM0_.ti;ab. •85349Row 5:\n4 •4 4 •106532Row 6:\n5 •(carcinom$ or cancer$ or neoplas$).ti,ab. ■3202195Row 7:\n6 •lung$.ti.ab. +930054Row 8:\n7 •or or (and and 6) •163414Row 9:\n8 •crossover procedure/ or double-blind procedure/controlled controlled trial/or single- blind procedure/·708522",
      "start_page": 102,
      "end_page": 102
    },
    {
      "heading": "heading heading Embase - 2021 update (column 1)",
      "text": "Row 1:\n19Row 2:\n20Row 3:\n21Row 4:\n22Row 5:\n23Row 6:\n24Row 7:\n25Row 8:\n26Row 9:\n27Row 10:\n28",
      "start_page": 102,
      "end_page": 102
    },
    {
      "heading": "heading heading Embase - 2021 update (column 1)",
      "text": "Row 1:\n Row 2:\n1Row 3:\n2Row 4:\n3Row 5:\n4Row 6:\n5Row 7:\n6Row 8:\n7Row 9:\n8",
      "start_page": 102,
      "end_page": 102
    },
    {
      "heading": "heading heading Embase - 2021 update (column 6)",
      "text": "Row 1:\n169791Row 2:\n51312Row 3:\n13703Row 4:\n137Row 5:\n1118684Row 6:\n1118699Row 7:\n2072Row 8:\n1117419Row 9:\n9466Row 10:\n4281",
      "start_page": 102,
      "end_page": 102
    },
    {
      "heading": "heading heading Embase - 2021 update (column 6)",
      "text": "Row 1:\nResultsRow 2:\n105188Row 3:\n14842Row 4:\n85349Row 5:\n106532Row 6:\n3202195Row 7:\n930054Row 8:\n163414Row 9:\n708522",
      "start_page": 102,
      "end_page": 102
    },
    {
      "heading": "heading heading  Embase - 2021 update (from previous page)",
      "text": "orrandom$or facto$or crossover$orcross over$or Cross-over$ or placebo$or (doubl$adj blind$)or (singl$dj blind $)or assign$or allocat$or volunteer$).ti,ab.",
      "start_page": 103,
      "end_page": 103
    },
    {
      "heading": "heading heading Embase - 2021 update (column column 1)",
      "text": "Row 1:\n9Row 2:\n10Row 3:\n11Row 4:\n12Row 5:\n13Row 6:\n14Row 7:\n15Row 8:\n16Row 9:\n17Row 10:\n18Row 11:\n19Row 12:\n20Row 13:\n21Row 14:\n22",
      "start_page": 103,
      "end_page": 103
    },
    {
      "heading": "heading heading Embase - 2021 update (column column 8)",
      "text": "Row 1:\n2312465Row 2:\n2412281Row 3:\n4232620Row 4:\n2193742Row 5:\n16797Row 6:\n6842Row 7:\n9955Row 8:\n2796Row 9:\n4278Row 10:\n7074Row 11:\n230158Row 12:\n383Row 13:\n265Row 14:\n505",
      "start_page": 103,
      "end_page": 103
    },
    {
      "heading": "heading heading  Embase - 2021 update (from previous page)",
      "text": "Row$*555228Row 3:\n2 ~lung cancer/ ab. ab.",
      "start_page": 104,
      "end_page": 104
    },
    {
      "heading": "heading heading Embase - 2021 update (column column 1)",
      "text": "Row 1:\n#Row 2:\n1Row 3:\n2Row 4:\n3Row 5:\n4Row 6:\n5Row 7:\n6Row 8:\n7Row 9:\n8Row 10:\n9Row 11:\n10Row 12:\n11Row 13:\n12Row 14:\n13Row 15:\n14Row 16:\n15Row 17:\n16Row 18:\n17",
      "start_page": 104,
      "end_page": 104
    },
    {
      "heading": "heading heading  Embase - 2021 update (from previous page)",
      "text": "Row=10$299-or placebo (single-blind single-blind procedure/ •137Row 10:\n9;14278Row 9:\n8; crossover procedure/ or double-blind process/controlled controlled trial/or single- blind procedure/",
      "start_page": 105,
      "end_page": 105
    },
    {
      "heading": "heading heading Embase - 2021 update (column column 1)",
      "text": "Row 1:\n#Row 2:\n1Row 3:\n2Row 4:\n3Row 5:\n4Row 6:\n5Row 7:\n6Row 8:\n7Row 9:\n8Row 10:\n9Row 11:\n10Row 12:\n11Row 13:\n12Row 14:\n13Row 15:\n14",
      "start_page": 105,
      "end_page": 105
    },
    {
      "heading": "heading heading Embase - 2021 update (column column 2)",
      "text": "Row 1:\nResultsRow 2:\n4365Row 3:\n3663Row 4:\n9820Row 5:\n12057Row 6:\n178044Row 7:\n54134Row 8:\n14278Row 9:\n137Row 10:\n1178914Row 11:\n1178829Row 12:\n2106Row 13:\n1177616Row 14:\n9948Row 15:\n517",
      "start_page": 105,
      "end_page": 105
    },
    {
      "heading": "heading heading  ras ras oncogene/ 9909",
      "text": "Row 1:\n#hSearches;ResultsRow 2:\n2: 1·cell cell cancer/",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "heading heading  ras ras oncogene/ 9909 (from previous page)",
      "text": "7: 30 30 (6) 660Row 8:\nepi epi epidemiology/or epidemic $or or V-Kirsten Kirsten RAS) adj5Row 3:\n•Row 4:\n~mutation$ or mutant$ or or gene$ or decoration$ Or Or RASK$ or or RUS) adj5 , or oncoke$ or fusion$ or oncegen$ or merger$ or expression$ or over .expression$ Row",
      "start_page": 108,
      "end_page": 108
    },
    {
      "heading": "heading heading  ras ras oncogene/ 9909 (column column 1)",
      "text": "Twenty-seven-six-size-two-twenty-three-show-two.Row-one-five-zero-four-two, Row-tw-twe-twer.Rown-tWrow-tah-tlf.ROW-Two-twice-one.Raw-Tw-Tho-Twe-Twi-Thr-Tright-Tree-Turk-Tri-Trip-Tax.Trow_twj-tv-RowRow 3:\n•Row 4:\n^mutation$ or mutant$ RowRow 5:\nor oncogene$ orRow 6:\nor inversion$ RowRow 7:\n12°RowRow 8:\n13° epidemiology/ RowRow 11:\n16·overall survival/or (RowRow 12:\n~prolong*orvival* or survival.: 22.ti.",
      "start_page": 108,
      "end_page": 108
    },
    {
      "heading": "heading heading  ras ras oncogene/ 9909 (column column 2)",
      "text": "Row 1:\n-K-ras or V-or or c-RowRow 2:\nRowRow 3:\nor or gene$ RowRow 4:\nfusion$ or expression$ or over?exprRow 5:\nn$)).RowRow 6:\n Row 7:\nw.Row 8:\n Row 9:\n Row 10:\nurvival* term term survival* RowRow 11:\nRowRow 12:\nRowRow 13:\n Row 14:\nnse or TTR).mp.Row 15:\n Row 16:\n Row 17:\n Row 18:\n Row 19:\n Row 20:\n Row 21:\n Row 22:\n Row 23:\n Row 24:",
      "start_page": 108,
      "end_page": 108
    },
    {
      "heading": "heading heading  ras ras oncogene/ 9909 (column column 3)",
      "text": "Row 1:\nc-k-rasRow 2:\nRowRow 3:\noratioRow 4:\nressioRow 5:\n Row 6:\n Row 7:\n Row 8:\n Row 9:\n Row 10:\nsurvivRow 11:\n Row 12:\nal).RowRow 13:\n Row 14:\n Row 15:\n Row 16:\n Row 17:\n Row 18:\n Row 19:\n Row 20:\n Row 21:\n Row 22:\n Row 23:\n Row 24:",
      "start_page": 108,
      "end_page": 108
    },
    {
      "heading": "heading heading  ras ras oncogene/ 9909 (column column 4)",
      "text": "Row 1:\ns or ki-•RowRow 2:\nS) adj5",
      "start_page": 108,
      "end_page": 108
    },
    {
      "heading": "heading heading  ras ras oncogene/ 12 293",
      "text": "Row 1:\n31°to to (or or \"review\" or short",
      "start_page": 109,
      "end_page": 109
    },
    {
      "heading": "heading heading  ras ras oncogene/ 12 293",
      "text": "1 1 0Row=RowRow 2:\n1-exp Carcinoma, Non-Small-Cell Lung/ an an anus) Rsulps Row: 1-aspexp Carcinoma, Non-Small-Cowl-Cel-Cow-Chow-Cown cancer).Ti,ab.",
      "start_page": 109,
      "end_page": 109
    },
    {
      "heading": "heading heading  ras ras oncogene/ 12 293 (from previous page)",
      "text": "right right right- right right right/RowRow 4:\n15pevalence/or survival.ti;kwowowwoww!Row 7:\n'Row 8:\n17jæsenon free survival* or overall survival* Or •RowRow 6:\n•prolong$ survival* and survival*or survival anal$).Sourvaval Sourvaval Analysis/or (disease specific survival* of sleep* or above again* orover* or survive* or survival*) or survival Anal$'. or survival' or survivalanal$ 7 7 7:",
      "start_page": 110,
      "end_page": 110
    },
    {
      "heading": "heading heading  ras ras oncogene/ 12 293 (column column 1)",
      "text": "Row 1:\n20/22 and 17: Rowis Rowis 15: 24.",
      "start_page": 110,
      "end_page": 110
    },
    {
      "heading": "heading heading  ras ras oncogene/ 12 293 (column column 2)",
      "text": "Row 1:\n Row 2:\n,RowRow 3:\n Row 4:\nw.Row 5:\nRowRow 6:\nl$).RowRow 7:\nGressioRow 8:\np.Row 9:\nesponRow 10:\n Row 11:\n Row 12:\n Row 13:\n Row 14:\n Row 15:\n Row 16:\n Row 17:\n Row 18:\n Row 19:\n Row 20:\n Row 21:\n Row 22:\nRowRow 23:\n\".mp.",
      "start_page": 110,
      "end_page": 110
    },
    {
      "heading": "heading heading  ras ras oncogene/ 12 293 (column column 3)",
      "text": "Row 1:\n Row 2:\nw.Row 3:\n Row 4:\n Row 5:\nUrvival* RowRow 6:\nRowRow 7:\nRowRow 8:\n Row 9:\nnse or TTR).mp.Row 10:\n Row 11:\n Row 12:\n Row 13:\n Row 14:\n Row 15:\n Row 16:\n Row 17:\n Row 18:\n Row 19:\n Row 20:\n Row 21:\n Row 22:\nview (topic)\"/ RowRow 23:\nor meta-analysis.mp",
      "start_page": 110,
      "end_page": 110
    },
    {
      "heading": "heading heading  ras ras oncogene/ 12 293 (column column 4)",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\nRowRow 6:\n Row 7:\nOresRow 8:\n Row 9:\n Row 10:\n Row 11:\n Row 12:\n Row 13:\n Row 14:\n Row 15:\n Row 16:\n Row 17:\n Row 18:\n Row 19:\n Row 20:\n Row 21:\n Row 22:\nYstemRow 23:\np.",
      "start_page": 110,
      "end_page": 110
    },
    {
      "heading": "heading heading  ras ras oncogene/ 12 293 (column column 5)",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\nvival*Row 6:\n Row 7:\nssion-fRow 8:\n Row 9:\n Row 10:\n Row 11:\n Row 12:\n Row 13:\n Row 14:\n Row 15:\n Row 16:\n Row 17:\n Row 18:\n Row 19:\n Row 20:\n Row 21:\n Row 22:\nmatic",
      "start_page": 110,
      "end_page": 110
    },
    {
      "heading": "heading heading  ras ras oncogene/ 12 293 (column column 6)",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\nRowRow 6:\n Row 7:\nRowRow 8:\n Row 9:\n Row 10:\n Row 11:\n Row 12:\n Row 13:\n Row 14:\n Row 15:\n Row 16:\n Row 17:\n Row 18:\n Row 19:\n Row 20:\n Row 21:\n Row 22:\nRevie",
      "start_page": 110,
      "end_page": 110
    },
    {
      "heading": "heading heading  ras ras oncogene/ 12 293 (column column 7)",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\nVerallRow 6:\n Row 7:\nSurvivaRow 8:\n Row 9:\n Row 10:\n Row 11:\n Row 12:\n Row 13:\n Row 14:\n Row 15:\n Row 16:\n Row 17:\n Row 18:\n Row 19:\n Row 20:\n Row 21:\n Row 22:\nRow",
      "start_page": 110,
      "end_page": 110
    },
    {
      "heading": "heading heading  ras ras oncogene/ 12 293 (column column 8)",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\nSurvivRow 6:\n Row 7:\nal).RowRow 8:\n Row 9:\n Row 10:\n Row 11:\n Row 12:\n Row 13:\n Row 14:\n Row 15:\n Row 16:\n Row 17:\n Row 18:\n Row 19:\n Row 20:\n Row 21:\n Row 22:\nRow",
      "start_page": 110,
      "end_page": 110
    },
    {
      "heading": "heading heading  ras ras oncogene/ 12 293 (column column 9)",
      "text": "Row 1:\n..RowRow 2:\n..RowRow 3:\n•RowRow 4:\n•RowRow 5:\nval* or •RowRow 6:\n•Row 7:\n■Row 8:\nab,kw. •Row",
      "start_page": 110,
      "end_page": 110
    },
    {
      "heading": "heading heading  ras ras oncogene/ 12 293 (from previous page)",
      "text": "Row 1:\n33·31 not 32·131Row 2:\n34·30 not 33·1430Row 3:\n35·from from 34·1427",
      "start_page": 111,
      "end_page": 111
    },
    {
      "heading": "heading heading  ras ras oncogene/ 12 293 (from previous page)",
      "text": "5j3 5j3 (Marque$ square square right) adJ3 (wwright) adj3: 1-expRccinoma, Non-Small-Cell Lung/=ceO3982 ororororrororwise 3: 2·lung lung cancer).ti,ab.•RowRow 4:\nRowRow 5:\nto to yr=\"2014 -Current\" [in in DARE; records were established]5674 or rectum$ or colon$ or sigma$ or segmo$ or rectosigm$ or sign$ or sell cancer/ or suggest cancer/or brain cancer/Or colectal tumor/RowRow 7:\n6",
      "start_page": 111,
      "end_page": 111
    },
    {
      "heading": "heading heading  ras ras oncogene/ 12 293 (column column 1)",
      "text": "Row 1:\n33 • RowRow 2:\n34 • RowRow 3:\n35 • from from 34",
      "start_page": 111,
      "end_page": 111
    },
    {
      "heading": "heading heading  ras ras oncogene/ 12 293 (column column 1)",
      "text": "US US 1*exp Carcinoma, Non-Small-Cell Lung/oRow: 2°lung lung cancer).ti,ab.",
      "start_page": 111,
      "end_page": 111
    },
    {
      "heading": "heading heading  ras ras oncogene/ 12 293 (column column 2)",
      "text": "Row 1:\n•131Row 2:\n• 1430Row 3:\n•1427",
      "start_page": 111,
      "end_page": 111
    },
    {
      "heading": "heading heading  ras ras oncogene/ 12 293 (column column 2)",
      "text": "Row 1:\n..5674Row 6:\n..7717Row 7:\nowel$or•RowRow 8:\ncinoma$°Row 9:\n. ..ti,ab.-Row 10:\n·RowRow 11:\n^RowRow 12:\n■RowRow 13:\n~65Row 14:\nras or ki-*1176Row 15:\nAS) adj5",
      "start_page": 111,
      "end_page": 111
    },
    {
      "heading": "heading heading  • Embase ~ updated search: 10 March 2021",
      "text": "Row 1:\n24 • Letter / • 0Row 2:\n25 •or/22-24 • 2133Row 3:\n26 •25 25 ■RowRow 4:\n27 • 26 26 ■ 651Row 5:\n28 •(animal$ not human$).sh,hw. • 2033Row 6:\n29 •28 28 ~651Row 7:\n30 •language language [DARE, DARE,CLCMR; records521",
      "start_page": 112,
      "end_page": 112
    },
    {
      "heading": "heading heading  • Embase ~ updated search: 10 March 2021",
      "text": "Row 1:\n#=Searches;ResultsRow 2:\n2: 1·cell cell cancer/",
      "start_page": 112,
      "end_page": 112
    },
    {
      "heading": "heading heading  • Embase ~ updated search: 10 March 2021 (column 1)",
      "text": "Row 1:\n24° Letter/Row 2:\n25°or/22-24Row 3:\n26°RowRow 4:\n27°RowRow 5:\n28°(animal$ not human$).RowRow 6:\n29°RowRow 7:\n30°language language [Row",
      "start_page": 112,
      "end_page": 112
    },
    {
      "heading": "heading heading  • Embase ~ updated search: 10 March 2021 (column 1)",
      "text": "Row 1:\n#·SearchesRow 2:\n1 •cell cell cancer/",
      "start_page": 112,
      "end_page": 112
    },
    {
      "heading": "heading heading  • Embase ~ updated search: 10 March 2021 (column 2)",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\n Row 6:\n Row 7:\nRowRow 8:\n Row 9:\nRowRow 10:\n Row 11:\nRowRow 12:\n Row 13:\n Row 14:",
      "start_page": 112,
      "end_page": 112
    },
    {
      "heading": "heading heading  • Embase ~ updated search: 10 March 2021 (column 2)",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\n Row 6:\n Row 7:\n$ RowRow 8:\nn$ RowRow 9:\nadenom$oRow 10:\n Row 11:\n Row 12:",
      "start_page": 112,
      "end_page": 112
    },
    {
      "heading": "heading heading  • Embase ~ updated search: 10 March 2021 (column 3)",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\n Row 6:\n Row 7:\nRE,CLCMR; recoRow 8:\n Row 9:\nRowRow 10:\n Row 11:\nRowRow 12:\n Row 13:\n Row 14:",
      "start_page": 112,
      "end_page": 112
    },
    {
      "heading": "heading heading  • Embase ~ updated search: 10 March 2021 (column 3)",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\n Row 6:\n Row 7:\nsigm$ or bowl$Row 8:\no?r$ RowRow 9:\nor lesion$)).RowRow 10:\n Row 11:\n Row 12:",
      "start_page": 112,
      "end_page": 112
    },
    {
      "heading": "heading heading  • Embase ~ updated search: 10 March 2021 (column 4)",
      "text": "Row 1:\n\"0Row 2:\n\"2133Row 3:\n\"RowRow 4:\n\" 651Row 5:\n\"2033Row 6:\n\"651Row 7:\nwords \"521Row 8:\n\"Row 9:\n\" RowRow 10:\n\" 'Row 11:\n\"RowRow 12:\n\" Bow 13: '0Row 14:\n\" 521Row 15:\n'507",
      "start_page": 112,
      "end_page": 112
    },
    {
      "heading": "heading heading  • Embase ~ updated search: 10 March 2021 (column 4)",
      "text": "Row 1:\n\"ResultsRow 2:\n\"106879Row 3:\n\"116340Row 4:\n\"160606Row 5:\n\"34076Row 6:\n\"339744Row 7:\n$ or \"367191Row 8:\n\"Row 9:\n'Row 10:\n' b. 'Row 11:\n'442830Row 12:\n'62540Row 13:\n'94311Row 14:\n'11065",
      "start_page": 112,
      "end_page": 112
    },
    {
      "heading": "heading heading  • Embase updated search: 10 March 2021 (from previous page)",
      "text": "7: 11 11 .35639Row 8:\n13 • epi epi epidemiology/or overexpression$ orright$ or mutant$ ormuted or reputation$ Kirsten Kirsten RAS) adj5",
      "start_page": 113,
      "end_page": 113
    },
    {
      "heading": "heading heading  • Embase updated search: 10 March 2021 (column column 1)",
      "text": "RowRowway 1 1: 11 ('or or V-Ki- stock$ or W-or or c-ROW ROW 3: •Row 4:\n^mutation$ or mutant$ or or gene$ RowRow 5:\n•rearrangement$ or oncogene$ or fusion$ or or expression$ or over ?expRow 6:\n...amplification$ or inversion$ or division$)).RowRow 7:\nRowRow 8:\n13.7. epidemiology/RowRow 9:\n14",
      "start_page": 113,
      "end_page": 113
    },
    {
      "heading": "heading heading  • Embase updated search: 10 March 2021 (column column 2)",
      "text": "Row 1:\nc-k-raRow 2:\nRowRow 3:\noratioRow 4:\nressioRow 5:\n Row 6:\n Row 7:\n Row 8:\n Row 9:\n Row 10:\nsurviRow 11:\n Row 12:\nval).ti,Row 13:\n Row 14:\n Row 15:\n Row 16:\n Row 17:\n Row 18:\n Row 19:\n Row 20:\n Row 21:\n Row 22:\n Row 23:\n Row 24:",
      "start_page": 113,
      "end_page": 113
    },
    {
      "heading": "heading heading  • Embase updated search: 10 March 2021 (column column 3)",
      "text": "Row 1:\nas or ki-",
      "start_page": 113,
      "end_page": 113
    },
    {
      "heading": "heading heading ras ras oncogene/ 12466",
      "text": "Row 1:\n31°to to (or or \"review\" or short",
      "start_page": 114,
      "end_page": 114
    },
    {
      "heading": "heading heading ras ras oncogene/ 12466",
      "text": "Row2 RowRaw 1: #=Searches-Rough-ResultsRow 2:\nCarcinoma, Non-Small-Cell Lung/ ororOrororrororway ororOrororrororway 3: 2·lung lung cancer).Ti,ab.n-Small-Cowl-Cill-to to yr=\"2019 -Current'-151554Row 6:\n5",
      "start_page": 114,
      "end_page": 114
    },
    {
      "heading": "heading heading ras ras oncogene/ 12466 (from previous page)",
      "text": "rightwaywayright rightwaywayright right-arrowing/Survival Survival Analysis/or (disease specific survival* term term survival*all all survival* and/or overall survival* RowRow 6:\ncelong$ survival*Or survival anal$).RowRow 9:\n18.Candoverall response: see 8: 17.",
      "start_page": 115,
      "end_page": 115
    },
    {
      "heading": "heading heading ras ras oncogene/ 12466 (column column 1)",
      "text": "Row 1:\n12° RowRow 2:\n13° epidemicology/ RowRow 3:\n14° incidence/ ti ti (disease specific survival* RowRow 6:\nprolong$ survival*orvival anal$).Row",
      "start_page": 115,
      "end_page": 115
    },
    {
      "heading": "heading heading ras ras oncogene/ 12466 (column column 2)",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\nRowRow 6:\n Row 7:\nRowRow 8:\n Row 9:\nmp.Row 10:\n Row 11:\n Row 12:\n Row 13:\n Row 14:\n Row 15:\n Row 16:\n Row 17:\n Row 18:\n Row 19:\n Row 20:\n Row 21:\n Row 22:\n)\"/ RowRow 23:\nalysis.mp.",
      "start_page": 115,
      "end_page": 115
    },
    {
      "heading": "heading heading ras ras oncogene/ 12466 (column column 3)",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\nSurvivRow 6:\n Row 7:\nGressRow 8:\n Row 9:\n Row 10:\n Row 11:\n Row 12:\n Row 13:\n Row 14:\n Row 15:\n Row 16:\n Row 17:\n Row 18:\n Row 19:\n Row 20:\n Row 21:\n Row 22:\nStama",
      "start_page": 115,
      "end_page": 115
    },
    {
      "heading": "heading heading ras ras oncogene/ 12466 (column column 4)",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\nval* oRow 6:\n Row 7:\nsion-fRow 8:\n Row 9:\n Row 10:\n Row 11:\n Row 12:\n Row 13:\n Row 14:\n Row 15:\n Row 16:\n Row 17:\n Row 18:\n Row 19:\n Row 20:\n Row 21:\n Row 22:\natic",
      "start_page": 115,
      "end_page": 115
    },
    {
      "heading": "heading heading ras ras oncogene/ 12466 (column column 5)",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\nRowRow 6:\n Row 7:\nRowRow 8:\n Row 9:\n Row 10:\n Row 11:\n Row 12:\n Row 13:\n Row 14:\n Row 15:\n Row 16:\n Row 17:\n Row 18:\n Row 19:\n Row 20:\n Row 21:\n Row 22:\nreview",
      "start_page": 115,
      "end_page": 115
    },
    {
      "heading": "heading heading ras ras oncogene/ 12466 (column column 6)",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\nVerallRow 6:\n Row 7:\nSurvivRow 8:\n Row 9:\n Row 10:\n Row 11:\n Row 12:\n Row 13:\n Row 14:\n Row 15:\n Row 16:\n Row 17:\n Row 18:\n Row 19:\n Row 20:\n Row 21:\n Row 22:\nRow",
      "start_page": 115,
      "end_page": 115
    },
    {
      "heading": "heading heading  ras ras oncogene/ 12466 (column column 7)",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\nsurviRow 6:\n Row 7:\nval).ti,Row 8:\n Row 9:\n Row 10:\n Row 11:\n Row 12:\n Row 13:\n Row 14:\n Row 15:\n Row 16:\n Row 17:\n Row 18:\n Row 19:\n Row 20:\n Row 21:\n Row 22:\nRow",
      "start_page": 115,
      "end_page": 115
    },
    {
      "heading": "heading heading  ras ras oncogene/ 12466 (column column 8)",
      "text": "Row 1:\n•24918Row 2:\n•198048Row 3:\n•888464Row 4:\n•745199Row 5:\nIval* or •361241Row 6:\n•Row 7:\n▪Row 8:\n,ab,kw.",
      "start_page": 115,
      "end_page": 115
    },
    {
      "heading": "heading heading  • Cochrane updated search: 10 March 2021",
      "text": "Row 1:\n33 • 32 32 • 19Row 2:\n34 • 33 33 ■ 407Row 3:\n35 • 34 34 ~ 407",
      "start_page": 116,
      "end_page": 116
    },
    {
      "heading": "heading heading  • Cochrane updated search: 10 March 2021",
      "text": "Row2Row square 1: #=Searches;ResultsRow 2:\n1-exp Carcinoma, Non-Small-Cell Lung/",
      "start_page": 116,
      "end_page": 116
    },
    {
      "heading": "heading heading  • Cochrane updated search: 10 March 2021 (column 1)",
      "text": "Row 1:\n33 • RowRow 2:\n34 • RowRow 3:\n35 • from from 34",
      "start_page": 116,
      "end_page": 116
    },
    {
      "heading": "heading heading  • Cochrane updated search: 10 March 2021 (column 1)",
      "text": "square square US-Row-Wow-ough-ROWS ough-ROWS 1#SearchesRow 2:\n1°exp Carcinoma, Non-Small-Cell Lung/Row 5:\n4 /to to yr=\"2019 -Current\" [in in DARE; records were established].Row 6:\n5",
      "start_page": 116,
      "end_page": 116
    },
    {
      "heading": "heading heading  • Cochrane updated search: 10 March 2021 (column 2)",
      "text": "Row 1:\n\"19Row 2:\n\"407Row 3:\n\" 407",
      "start_page": 116,
      "end_page": 116
    },
    {
      "heading": "heading heading  • Cochrane updated search: 10 March 2021 (column 2)",
      "text": "Row 1:\n#ResultsRow 2:\n#4656Row 3:\n#14347Row 4:\n#14819Row 5:\n#2010Row 6:\n#8922Row 7:\n#25271Row 8:\n#144Row 9:\n#Row 10:\n#10,ab.#Row 11:\n#26344Row 12:\n#3676Row 13:\n#5654Row 14:\n#66Row 15:\nas or ki-",
      "start_page": 116,
      "end_page": 116
    },
    {
      "heading": "heading heading • Cochrane updated search: 10 March 2021 (from previous page)",
      "text": "holder holder is:RowRightway 1; RowRawright Rive 1: 14.RowStore/ownership, ownership,right-right-of of survival* term term survival*or overall survival* and/RowRow 4:\n\"prolong$ survival*and survival' or survival anal$).kwew. kwew.:25533Row 5:\n•Row 6:\nfree free survival/or (progression-free progression-free survival) or progression -free survival).ti,akwww...7 7 7: 18 : 18",
      "start_page": 117,
      "end_page": 117
    },
    {
      "heading": "heading heading  • Cochrane updated search: 10 March 2021 (column column 1)",
      "text": "right-right right-right right/ab, ab,kw:Row 2:\n15;right right right/ rightway rightway right/Way Way 1: 14;incident/RowRow 5:\n•Row 6:\n17jædeon free survival/or (RowRow 7:\nor or _ORR_).mp.Row 8:\n19.",
      "start_page": 117,
      "end_page": 117
    },
    {
      "heading": "heading heading • Cochrane updated search: 10 March 2021 (column column 2)",
      "text": "Row 1:\n Row 2:\n Row 3:\nval* RowRow 4:\n Row 5:\nRowRow 6:\n Row 7:\n Row 8:\n Row 9:\n Row 10:\n Row 11:\n Row 12:\n Row 13:\n Row 14:\n Row 15:\n Row 16:\n Row 17:\n Row 18:\nRowRow 19:\n Row 20:\nRowRow 21:\n Row 22:\nRowRow 23:",
      "start_page": 117,
      "end_page": 117
    },
    {
      "heading": "heading heading • Cochrane updated search: 10 March 2021 (column column 3)",
      "text": "Row 1:\n• 123869Row 2:\n• 41883Row 3:\nsurvival* or • 105477Row 4:\n•Row 5:\n▪Row 6:\nval).kw. kw.",
      "start_page": 117,
      "end_page": 117
    },
    {
      "heading": "heading heading 34 34 65",
      "text": "Row 1:\n34°30 not 33°65Row 2:\n35°from from 34°65",
      "start_page": 118,
      "end_page": 118
    },
    {
      "heading": "heading heading 34 34 65",
      "text": "_ _ __MEDTERM2_right-still-st-stable_ t2_during_right_right (Row_right) Row: Population_Adults (18 years) metastatic metastatic (stage IIIB-IV) separately separately '. limited limited to: • PD-L1 expression • Prior PD- L1 exit • Pre-PD-(L)1 therapies • progressorsonsors progressorsonsors • adolescent adolescent (< 18 years) Patients • Patients with cancer'_BAR _BAR P-ind-and L) 2__ 2__ • Ear-stin-T2_T2 T2_T2 [...] s s S",
      "start_page": 118,
      "end_page": 118
    },
    {
      "heading": "heading heading  Safety and tolerability:",
      "text": "\"Rowights' 2 2 (1) (a) of Directive 2014/65/Council Council [9];",
      "start_page": 119,
      "end_page": 119
    },
    {
      "heading": "heading heading  Safety and tolerability: (column 1)",
      "text": "Row 1:\nCriteria",
      "start_page": 119,
      "end_page": 119
    },
    {
      "heading": "heading heading  Safety and tolerability: (column 2)",
      "text": "case, \"Row-Right- than-right-over-rightRow 2:\n• rate rate (ORR_) • Partial response (PR) ♪ Complete response (CR) ■ rates rates • response response • rate rate • termination termination (etc. etc.) Safety and tolerability: • AEs AEs • 4 4 AEs; • SAEs SAEs ● • Tolerantability: discontination discontination (any reason), discontuation (due to AEs) ]",
      "start_page": 119,
      "end_page": 119
    },
    {
      "heading": "heading heading 2) SLR Screen:",
      "text": "through through 4: NSCLC_ NSCLC_ (RowRow 5:\nProceedings) RowRow 6:\n•Row 7:\n\"Row 7:\n'mutation mutation (KRASm)Row 8:\nInterventions and 8: treatment treatment or",
      "start_page": 120,
      "end_page": 120
    },
    {
      "heading": "heading heading 2) SLR Screen:",
      "text": "Row 1:\nDateRow 2:\nrestrictions",
      "start_page": 120,
      "end_page": 120
    },
    {
      "heading": "heading heading 2) SLR Screen: (column 1)",
      "text": "Row 1:\n\"EligibiliRow 2:\n\"criteriaRow 3:\n\"PopulaRow 4:\n\"InterveRow 5:\n\"CompaRow 6:\n\"OutcomRow 7:\nStudy d· RowRow 8:\nDate restrictive\" DateRow 9:\n\"RestrictRow 10:\n\"LanguaRow 11:\n\"restrict\"",
      "start_page": 120,
      "end_page": 120
    },
    {
      "heading": "heading heading 2) SLR Screen: (column 2)",
      "text": "Row 1:\nityRow 2:\naRow 3:\nationRow 4:\n Row 5:\nentryRow 6:\n Row 7:\naratorRow 8:\nmesRow 9:\n Row 10:\ndesignRow 11:\n Row 12:\n Row 13:\ntionsRow 14:\n Row 15:\nageRow 16:\ntions",
      "start_page": 120,
      "end_page": 120
    },
    {
      "heading": "heading heading 2) SLR Screen: (column 3)",
      "text": "RowRowway Hoover Criteria:ExcluRow 2:\nin:Row 3:\n•Row 3:\n# Ro 4: #NSCLC_ NSCLC_ (Row",
      "start_page": 120,
      "end_page": 120
    },
    {
      "heading": "heading heading 2) SLR Screen: (column 3)",
      "text": "Row 1:",
      "start_page": 120,
      "end_page": 120
    },
    {
      "heading": "heading heading 2) SLR Screen: (column 4)",
      "text": "Row 1:\nRowRow 2:\n Row 3:\nRowRow 4:\n Row 5:\nRowRow 6:\naccustomed comparator arm)Row 7:\n Row 8:\n Row 9:\n Row 10:\nout animal/RowRow 11:\nRowRow 12:\n Row 13:\n Row 14:\n Row 15:",
      "start_page": 120,
      "end_page": 120
    },
    {
      "heading": "heading heading 2) SLR Screen: (column 5)",
      "text": "Row 1:\n Row 2:\n Row 3:\nSCLCRow 4:\n Row 5:\nreputation (uRow 6:\n Row 7:\n Row 8:\n Row 9:\n Row 10:\nstudioRow 11:\n Row 12:\n Row 13:\n Row 14:\n Row 15:",
      "start_page": 120,
      "end_page": 120
    },
    {
      "heading": "heading heading 2) SLR Screen: (column 6)",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\nUnlessRow 6:\n Row 7:\n Row 8:\n Row 9:\n Row 10:\nRowRow 11:\n Row 12:\n Row 13:\n Row 14:\n Row 15:",
      "start_page": 120,
      "end_page": 120
    },
    {
      "heading": "heading heading 2) SLR Screen: (column 7)",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\nRowRow 6:\n Row 7:\n Row 8:\n Row 9:\n Row 10:\ncaseRow 11:\n Row 12:\n Row 13:\n Row 14:\n Row 15:",
      "start_page": 120,
      "end_page": 120
    },
    {
      "heading": "heading heading excluded excluded RCTs",
      "text": "Row 1:\nPublication type...and and ..Row 2:\nsystematic systematic reviews*.. ..Row 3:\n•Row 4:\n\"Country\"",
      "start_page": 121,
      "end_page": 121
    },
    {
      "heading": "reliability reliability criteria",
      "text": "2 mg/RowRow 2:\nRowRow 3:\n2015 2015 (2011/101) study study (United United States) concluded b ¥ daily daily (n=86) United United states) July July 2012] day day (n = 2 mg / h=86), WITM0 - received received >were were excluded*0 0 , function function 2) medications. medications.",
      "start_page": 123,
      "end_page": 123
    },
    {
      "heading": "reliability reliability criteria",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nreason",
      "start_page": 123,
      "end_page": 123
    },
    {
      "heading": "reliability reliability criteria",
      "text": "Row 1:\nRowRow 2:\n2015(101)Row 3:\nNCT01362296Row 4:\nPhase 2",
      "start_page": 123,
      "end_page": 123
    },
    {
      "heading": "reliability reliability criteria",
      "text": "Row 1:\nNCT01229150; CTEP: 8444Row 2:\nPhase 2",
      "start_page": 123,
      "end_page": 123
    },
    {
      "heading": "reliability reliability criteria",
      "text": "Row 1:\nregion region • patients patients •Prior therapy •Inclusion criteria •Exclusion criteria",
      "start_page": 123,
      "end_page": 123
    },
    {
      "heading": "reliability reliability criteria",
      "text": "2015 2015 (101) NCT01362296 Phase 2=International study (United United States) daily daily (n=86) Docetaxel 75 mg/weeks weeks (n=3) (1) advanced advanced stage/metstatic stage __MEDERTM8_1) Patients aged ≥ ECOG ECOG 2010waywayway",
      "start_page": 123,
      "end_page": 123
    },
    {
      "heading": "reliability reliability criteria",
      "text": "Row 1:\nRowRow 2:\n Row 3:\nRowRow 4:\nRowRow 5:\nappropriate appropriate intervention",
      "start_page": 123,
      "end_page": 123
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (from previous page)",
      "text": "75 75 mg/m2 day (n=51) daily daily (n = 51) Investitor'500 500 mg/ mg mg / 21day 21day (n=3 12 mg/ma2 days (1) 21 21 days;",
      "start_page": 124,
      "end_page": 124
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (from previous page)",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nreason",
      "start_page": 124,
      "end_page": 124
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (from previous page)",
      "text": "Row 1:\nNCT02152631Row 2:\nPhase 3",
      "start_page": 124,
      "end_page": 124
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (column column 1)",
      "text": "(21 21 days) (n=45)",
      "start_page": 124,
      "end_page": 124
    },
    {
      "heading": "heading heading reliability reliability criteria (column column 3)",
      "text": "Row 1:\nRowRow 2:\n Row 3:\nrelevant relevant intervention",
      "start_page": 124,
      "end_page": 124
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (from previous page)",
      "text": "region region •RowRow 2:\nJanuary January 2016;__MEDTERMM0___ __MEDTERMM0___ (hydrogen chaine) 2017 2017 (72) Phase Phase 3·2016 2016 2) tumor tumor 3) 1 1 January1) compression compression (for for ≥ to to screening).",
      "start_page": 125,
      "end_page": 125
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (from previous page)",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nreason",
      "start_page": 125,
      "end_page": 125
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (from previous page)",
      "text": "Row 1:\nNCT01933932Row 2:\nSELECT-1Row 3:\nPhase 3",
      "start_page": 125,
      "end_page": 125
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (from previous page)",
      "text": "Row 1:\n2016 (106)Row 2:\nBATTLE-2Row 3:\nPhase 2",
      "start_page": 125,
      "end_page": 125
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (column column 1)",
      "text": "Row 1:\n•Row 2:\n3 3 • RowRow 3:\n• NCT0933932Row 4:\n• SELEKT-1Row 5:\n• RowRow 6:\nPapadimitrakop 2016 (106) 2 2 • Papadimitracop",
      "start_page": 125,
      "end_page": 125
    },
    {
      "heading": "heading heading reliability reliability criteria (column column 2)",
      "text": "of of patients;Study Study , Interferences Interferences details; passengersPriory passengersPriory anyway;RowRow 2:\n•RowRow 3:\n7 (72) 'selumetinib selumetinib (hydrogen agencies) twice daily + 75 mg/daily daily +75 mg/ every every 21- day cycle (n=254) sleeper sleeper (n=54)) (n = n=256)Row 4:\ndaily daily (n=22) weekly weekly (n=42) inhibitor inhibitor AZD6244",
      "start_page": 125,
      "end_page": 125
    },
    {
      "heading": "heading heading reliability reliability criteria (column column 2)",
      "text": "Row 1:\n Row 2:",
      "start_page": 125,
      "end_page": 125
    },
    {
      "heading": "heading heading reliability reliability criteria (column column 3)",
      "text": "Row 1:\nRowRow 2:\n Row 3:\nRowRow 4:\nrelevant relevant intervention",
      "start_page": 125,
      "end_page": 125
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (from previous page)",
      "text": "criteriaExclusion criteriaExclusion criteriaeria;RowRow 2:\n•week week (n=75) daily daily (n=161) •3) Patients with unstable/RowRow 3:\n2015 2015 (102) NCT0066637910 TAILM0] 2012 2012 (cut-off-off January 2013)) Patients with stable/RowRow 3:\n2015 2015 (102) NC006379 10 (102 2) NC) N. N.",
      "start_page": 126,
      "end_page": 126
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (from previous page)",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nreason",
      "start_page": 126,
      "end_page": 126
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (from previous page)",
      "text": "Row 1:\nNCT00637910Row 2:\nTAILOR",
      "start_page": 126,
      "end_page": 126
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (column column 1)",
      "text": "2 mg/m2 TAILOR=daily daily (n=61) • Patients with unstable/RowRow 3:\n2015 2015 (102) NCT0067910 TAILor·2012 2012 (cut-off January 2013) ■75 75 mg/ 35 35 mg_m2",
      "start_page": 126,
      "end_page": 126
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (column column 1)",
      "text": "Row 1:\n•2015 2015 (107) •International study (Argentina, •_MEDTERM0_3 mg/weeks weeks •1) prior prior • 1) Patients aged ≥ non non •RowRow 2:\n•NCT01673867",
      "start_page": 126,
      "end_page": 126
    },
    {
      "heading": "heading heading reliability reliability criteria (column column 2)",
      "text": "Row 1:\nRowRow 2:\n Row 3:\nRowRow 4:\n Row 5:\nExcluded",
      "start_page": 126,
      "end_page": 126
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (from previous page)",
      "text": "Spain, Spain, Switzerland) 2013. 2013..Tiren=292) Docetaxel 75 mg/weeks weeks (n=290) ham-based construction, Singapore; Spain, SWitzerland) 2013. 2013. 3) to to relapse/recurrence of •1) Patients aged ≥ clinically clinically and/NSCLC_and NSCLC_and __MIDTERM6___0",
      "start_page": 127,
      "end_page": 127
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (from previous page)",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nreason",
      "start_page": 127,
      "end_page": 127
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (from previous page)",
      "text": "Row 1:\nRow",
      "start_page": 127,
      "end_page": 127
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (from previous page)",
      "text": "Row 1:\nNCT01708993Row 2:\nRowRow 3:\nRow",
      "start_page": 127,
      "end_page": 127
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (column column 1)",
      "text": "RowRow 2:\nSpain, Switzerland) 2013 2013 (n=292) Docetaxel 75 mg/weeks weeks (n=290) more more 3) to to relapse/recurrence of...1) Patients aged ≥ clinically clinically and/NSCLC_and NSCLC_and ECOG PS_0",
      "start_page": 127,
      "end_page": 127
    },
    {
      "heading": "heading heading reliability reliability criteria (column column 2)",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nrelevant relevant mutation",
      "start_page": 127,
      "end_page": 127
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (from previous page)",
      "text": "RowRow 2:\n•75 75 mg/4. 4.5×days days (n=39) mg mg /4, 4,5×4. 4.5× Day Day (n =39) 75 75 mg",
      "start_page": 128,
      "end_page": 128
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (from previous page)",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nreason",
      "start_page": 128,
      "end_page": 128
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (from previous page)",
      "text": "Row 1:\nNCT00556322Row 2:\nTITANRow 3:\nPhase 3",
      "start_page": 128,
      "end_page": 128
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (column column 1)",
      "text": "1 1 , 21 21 mg/4. 4.5×I I , 75 75 mg/ day day one; days days & 5 5 × 1 1 .days days (n=39) mg mg /day day one",
      "start_page": 128,
      "end_page": 128
    },
    {
      "heading": "heading heading reliability reliability criteria (column column 3)",
      "text": "Row 1:\nRowRow 2:\n Row 3:\nrelevant relevant mutation",
      "start_page": 128,
      "end_page": 128
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (from previous page)",
      "text": "of of patients",
      "start_page": 129,
      "end_page": 129
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (from previous page)",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nreason",
      "start_page": 129,
      "end_page": 129
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (from previous page)",
      "text": "Row 1:\nNCT01798485Row 2:\nGALAXY-2Row 3:\nPhase 3",
      "start_page": 129,
      "end_page": 129
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (from previous page)",
      "text": "Row 1:\n(111)Row 2:\nGALAXY-1Row 3:\nPhase 2",
      "start_page": 129,
      "end_page": 129
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (from previous page)",
      "text": "Row 1:\nNCT02008227Row 2:\nOAKRow 3:\nPhase 3",
      "start_page": 129,
      "end_page": 129
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (from previous page)",
      "text": "2 2 (1) of Regulation (EC) No 659/TTP TTP 2°: __medTERM14__, __medTERM14__, ~study study (and and Australia) 2012 2012 (15, 15, 2012) •orally orally + orally orally (n=526) Placebo + orally orally (N=522) ] (1) created created 1",
      "start_page": 130,
      "end_page": 130
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (from previous page)",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nreason",
      "start_page": 130,
      "end_page": 130
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (from previous page)",
      "text": "Row 1:\nRowRow 2:\n(113)Row 3:\nNCT00440414Row 4:\nHORGRow 5:\nPhase 3",
      "start_page": 130,
      "end_page": 130
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (from previous page)",
      "text": "Row 1:\nNCT01244191Row 2:\nMARQUEERow 3:\nRow",
      "start_page": 130,
      "end_page": 130
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (from previous page)",
      "text": "Row 1:\nOAM4971g (METLung)Row 2:\nNCT01456325",
      "start_page": 130,
      "end_page": 130
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (column column 1)",
      "text": "Row 1:\nRowRow 2:\nexcluded. excluded.",
      "start_page": 130,
      "end_page": 130
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (column column 1)",
      "text": "regime regime (older older patients) were were examined) aged aged < expected expected (1) Patients aged <___ARMM10___MEDM10_. ___ARMM10___MEDM10_...Row 3:\n2017 2017 (115) OAM4971g (_MEDTERM7__Lung) NCT01456325• 2013 2013 (cut-offOnartuzumab 15 mg/cycle cycle +",
      "start_page": 130,
      "end_page": 130
    },
    {
      "heading": "heading heading reliability reliability criteria (column column 2)",
      "text": "Row 1:\nRowRow 2:\n Row 3:\n Row 4:\nRowRow 5:\nRowRow 6:\nrelevant relevant assistance",
      "start_page": 130,
      "end_page": 130
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (from previous page)",
      "text": "criteriaExclusion criteriaExclusion criteriaeria;RowRow 2:\n26, 2013).",
      "start_page": 131,
      "end_page": 131
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (from previous page)",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nreason",
      "start_page": 131,
      "end_page": 131
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (from previous page)",
      "text": "Row 1:\n2017 2017 (116)Row 2:\nNCT01186861Row 3:\nRow",
      "start_page": 131,
      "end_page": 131
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (column column 1)",
      "text": "Row 1:\nRowRow 2:\nPhase 3°2013. 2013...mg mg (n=250) Placebo IV + orally orally (n=49) (2) disease. disease.",
      "start_page": 131,
      "end_page": 131
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (column column 1)",
      "text": "Row 1:\n2017 2017 (116) NCT01186861 Phase 2",
      "start_page": 131,
      "end_page": 131
    },
    {
      "heading": "heading heading reliability reliability criteria (column column 3)",
      "text": "Row 1:\nRowRow 2:\nsubmissionRow 3:\nreason",
      "start_page": 131,
      "end_page": 131
    },
    {
      "heading": "heading heading reliability reliability criteria (column column 4)",
      "text": "Row 1:\nDanishRow 2:\nand",
      "start_page": 131,
      "end_page": 131
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (from previous page)",
      "text": "(n = n-c) NCT-NCurrent) (NC01362296 Phase 2_MEDTERM0_en) (n=n=N-CowSighter) (now) arm arm (n)years years (range) [ 95% CI]R*Male, n (%).p p (%)n n (%)",
      "start_page": 132,
      "end_page": 132
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (from previous page)",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nexclusion",
      "start_page": 132,
      "end_page": 132
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (from previous page)",
      "text": "Row 1:\nRowRow 2:\nal 2015 (101)Row 3:\nNCT01362296Row 4:\nPhase 2",
      "start_page": 132,
      "end_page": 132
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (from previous page)",
      "text": "Row 1:\n(103)Row 2:\nNCT01229150;Row 3:\nCTEP: 8444Row 4:\nPhase 2",
      "start_page": 132,
      "end_page": 132
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (from previous page)",
      "text": "Row 1:\n(104)Row 2:\nNCT01395758Row 3:\nPhase 2",
      "start_page": 132,
      "end_page": 132
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (from previous page)",
      "text": "(NCT01933932) SEL: NCRawH2Right) RowShway 1: arm arm (n))years years (range) [ 95% CI]=Male, n (%).p p (%)-N-clle N-clle c/P-n n % •KRAS £G12C: 18 (40) ] ]Row 4:\n2017 2017 (72) NCTC0193533932 marked: pemetrexed pemetrexed (n=45) [58 /71) ]Former: 40 (89)KRASmG12 C: 18.40) ]Row 4:\n2017, (72): NCTT01939339332.32",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (from previous page)",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nexclusion",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (from previous page)",
      "text": "Row 1:\n(72)Row 2:\nNCT01933932Row 3:\nSELECT-1Row 4:\nPhase 3",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (from previous page)",
      "text": "Row 1:\n(102)Row 2:\nNCT00637910Row 3:\nTAILOR",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (from previous page)",
      "text": "Row 1:\nnames names •Thandling arm (n) •years years (range) [ 95% CI] •Male, n (%) •n n 1% •Histology, n % •n n (*) • na na (%) ■RowRow 2:\n•a a Sc·N-clle N-clle c",
      "start_page": 134,
      "end_page": 134
    },
    {
      "heading": "heading heading criteria criteria (KRAS G12C KRAS G12C mutation) (from previous page)",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nexclusion",
      "start_page": 134,
      "end_page": 134
    },
    {
      "heading": "heading heading reliability reliability criteria (column column 4)",
      "text": "Row 1:\nyears years (range) [ 95% CI]",
      "start_page": 134,
      "end_page": 134
    },
    {
      "heading": "heading heading reliability reliability criteria (column column 6)",
      "text": "Row 1:\nHistology, n (%) • n n %Row 2:\nN-clle N-clle c",
      "start_page": 134,
      "end_page": 134
    },
    {
      "heading": "heading heading reliability reliability criteria (column column 9)",
      "text": "Row 1:\nRowRow 2:\nsotorasib. sotorasib.",
      "start_page": 134,
      "end_page": 134
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "of of 2; Prior Prior \"Countover\"Key Inclusion Criteria·Secondary Secondary Endpoints/Oligitives",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nAuthorRow 2:\nCountry",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nStudy",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nCriteria",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nSecondaryRow 3:\nEndpoints/Objects",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nSotorasibRow 2:\n14",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\n> 2 (including anti-Row 2:\nPD-[L]1 therapies)",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nHistologicallyRow 2:\nRowRow 3:\nRowRow 4:\nRowRow 5:\nthe KRASG12C mutation;Row 6:\n0 0 - 2;Row 7:\nRowRow 8:\nv1. v1.1; forRow 9:\nRowRow 10:\nprevious platinum-Row 11:\nRowRow 12:\nRowRow 13:\ntherapies, or both",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nActive (untreated)Row 2:\nbrain metastases;Row 3:\nRowRow 4:\nRowRow 5:\nRowRow 6:\nof sotorasib therapy;Row 7:\nRowRow 8:\nRowRow 9:\nRowRow 10:\nRowRow 11:\nRowRow 12:\nRowRow 13:\nmonths",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nSotorasibRow 2:\n13",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nSotorasibRow 2:\n40",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\n≥ 2: 31 (77.5)Row 2:\n≥ 3: 19 (47.5)",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nInternational",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nSotorasibRow 2:\n59",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nInternational",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nSotorasibRow 2:\n126",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nAnti-PD-(L)1: 91.3%Row 2:\nPlatinum-based CHT",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Level:Rowway:Right right;Right:Rough-Run-T1:R2+Rightway:Showy Name: Study-Dates. Study-Dates.Intervention/Oakables.Row 2:\n•RowRow 3:\n•lot lot (Range), •Row 4:\n_NSCLC in Total",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nAuthorRow 2:\nCountry",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nStudy",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nCriteria",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nSecondaryRow 3:\nEndpoints/Objects",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nNCT03600883Row 2:\nRowRow 3:\nPhase 2",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nSotorasibRow 2:\n126",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nUSA",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nNCT03785249Row 2:\nCRYSTAL-1Row 3:\nPhase 1/2",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nAdagasibRow 2:\n79",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nan an anti-PD-Row 2:\n(L)1",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nEudraCT: 2005-Row 2:\n005393-73Row 3:\n Row 4:\nPhase 2",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nErlotinibRow 2:\n34",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nadvanced NSCLC",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nlesion; __MEDTERM0_0 - 2;Row 4:\nRowRow 5:\nRowRow 6:\nadvanced NSCLC",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "heading heading Local adaptation (column column 1)",
      "text": "AgainT2 AgainT2 Right: StudyNow StudyNow 2: RowRow 3:\n•Median Median (Range), •Row 4:\n__NSCLC in Total#n n (%)Row 5:\nstrengthenand anti-PD-(L) 1:9: 91.3% and and anti-PPD-Í (L)): 81.0%;2 2 /Data-†Soorrasib 126·Anti-PD‐R-( L) 1: 91.3%) anti anti -PD-$-L): 81.0%)NCT 03600883) 81.",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "heading heading Local adaptation (column column 2)",
      "text": "Row 1:\nExclusiveRow 2:\nriteriaRow 3:\n Row 4:\n Row 5:\n Row 6:\n Row 7:\n Row 8:\n Row 9:",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "heading heading Local adaptation (column column 3)",
      "text": "Row 1:\nn",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "heading heading Local adaptation (column column 3)",
      "text": "Row 1:\n\"Secondary Secondary Endpoints/Objectives\"Row 2:\n\"Row 3:\n\"Row 4:\n\"NR\"Row 5:\n\"Row 6:\n\"following following erlotinibtherapy·FDG FDG &amp; •Row 7:\n\"RowRow 8:\n\"prediction of non",
      "start_page": 137,
      "end_page": 137
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Commission Regulation (EU) even even 1: Inclusion Inclusion Criteria·Secondary Secondary Endpoints/ObligitiesRow 2:\nRowRow 3:\n•chargeLoTmedien chargeLoTmedien (Range), ---Row 4:\n__NSCLC_REMEDTERM0__ in Total]n n (%)Row 5:\nNCT02774278 International=NCT0277478 Phase 2",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nAuthorRow 2:\nCountry",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nStudy",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nCriteria",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nSecondaryRow 3:\nEndpoints/Objects",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nNCT02774278Row 2:\nInternational",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nNCT02774278Row 2:\n Row 3:\nPhase 2",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\n2009",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\ndisease; otherRow 3:\nRowRow 4:\nlast 5 years; brainRow 5:\nmetastases; priorRow 6:\nanti-Row anti-Row 7:\nEGFRtherapy",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nPrimary: RowRow 2:\nRowRow 3:\nRowRow 4:\nclinical benefit (includingRow 5:\nKRASm)Row 6:\nSecondary: __MEDTERM0_, CBR",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nUSA",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nNRRow 2:\n Row 3:\nPhase 1/2",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRilotumumabRow 2:\nRowRow 3:\n45",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nRowRow 4:\n__MIDTERM1__",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nPrimary: RowRow 2:\neffectiveness (RowRow 3:\n70%)Row 4:\nSecondary: OS, PFS",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nChina",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nNCT00816868Row 2:\nC-TONG0807Row 3:\nPhase 2",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nEnrollmeRow 2:\nnt: FebRow 3:\nRowRow 4:\nSeptRow 5:\n2009",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\ncapcitabineRow 3:\n58",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\ntreatment",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nPrimary: 12-weekRow 2:\nRowRow 3:\nSecondary: RowRow 4:\n__MIDTERM2___. __MIDTERM2___.",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading Local adaptation (column column 1)",
      "text": "Row 1:\nAuthor Country...AuthorRow 2:\n• CountryRow 3:\nNCT0277427 International • NCCT0277427Row 4:\n• InternationalRow 5:\nUSA USA • RowRow 6:\n• USARow 7:\nZhao, 201 China",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading Local adaptation (column column 2)",
      "text": "Row 1:",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading Local adaptation (column column 2)",
      "text": "Commission Regulation (EC) right right holder: Study. Study.DatesIntervention/RowRow 2:\nCERow CERow 3:\n•Patients with \"LoT\" (Range), • 'Range', 'Row 4:\n~n n (%) 0 5: 2 2 /June June 2009^responsibilityAdvanced responsibilityAdvanced ___MEDTM9___; •Unstable system disease; 5 5 years; brain mettasses; previous metise; previous actions;",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading Local adaptation (column column 2)",
      "text": "Row 1:\n78Row 2:\nl",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading Local adaptation (column column 2)",
      "text": "Row 1:\n17",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading Local adaptation (column column 2)",
      "text": "Row 1:\n15",
      "start_page": 138,
      "end_page": 138
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Commission Regulation (58) Canada/IND.196 Phase: 9 (59) ]Media 2 (29) /and and __MEDTERM9_Drimary: 2 CHT: 31 (100) Radiation: 18 (55) Other: 9 (229) (1) and and ...n n (%)Row 5:\nJan Jan 2013",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nAuthorRow 2:\nCountry",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nStudy",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nCriteria",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nSecondaryRow 3:\nEndpoints/Objects",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nCanada",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nPhase 1",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\n2013",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nPrimary: RP2DRow 2:\nSecondary: descriptiveRow 3:\nRowRow 4:\nand and PD",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nUSA",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nNCT01302808Row 2:\n Row 3:\nPhase 1",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\n2014a",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nerlotinibRow 3:\n17",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nPrimary: safety,Row 2:\nRowRow 3:\nSecondary: RowRow 4:\nPK",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nUSA",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nAntroquinoneolRow 2:\n30",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nhistologicallyRow 3:\nconfirmed non-",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "cancer cancer prevention;2 2 (anti-dumping anti-dumping law; More than 5: Phase Phase 2•Dec Dec 2018[set set up: set set set: 31 ]Antrohoh wol/n (%)Row 5:\nnCT02077344 International",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nAuthorRow 2:\nCountry",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nStudy",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nCriteria",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nSecondaryRow 3:\nEndpoints/Objects",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nNCT02047344Row 2:\nInternational",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nNCT02047344Row 2:\n Row 3:\nPhase 2",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\n2018",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\n(stage IV); diseaseRow 3:\nRowRow 4:\nPrior LoTs (RowRow 5:\nplatinum-based) orRow 6:\nRowRow 7:\nRowRow 8:\napproved treatments;Row 9:\nRowRow 10:\nRowRow 11:\nRECIST v1.1; RowRow 12:\nRowRow 13:\navailable; __MIDTERM1_0 - 2",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nUSA",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nNCT02417701Row 2:\n Row 3:\nPhase 2",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nRowRow 4:\n2020a",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nTAK228Row 2:\n21",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nPrimary: ORR Secondary:Row 2:\nPFS",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nUnited States",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nNRRow 2:\n Row 3:\nPhase 2",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nEnrollmeRow 2:\nnt: SeptRow 3:\nRowRow 4:\nJun 2016",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nDefactinibRow 2:\n55",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nLeptomeningealRow 2:\nmetastasis",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nPrimary: 12-week PFSRow 2:\nrateRow 3:\nSecondary: __MIDTERM0__, OS, ~MEDTERM3__,Row 4:\nand safety",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading Local adaptation (column column 1)",
      "text": "Row 1:\nAuthor Country...AuthorRow 2:\n• CountryRow 3:\nNCT0204734 Internationa.. . . ..RowRow 4:\n\"InternationaRow 5:\nUSA. USA...\"RowRow 6:\n\"USARow 7:\nA. A.\"",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading Local adaptation (column column 2)",
      "text": "Row 1:",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading Local adaptation (column column 2)",
      "text": "to to right;Key Inclusion Criteria:Secondary Secondary Endpoints/ObligivesRow 2:\nRowRow 3:\nDec Dec 2018;set set set: 30 Safety set: 31 •cancer cancer analysis; 2018, Set: 30 Security set: 32",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading Local adaptation (column column 2)",
      "text": "Row 1:\n44Row 2:\nal",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading Local adaptation (column column 2)",
      "text": "Row 1:\n20",
      "start_page": 140,
      "end_page": 140
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row+Row+T2: 1:Jun 2014_MEDM0_ 20ah- 2hH1:Row=to to 1: 0RowGo right: Study. Study.DatesIntervention/OakiesRow 2:\n•RowRow 3:\n•Criteria Criteria (Range), •Row 4:\nn n (%) -Row 5:\nRowRow 6:\n\"Row 6:\n'FAK inhibitor; __MEDERTM14_Row 7:\n~1. 1. ■Row 8:\nPhase Phase 1: 'Enrollme nt: Jun Jun 2014",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nAuthorRow 2:\nCountry",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nStudy",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nCriteria",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nSecondaryRow 3:\nEndpoints/Objects",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nNokihara,Row 2:\n2019Row 3:\nJapan",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nNCT0153656Row 2:\n Row 3:\nPhase 1",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nEnrollmeRow 2:\nnt: 28Row 3:\nMarchRow 4:\nRowRow 5:\nJun 2014",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nCabozantinibRow 2:\n20",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\n≥ 3: 20 (100)Row 2:\nCHT: 20 (100),Row 3:\nBEV: 10 (50)Row 4:\nNivolumab: 1 (5)Row 5:\nTKI: 19 (95)Row 6:\nCrizotinibs: 1 (5),Row 7:\n~MEDTERM2__S: 10/50)Row 8:\n}MEDTERM3___Y: 13 (65)Row 9:\n•MEDTERM4___: 1 (20)",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nPrimary: MTD and/orRow 2:\nRowRow 3:\nRowRow 4:\nRowRow 5:\nRowRow 6:\nRowRow 7:\nreceived ≥ RowRow 8:\ncabozantinib.",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "heading heading Local adaptation (column column 1)",
      "text": "Row 1:\nAuthor Country...AuthorRow 2:\n\"CountryRow 3:\n\"Row 4:\nNokihara, 2019 Japan\" Nokihara,Row 5:\n\"2019Row 6:\n\"Japan\"",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "heading heading Local adaptation (column column 2)",
      "text": "Row 1:",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "heading heading Local adaptation (column column 2)",
      "text": "Row 1:\nRowRow 2:\n• RowRow 3:\n• StudyRow 4:\n•Row 5:\n• 1 1 • NLT0155365Row 6:\n■Row 7:\n▪ phase 1",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "heading heading Local adaptation (column column 3)",
      "text": "Row 1:\ntudyRow 2:\nRowRow 3:\ny",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "heading heading Local adaptation (column column 3)",
      "text": "Row 1:\n\"Dates\" InterfaceRow 2:\n\"RowRow 3:\n\"RowRow 4:\n\"RowRow 5:\n\"Row 6:\n56\" \"Enrollme nt: Jun Jun 2014·_MEDTERM0___20__MEDTERM0_\"Row 7:\n\"20Row 8:\n\"",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "heading heading Local adaptation (column column 4)",
      "text": "Row+H H , Wow Wow 3: ithowow-T Median (Range), ororRow 4:\nn n (%) •Row 5:\nCERow 6:\nceFAK inhibitor; Nivolumab_5 (5) TKI: 19 (95) __ENTTERM1___: 1 (5) ___MEDERTM1__: 5 (5) __medTERM2___: 10 (50) __midTERM3_ 20 (100) CHT: 20 (100] BEV: 10 (565) ___MIDTERM4___ 1: 1 (5) TCI: 1995 ___",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "heading heading Local adaptation (column column 5)",
      "text": "Row 1:\nRowRow 2:\nCritRow 3:\n Row 4:\n Row 5:\nR",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "heading heading Local adaptation (column column 6)",
      "text": "Row 1:\nxclusionRow 2:\nteriaRow 3:\n Row 4:\n Row 5:",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "heading heading Local adaptation (column column 7)",
      "text": "Row 1:\n\"Secondary Secondary Endpoints/ObjectsRow 2:\n\"Row 3:\n\"Primary: MTD and/received received ≥ __MEDTERM0_. __MEDTERM0_.",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row+RightH1:right right right- right right right= Secondary Secondary Endpoints/OaksRow 2:\nRowRow 3:\n•Media Media (Range), ---Row 4:\nn n (%) #Row 5:\n2. 2.6) 2: 6 (31.6)2: 13 (68.4) KRASav12C 1: 6 (38.4) May May 2019·May May 2019; ___MEDTERMM0__in Total",
      "start_page": 142,
      "end_page": 142
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nAuthorRow 2:\nCountry",
      "start_page": 142,
      "end_page": 142
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nStudy",
      "start_page": 142,
      "end_page": 142
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nCriteria",
      "start_page": 142,
      "end_page": 142
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nSecondaryRow 3:\nEndpoints/Objects",
      "start_page": 142,
      "end_page": 142
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nNCT02642042Row 2:\nUSA",
      "start_page": 142,
      "end_page": 142
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nNCT02642042Row 2:\n Row 3:\nPhase 2",
      "start_page": 142,
      "end_page": 142
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nRowRow 4:\n2019",
      "start_page": 142,
      "end_page": 142
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nPrimary: RowRow 2:\nSecondary: RowRow 3:\nRowRow 4:\nKRAsm Non-G12C; gradeRow 5:\n3 - 5 AE",
      "start_page": 142,
      "end_page": 142
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nUSA",
      "start_page": 142,
      "end_page": 142
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nNCT01192165Row 2:\n Row 3:\nPhase 1b",
      "start_page": 142,
      "end_page": 142
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nOctRow 4:\n2013a",
      "start_page": 142,
      "end_page": 142
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nRowRow 4:\n(RowRow 5:\ncolony-Row 6:\nstimulatingRow 7:\nfactor [G-CSF])Row 8:\nRowRow 9:\nRowRow 10:\n95",
      "start_page": 142,
      "end_page": 142
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nPrimary (Part 1): RP2DRow 2:\nPrimary (expansionRow 3:\ncohort): ORR",
      "start_page": 142,
      "end_page": 142
    },
    {
      "heading": "heading heading Local adaptation (column column 1)",
      "text": "Row 1:\nAuthor Country...AuthorRow 2:\n..CountryRow 3:\nNCT0264204 USA.. . . ..NCT026504Row 4:\n..USARow 5:\nUSA. USA. ..RowRow 6:\nA. A.",
      "start_page": 142,
      "end_page": 142
    },
    {
      "heading": "heading heading Local adaptation (column column 2)",
      "text": "Row 1:",
      "start_page": 142,
      "end_page": 142
    },
    {
      "heading": "heading heading Local adaptation (column column 2)",
      "text": "5 (68.4) KRASm Non-G12C1 (28.6) 2: 25 (71.4):16 (29.6) 2: 38 (70.5) KRASG12C 1: 6 (31.6) 2: 13 (68.4) 12C 12C 1:10 (28.6.6) 2:25 (771.4), 16 (29.6)):16 (229.6). 2:38 (69.6) G12C G12C 1:13 (28.5) 2:25 (71.14.4) +2 (79.6):16 (9.29.6)2:29.6 2:38 (770.4) RRASG 12C 1:6 2: 13 (31.6) KRACSm Nnon-G11C 1: 10 (28.6) C 1:10 (\"2.4) 2:21.4) 4:16 (27.6) 3:16 (39.6) 2.38 (70.7.4) n n (%):9.4) DRASG2:26.) KREAS_QTURRP 1: SeaRSSS+United United AG; WE: 7R even USRA: right:iR",
      "start_page": 142,
      "end_page": 142
    },
    {
      "heading": "heading heading Local adaptation (column column 2)",
      "text": "Row 1:\n42",
      "start_page": 142,
      "end_page": 142
    },
    {
      "heading": "heading heading Local adaptation (column column 2)",
      "text": "Row 1:\n17",
      "start_page": 142,
      "end_page": 142
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "of of Justice; right right right: \"RowRow 3:\n\"lies lies (Range), ---Row 4:\n_NSCLC_ in Total·n n (%) 0 5: •or uncontrolled •Row 3:\n•Patents over •systemic diseases •Row 7:\nPhase Phase 1b£Conduct eded: more. more.KRASASm; metastatic=Question Question (21 days_toward_ into",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nAuthorRow 2:\nCountry",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nStudy",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nCriteria",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nSecondaryRow 3:\nEndpoints/Objects",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nUSA",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nNCT02258607Row 2:\nNRRow 3:\nPhase 1b",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nConductRow 2:\ned:Row 3:\nMarchRow 4:\nRowRow 5:\nMarchRow 6:\n2017",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nMomelotinibRow 2:\nRowRow 3:\n21",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nPrimary: RowRow 2:\nRowRow 3:\ncycleRow 4:\nSecondary: RowRow 5:\n8; ORR; PFS, __MIDTERM2__",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nHuijberts,Row 2:\n2020Row 3:\nNetherlands",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nNCT02230553Row 2:\n Row 3:\nPhase 1",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\n2019a",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\ntrametinibRow 3:\n15",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nPrimary: RP2RRow 2:\nSecondary: RowRow 3:\nRowRow 4:\nRowRow 5:\nand PK",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading Local adaptation (column column 1)",
      "text": "Row 1:\nAuthor Country...AuthorRow 2:\n\"CountryRow 3:\n\"Row 4:\nBarbie, 201 USA\" \"RowRow 5:\n\"USARow 6:\nHuijberts, 2020\" \"Huijberts,\"Row 7:\n\"2020Row 8:\n\"Netherlands\"",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading Local adaptation (column column 2)",
      "text": "Row 1:",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading Local adaptation (column column 2)",
      "text": "Row 1:\n\"RowRow 2:\n\"RowRow 3:\n\"StudyRow 4:\n\"Row 5:\n\" 18 \" 1b 1b \" Nct022586\"Row 6:\n\"NRRow 7:\n\"RowRow 8:\n\"NCT0223055 Phase 1\" NCT0223055Row 9:\n\"Row 10\": \"Phase 1\"",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading Local adaptation (column column 2)",
      "text": "Row 1:\n Row 2:",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading Local adaptation (column column 3)",
      "text": "Row 1:\ntudyRow 2:\nRowRow 3:\ny",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading Local adaptation (column column 3)",
      "text": "Row 1:\n\"Dates\" DatesRow 2:\n\"Row 3:\n\"07\" Conduct ed: 2017 2017 \"ConductRow 4:\n\"Added:Row 5:\n\"MarchRow 6:\n\"RowRow 7:\n\"MarchRow 8:\n\"2017Row 9:\n\"De De 2019a· RowRow 10:\n\"RowRow 11:\n\"2019a",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading Local adaptation (column column 3)",
      "text": "Row 1:\n53Row 2:",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading Local adaptation (column column 4)",
      "text": "The right-over-Right of DRT-tas-path path inhibitors;Aright-way_right-a- right-way-way=Right-way -right, right-on-right, right: secondary secondary Endpoints/OobjectivesRow 2:\n\"RowRow 3:\n\"Median Median (Range), 'Row 4:\nn n (%) ---Row 5:\n•RowRow 6:\n^systemagy (21 days)Row 7:\nto to study; inhibitors inhibitors (21 day) systems systems (28 days) or immuno",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading Local adaptation (column column 4)",
      "text": "Row 1:\n14Row 2:\nec",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "right right USA: Inclusion Inclusion Criteria·Secondary Secondary Endpoints/OliteivesRow 2:\n\"RowRow 3:\n\"Patients within 'LoT Middle (Range), 'Row 4:\n_NSCLC_ in Total#n n (%) # 5:",
      "start_page": 144,
      "end_page": 144
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nAuthorRow 2:\nCountry",
      "start_page": 144,
      "end_page": 144
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nStudy",
      "start_page": 144,
      "end_page": 144
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nCriteria",
      "start_page": 144,
      "end_page": 144
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nSecondaryRow 3:\nEndpoints/Objects",
      "start_page": 144,
      "end_page": 144
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\n5 countries:Row 3:\nRowRow 4:\nand Europe.",
      "start_page": 144,
      "end_page": 144
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nNCT01155453Row 2:\n Row 3:\nPhase 1b",
      "start_page": 144,
      "end_page": 144
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nEnrollmeRow 2:\nnt: MayRow 3:\nRowRow 4:\nJan 2013",
      "start_page": 144,
      "end_page": 144
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\n__MEDTERM0_17",
      "start_page": 144,
      "end_page": 144
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\n3 (1 - 14)",
      "start_page": 144,
      "end_page": 144
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nPrimary: RowRow 2:\nRowRow 3:\nSecondary: safety, PK;Row 4:\nRowRow 5:\npredictive/PD biomarkers",
      "start_page": 144,
      "end_page": 144
    },
    {
      "heading": "heading heading Local adaptation (column column 1)",
      "text": "Row 1:\nAuthor Country...AuthorRow 2:\n\"CountryRow 3:\n\"Row 4:\n\"Europe. Europe.\"\"RowRow 5:\n\"RowRow 6:\n\"RowRow 7:\n\"and Europe.\"",
      "start_page": 144,
      "end_page": 144
    },
    {
      "heading": "heading heading Local adaptation (column column 2)",
      "text": "Row 1:",
      "start_page": 144,
      "end_page": 144
    },
    {
      "heading": "heading heading Local adaptation (column column 2)",
      "text": "right right right- right right right: Secondary Secondary Endpoints/OobjectivesRow 2:\n\"RowRow 3:\n\"a a 'LoT Media' (Range), 'Row 4:\n___medTERM2__in Total#n n (%)Row 5:\n•occlusion; previous",
      "start_page": 144,
      "end_page": 144
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Commission Regulation (right right right: secondary secondary Endpoints/OliteivesRow 2:\n\"Number of sleep'Row 3:\n\"time time Time' (Range), 'Row 4:\n_NSCLC in Total·n n (%) #5: Bardia, 2020 International",
      "start_page": 145,
      "end_page": 145
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nAuthorRow 2:\nCountry",
      "start_page": 145,
      "end_page": 145
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nStudy",
      "start_page": 145,
      "end_page": 145
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nCriteria",
      "start_page": 145,
      "end_page": 145
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nSecondaryRow 3:\nEndpoints/Objects",
      "start_page": 145,
      "end_page": 145
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nInternational",
      "start_page": 145,
      "end_page": 145
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nNCT01363232Row 2:\n Row 3:\nPhase 1b",
      "start_page": 145,
      "end_page": 145
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nRowRow 4:\n2014Row 5:\n(dataRow 6:\ncutoff)",
      "start_page": 145,
      "end_page": 145
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\ntumors; diseaseRow 3:\nRowRow 4:\nRowRow 5:\nand/RowRow 6:\nRowRow 7:\navailable; evaluableRow 8:\nRowRow 9:\nv1.1; 2. 2.",
      "start_page": 145,
      "end_page": 145
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nPrimary: RowRow 2:\nSecondary: RowRow 3:\nPD",
      "start_page": 145,
      "end_page": 145
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nSwitzerland",
      "start_page": 145,
      "end_page": 145
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nNCT02964689Row 2:\n Row 3:\nPhase 1b",
      "start_page": 145,
      "end_page": 145
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nEnrollmeRow 2:\nnt: MayRow 3:\nRowRow 4:\nDec 2019",
      "start_page": 145,
      "end_page": 145
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nBinimetinib,Row 2:\nRowRow 3:\ncisplatinRow 4:\n18",
      "start_page": 145,
      "end_page": 145
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nAustralia &Row 3:\nNew Zealand",
      "start_page": 145,
      "end_page": 145
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nNRRow 2:\n Row 3:\nPhase 1",
      "start_page": 145,
      "end_page": 145
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nConductRow 2:\ned: 20Row 3:\nRowRow 4:\nRowRow 5:\n2017",
      "start_page": 145,
      "end_page": 145
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nLifirafenibRow 2:\n19 (RowRow 3:\nescalation + 10Row 4:\ndose expansion)",
      "start_page": 145,
      "end_page": 145
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nAll cancers: ≥ 3 (inc.Row 2:\nRowRow 3:\ntreatment) 50%Row 4:\nprior surgery ≥ 75%",
      "start_page": 145,
      "end_page": 145
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nescalation: RowRow 3:\nRowRow 4:\nRowRow 5:\nSecondary: RowRow 6:\nof of SD",
      "start_page": 145,
      "end_page": 145
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Commission Regulation (EU) right right right- Secondary Secondary Endpoints/OakiesRow 2:\n\"RowRow 3:\n\"journey journey Criteria', 'Range), 'Row 4:\n_NSCLC in Total#n n (%) 0 5: •mutation-grade mutation-grade ≥ prior prior ]Row 3:\n'Patents of slowly'Row 6:\ntumors tumors ~ RowRow 7:\nPase Pase 1;Enrolle nt nt: Apr Apr 2018__MEDTERTERM0_/PD-03-0325901 to 11",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nAuthorRow 2:\nCountry",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nStudy",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nCriteria",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nSecondaryRow 3:\nEndpoints/Objects",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nNetherlands",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nNCT02039336Row 2:\n Row 3:\nPhase 1",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nEnrollmeRow 2:\nnt: AprRow 3:\nRowRow 4:\nApr 2018",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nDacomitinib_/PD-Row 2:\n0325901Row 3:\n11",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nAt least 2:Row 2:\nantineoplasticRow 3:\nRowRow 4:\ndisease",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nPrimary: RowRow 2:\nscheduleRow 3:\nSecondary: RowRow 4:\nRowRow 5:\nactivity, PK",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nGermany",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nNRRow 2:\n Row 3:\nPhase 1",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nEnrollmeRow 2:\nnt: OctRow 3:\nRowRow 4:\nDec 2013",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nsorafenibRow 3:\n16",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nPrimary: RowRow 2:\nSecondary: RowRow 3:\nRowRow 4:\nresponse",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nNCT00098254,Row 2:\n2021Row 3:\nUSA",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nNCT00098254Row 2:\n Row 3:\nPhase 2",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\n2011",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\n(Sorafenib_)Row 3:\n37",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading Local adaptation (column column 1)",
      "text": "Row 1:\nAuthor Country...AuthorRow 2:\n\"CountryRow 3:\n\"Row 4:\nNetherlands. Netherlands...\"van Geel,\" 202Row 5:\n\"NetherlandsRow 6:\nNogova, 202 Germany\" \"RowRow 7:\n\"GermanyRow 8:\nNCT0009825 2021 \"USA\" NCT009825Row 9:\n\"2021Row 10:\n\"USA",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading Local adaptation (column column 2)",
      "text": "Row 1:",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading Local adaptation (column column 2)",
      "text": "Row 1:\n\"RowRow 2:\n\"RowRow 3:\n\"StudyRow 4:\n\"Row 5:\n\" 20 \" 1 1 \" Nct020392Row 6:\n\"Row 7:\n\" RowRow 8:\n\" 1 1 'NRRow 9:\n\" Bow 10 \": \"RowRow 11:\n\" 2 2 \" NTT000982Row 12:\n\"Row 13:\n\" Phase 2",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading Local adaptation (column column 2)",
      "text": "Row 1:\n20",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading Local adaptation (column column 2)",
      "text": "Row 1:\n54,Row 2:",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading Local adaptation (column column 3)",
      "text": "Row 1:\ntudyRow 2:\nRowRow 3:\ny",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading Local adaptation (column column 3)",
      "text": "Secondary Secondary Endpoints/Oobjectives)Row 2:\nNumber of 5: cup 5: \"grade grade ≥ RowRow 6:\n• RowRow 7:\n36;Enrollme nt: Apr Apr 2018Dacomitinib___/PD-0325901 11 ]At least 2: advancedd advancedd disease; At least 2: anteoplast 2: advanced advanced disease;Histologically or",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading Local adaptation (column column 3)",
      "text": "Row 1:\n Row 2:",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading Local adaptation (column column 3)",
      "text": "Row 1:\n54Row 2:",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "NIRNRowRight+rightHonder1 rightHonder1 1: Secondary Secondary Endpoints/ObligeicesRow 2:\n\"RowRow 3:\n\"Middle Middle (Range), #Row 4:\nn n (%) RegisterRow 5:\n•RowRow 6:\n\"with KRASm^Row 7:\nin in Total#p p (%) 0 5: n n % Ro Ro 5:Row 6:\n'WIT WIT 6: 3 (1 - 10) ];NR",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nAuthorRow 2:\nCountry",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nStudy",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nCriteria",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nSecondaryRow 3:\nEndpoints/Objects",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nNR",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nNCT01021748Row 2:\nNRRow 3:\nPhase 1",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nselumetinibRow 3:\n19",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nLopez-Chavez,Row 2:\n2015Row 3:\nUSA",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nNCT01306045Row 2:\nCUSTOMRow 3:\nPhase 2",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nSelumetinibRow 2:\nmonotherapyRow 3:\nRowRow 4:\nRowRow 5:\nmutationbRow 6:\n481",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nHistologicallyRow 2:\nRowRow 3:\nRowRow 4:\n(RowRow 5:\nneuroendocrineRow 6:\ntumors), RowRow 7:\nmalignancies",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nHuijberts,Row 2:\n2020Row 3:\nNetherlands",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nNCT2450656Row 2:\n Row 3:\nPhase 1",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nPrimary: RP2RRow 2:\nSecondary: anti-tumorRow 3:\nand and PD",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading Local adaptation (column column 1)",
      "text": "Row 1:\nAuthor Country...AuthorRow 2:\n\"CountryRow 3:\n\"Row 4:\nNR NR 'Tolcher', 201Row 5:\n\"NRRow 6:\n\"Lopez-Chave 2015 \" USA \" Lopez -ChaveRow 7:\n\" 2015Row 8:\n\"USARow 9:\n\"Huijberts, 2020\" Netherlands \"Huijberts,\"Row 10:\n\"2020Row 11:\n\"Netherlands\"",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading Local adaptation (column column 2)",
      "text": "Row 1:",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading Local adaptation (column column 2)",
      "text": "RowRow+Case Case (Range) -Ex Ex Crit=RowRow 2:\n\"RowRow 5:\n'Row 6:\n15°Phase Phase 1: 'All All cancers: 3 (1 - 10) n n (%) 0 0 5: 0 0 ]5 5 7: Row",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading Local adaptation (column column 2)",
      "text": "Row 1:\nez,Row 2:",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading Local adaptation (column column 2)",
      "text": "Row 1:\n Row 2:",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading Local adaptation (column column 3)",
      "text": "Row 1:\nxclusionRow 2:\nteriaRow 3:\n Row 4:\n Row 5:\n Row 6:\n Row 7:\n Row 8:\n Row 9:",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading Local adaptation (column column 4)",
      "text": "Row 1:\n•Secondary Secondary Endpoints/Objects •Row 2:\n• response response • Raw 3: • With KRASm·Row 4:\n• Dose finding: MTD in",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "right right Run: right right right: Secondary Secondary Endpoints/Oliteives.Row 2:\n\"RowRow 3:\n\"Middle Middle (Range), #Row 4:\n_NSCLC in Total",
      "start_page": 148,
      "end_page": 148
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nAuthorRow 2:\nCountry",
      "start_page": 148,
      "end_page": 148
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nStudy",
      "start_page": 148,
      "end_page": 148
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nCriteria",
      "start_page": 148,
      "end_page": 148
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nSecondaryRow 3:\nEndpoints/Objects",
      "start_page": 148,
      "end_page": 148
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nClinicalTrRow 2:\nils.gov",
      "start_page": 148,
      "end_page": 148
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nsites",
      "start_page": 148,
      "end_page": 148
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nNRRow 2:\n Row 3:\nPhase 1",
      "start_page": 148,
      "end_page": 148
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\n1: 2 (8)Row 2:\n2: 12 (50)Row 3:\n≥ 3: 10 (42)",
      "start_page": 148,
      "end_page": 148
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nNSCLC with KRASm;Row 4:\nECOG PS ≤ 1; lifeRow 5:\nexpectancy ≥ 12Row 6:\nweeks; MeasurableRow 7:\nRowRow 8:\nv1.1; ≤ RowRow 9:\n__MIDTERM0__",
      "start_page": 148,
      "end_page": 148
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nRowRow 4:\nRowRow 5:\nRowRow 6:\nRowRow 7:\nocular disorders",
      "start_page": 148,
      "end_page": 148
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nand antitumour activity",
      "start_page": 148,
      "end_page": 148
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nNCT02031458Row 2:\nBIRCHRow 3:\nPhase 2",
      "start_page": 148,
      "end_page": 148
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nAtezolizumabRow 2:\n667",
      "start_page": 148,
      "end_page": 148
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nCohort 1: noneRow 2:\nCohorts 2: 1Row 3:\nCohorth 3: ≥ 2",
      "start_page": 148,
      "end_page": 148
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nRowRow 4:\nNSCLC; RowRow 5:\nexpression; RowRow 6:\nor 1; Measurable",
      "start_page": 148,
      "end_page": 148
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\npneumonitis,Row 4:\nautoimmuneRow 5:\nRowRow 6:\nviral diseases; PriorRow 7:\ntreatment with",
      "start_page": 148,
      "end_page": 148
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Commission Regulation (EU) 2RS2 2RS2 Run:of of StudySubDatesInterventionInventions/OobjectivesRow 2:\n•RowRow 3:\n\"1. 1. .1. 1.).or or ICIRange), --- Ro 4: __medTERM5__in Total",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nAuthorRow 2:\nCountry",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nStudy",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nCriteria",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nSecondaryRow 3:\nEndpoints/Objects",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nv1.1.",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nICIs",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nAtezolizumabRow 2:\n204",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nMayRow 4:\n2016",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nAtezolizumabRow 2:\nRowRow 3:\n28",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\n__MEDTERM0_0 or 1;Row 2:\nRowRow 3:\n1. 1.",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nPrimary: RowRow 2:\ntolerabilityRow 3:\nSecondary: RowRow 4:\nresponse; DoR, __MIDTERM1__, OS",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nUnclear",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nNCT02779751Row 2:\n Row 3:\nPhase 1b",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\npembrolizumabRow 3:\n50",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nCohort A: CHT-naïveRow 2:\nCohorts B: 68% RowRow 3:\nline of CHT",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nwith ≥ 1% RowRow 3:\nnon-Row non-Row 4:\nsquamous __MEDTERM0_Row 5:\nRowRow 6:\nsubtype; ≤ RowRow 7:\nplatinum-containingRow 8:\nCHT regimenn",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nPrimary: RowRow 2:\nRowRow 3:\nRowRow 4:\nSecondary: RowRow 5:\nDoR, __MIDTERM2__, ~MEDTERM3__, PK",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading Local adaptation (column column 1)",
      "text": "Row 1:\nAuthor Country...AuthorRow 2:\n\"CountryRow 3:\n\"Row 4:\n\"Eberhardt,Row 5:\n\"2017Row 6:\n\"UnclearRow 7:\n\"Hellmann, 2019 International\"Hellman,Row 8:\n\"2019Row 9:\n\"InternationalRow 10:\nPujol,\" 202 Unclear \"RowRow 11:\n\"unclear\"",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading Local adaptation (column column 2)",
      "text": "Row 1:",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading Local adaptation (column column 2)",
      "text": "Commission Regulation (EC) 1T2Sa 1T2Sa right= ShownH1Right+Rowpjump1RowRunHo Hoer 1: Criteria Criteria Criteria·Criteria Criteria (\"Key Review Criteria')Key Key 4: ___medTERM5___in Total#n n (%)Row 5:\n•number of justice: 1;1. 1.",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading Local adaptation (column column 2)",
      "text": "Row 1:\n20",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Commission Regulation (EU) No 561 II: 32 -B5: 3Paclitma: 76 (41) Cable: 76, 76: 76-Pace of Study_Supp_T2: Rowt+T2Rightway; RowsRowt=1B 1B (85) PemeLIN Phase 1b) initiation initiation : n n (%) 5: phase phase 1b/initiation initiation :184, / n n (%) # (%)Row 5:\n1 1 b",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nAuthorRow 2:\nCountry",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nStudy",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nCriteria",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nSecondaryRow 3:\nEndpoints/Objects",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nUSA",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nNCT01772004Row 2:\nJAVELINRow 3:\nPhase 1b",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nEnrollmeRow 2:\nRowRow 3:\ntreatmenRow 4:\ntRow 5:\ninitiationRow 6:\n: RowRow 7:\nRowRow 8:\nRowRow 9:\n2014",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nPrimary:RowRow 2:\nRowRow 3:\nRowRow 4:\nSecondary: RowRow 5:\nRowRow 6:\nPD-Row PD-Row 7:\nRowRow 8:\nIC",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nUSA",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nNivolumabRow 2:\n129",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\n≥ 3 prior therapies:Row 2:\n54%",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nUSA",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nEnrollmeRow 2:\nnt: JulRow 3:\nRowRow 4:\nMarchRow 5:\n2018",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nipilimumabRow 3:\n9",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nIB - IIIA treatment-Row 3:\nRowRow 4:\nconfirmed NSCLC;Row 5:\n__MIDTERM1__0 • 1ALK",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nPrimary: RowRow 2:\nRowRow 3:\nRowRow 4:\nRowRow 5:\nsecondary secondary endpoint",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading Local adaptation (column column 1)",
      "text": "Row 1:\nAuthor Country...AuthorRow 2:\n..CountryRow 3:\nUSA. USA.. ..RowRow 4:\n..USARow 5:\nRizvi Rizvi , 201Row 6:\n•USARow 7:\nUSA. USA. . . ..RowRow 8:\n■USA",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading Local adaptation (column column 2)",
      "text": "Row 1:",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading Local adaptation (column column 2)",
      "text": "Row 1:\nRow",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading Local adaptation (column column 2)",
      "text": "Row 1:\n17",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading Local adaptation (column column 2)",
      "text": "Row 1:\n14",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading Local adaptation (column column 2)",
      "text": "Row 1:\n20",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading Local adaptation (column column 3)",
      "text": "Row 1:\ntudyRow 2:\nRowRow 3:\ny",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading Local adaptation (column column 3)",
      "text": "7Rightway ¡of of Justice: \"n n (%) accountRow 5:\n•initiation initiation : p p (%) n n (%) rain 5: 'treatmentitiation treatmentitiation : _ _ 25) Gemminage: 32 (17) ___MEDTERMM2_: 20 (11) Doce exports:18 (10) Vinorelbine: 9 (5) (5) Cabboline: 77 100 (54) Pacli nt: 76 (41) 76 76 (44) Cesplatin: 46 (25 (2525) C Ces: 46 (27) (25 (25) 2_ 2_ 6_: 18; DoD: 18 (10) Office: 18 (9) (10) W): 18 (10) Commission: 18-10:I (10): Iran (10): 9 (10): Commission: Commission Commission: 9: Ho: Union: 9!: Commission C: Commission Council: 9 (5), C: 9 5: Commission CarIn: Commission -: Commission.: Commission rent: Commission",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading Local adaptation (column column 3)",
      "text": "Row 1:\n04Row 2:",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading Local adaptation (column column 4)",
      "text": "Row 1:\n\"Secondary Secondary Endpoints/ObjectsRow 2:\n\"Primary:treatment treatment Secondary: __MEDTERM1_, ~RowRow 3:\n\"NRRow 4:\nun",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Commission Regulation (EUR even lotsRight) 1 2R2RSa right=Right+Inclusion Inclusion Criteria·Secondary Secondary Endpoints/RowRow 2:\n•RowRow 3:\nlung lung ~Row 7:\n\"dise; ...Row 8:\n\"preoperative CHT; n n (%)",
      "start_page": 151,
      "end_page": 151
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nAuthorRow 2:\nCountry",
      "start_page": 151,
      "end_page": 151
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nStudy",
      "start_page": 151,
      "end_page": 151
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nCriteria",
      "start_page": 151,
      "end_page": 151
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nSecondaryRow 3:\nEndpoints/Objects",
      "start_page": 151,
      "end_page": 151
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nUnclear",
      "start_page": 151,
      "end_page": 151
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nNCT01124864Row 2:\nNRRow 3:\nPhase 2",
      "start_page": 151,
      "end_page": 151
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nConductRow 2:\ned: OctRow 3:\nRowRow 4:\nNov 2014",
      "start_page": 151,
      "end_page": 151
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nAUY922Row 2:\n153",
      "start_page": 151,
      "end_page": 151
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\ncytologicallyRow 3:\nRowRow 4:\nNSCLC; ≥ RowRow 5:\nRowRow 6:\nRowRow 7:\ncohort (_MEDTERM0___ < 2).",
      "start_page": 151,
      "end_page": 151
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "5 (41.8) + 0 0 9: •Targeted yesterday (41.2) 0 (41) 9 9 9: \"Row 6 10: \"KRASwt 1 (2.9) • Row 11 (32.4) • KREASm 7: ^KRASm 6 (21.4) ] •KRASm 6 (6.21.4) ---",
      "start_page": 152,
      "end_page": 152
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nAuthorRow 2:\nCountry",
      "start_page": 152,
      "end_page": 152
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nStudy",
      "start_page": 152,
      "end_page": 152
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nCriteria",
      "start_page": 152,
      "end_page": 152
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nSecondaryRow 3:\nEndpoints/Objects",
      "start_page": 152,
      "end_page": 152
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nUSA",
      "start_page": 152,
      "end_page": 152
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\n Row 3:\nPhase 2",
      "start_page": 152,
      "end_page": 152
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\n2019a",
      "start_page": 152,
      "end_page": 152
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nBortezomibRow 2:\n16",
      "start_page": 152,
      "end_page": 152
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nUncontrolledRow 2:\nRowRow 3:\ninvolved the CNS; atRow 4:\nRowRow 5:\nperipheralRow 6:\nneuropathy;Row 7:\nRowRow 8:\nboron or mannitol",
      "start_page": 152,
      "end_page": 152
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nPrimary: RowRow 2:\nSecondary: RowRow 3:\ntoxicity",
      "start_page": 152,
      "end_page": 152
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nMalhotra,Row 2:\n2018Row 3:\nUSA",
      "start_page": 152,
      "end_page": 152
    },
    {
      "heading": "heading heading Local adaptation",
      "text": "Row 1:\nNCT01649947,Row 2:\nNCT00728845Row 3:\n Row 4:\nPhase 1b",
      "start_page": 152,
      "end_page": 152
    },
    {
      "heading": "heading heading Local adaptation (column column 1)",
      "text": "Row 1:\nAuthor Country...AuthorRow 2:\n\"CountryRow 3:\n\"Row 4:\n\"USA USA \"RowRow 5:\n\"USARow 6:\nUSA USA \"Malhotra,\"Row 7:\n\"2018Row 8:\n\"US",
      "start_page": 152,
      "end_page": 152
    },
    {
      "heading": "heading heading Local adaptation (column column 2)",
      "text": "Row 1:",
      "start_page": 152,
      "end_page": 152
    },
    {
      "heading": "heading heading Local adaptation (column column 2)",
      "text": "right right right- Secondary Secondary Endpoints/OligitivesRow 2:\n\"RowRow 3:\n\"Patients with 'LoT Media' (Range), 'Row 4:\n___medTERM0___in Total#n n (%)Row 5:\n'Targeted therapy': 'Row 6 (32.4) •KRASwt 1 (2.9) ] ] Row 7 7: ^KRasm 6 (21.4) --- Row 8 8: lies 8: .All 64 (41.8)",
      "start_page": 152,
      "end_page": 152
    },
    {
      "heading": "heading heading Local adaptation (column column 2)",
      "text": "Row 1:\n Row 2:",
      "start_page": 152,
      "end_page": 152
    },
    {
      "heading": "heading heading Local adaptation:",
      "text": "into into account:Right-right-right, Right-arrow-rightright-way-ways of-waywayway-way way-waysway-through-way.Row 3:\n•Row 4:\nPopulationPopulation/NSCLC_ NSCLC_ (NSCLCRow NSCLCRow 5:\nnight-time) __medTERM0__mutation __medTERM0__mutation or",
      "start_page": 153,
      "end_page": 153
    },
    {
      "heading": "heading heading Local adaptation:",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\n• RowRow 4:\n• RowRow 5:\n• RowRow 6:\nRowRow 7:\nRowRow 8:\nterms. terms.",
      "start_page": 153,
      "end_page": 153
    },
    {
      "heading": "heading heading  local local adaptation",
      "text": "Row 1:\nPublication type...and and ..Row 2:\n•systematic systematic reviews*.. ..Row 3:\n•Row 4:\n• Country • Not restricted • Raw 5: Other criteria • Other criteriaia•population population (size) and • Bow 6: reporting (baseline characteristics) RowRow 7:\n■",
      "start_page": 154,
      "end_page": 154
    },
    {
      "heading": "heading heading  local local adaptation",
      "text": "Commission Regulation (EU) 2015-A-PD-Storasib-Ansti-P (L)): 91.",
      "start_page": 154,
      "end_page": 154
    },
    {
      "heading": "heading heading  local local adaptation",
      "text": "Row 1:\nAuthorRow 2:\nCountry",
      "start_page": 154,
      "end_page": 154
    },
    {
      "heading": "heading heading  local local adaptation",
      "text": "Row 1:\nRowRow 2:\nStudyRow 3:\nName,Row 4:\nRowRow 5:\nStudy",
      "start_page": 154,
      "end_page": 154
    },
    {
      "heading": "heading heading  local local adaptation",
      "text": "Row 1:\nDateRow 2:\ns",
      "start_page": 154,
      "end_page": 154
    },
    {
      "heading": "heading heading  local local adaptation",
      "text": "Row 1:\nPriorRow 2:\nTherapyRow 3:\n Row 4:\nRowRow 5:\n(Range),Row 6:\nRowRow 7:\n(%)",
      "start_page": 154,
      "end_page": 154
    },
    {
      "heading": "heading heading  local local adaptation",
      "text": "Row 1:\nRowRow 2:\nCriteria",
      "start_page": 154,
      "end_page": 154
    },
    {
      "heading": "heading heading  local local adaptation",
      "text": "Row 1:\nKeyRow 2:\nExclusionRow 3:\nCriteria",
      "start_page": 154,
      "end_page": 154
    },
    {
      "heading": "heading heading  local local adaptation",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nEndpoints/ObjRow 4:\nectives",
      "start_page": 154,
      "end_page": 154
    },
    {
      "heading": "heading heading  local local adaptation",
      "text": "Row 1:\nSkoulidisRow 2:\n,2021",
      "start_page": 154,
      "end_page": 154
    },
    {
      "heading": "heading heading  local local adaptation",
      "text": "Row 1:\nNCT03600Row 2:\n883Row 3:\nCodeBreaRow 4:\nRowRow 5:\nPhase 2",
      "start_page": 154,
      "end_page": 154
    },
    {
      "heading": "heading heading  local local adaptation",
      "text": "Row 1:\nData-Row 2:\ncutofRow 3:\nRowRow 4:\n15,Row 5:\nMarcRow 6:\nhRow 7:\n2021.",
      "start_page": 154,
      "end_page": 154
    },
    {
      "heading": "heading heading  local local adaptation",
      "text": "Row 1:\nAnti-PD-Row 2:\n(L)1: 91.3%Row 3:\nPlatinum-Row 4:\nRowRow 5:\nand anti-PDF-ROW 6: (L): 81.0%",
      "start_page": 154,
      "end_page": 154
    },
    {
      "heading": "heading heading  local local adaptation",
      "text": "Row 1:\nPrimary:Row 2:\nsafety,Row 3:\nRowRow 4:\nRowRow 5:\nDLTRow 6:\nSecondary: PK,Row 7:\nRowRow 8:\nRowRow 9:\nof SD",
      "start_page": 154,
      "end_page": 154
    },
    {
      "heading": "heading heading  local local adaptation (from previous page)",
      "text": "Row 1:\n...right right right- tumor tumor 3) January January 1) for for ≥ to to screening). (1) Mixed •1°: Row",
      "start_page": 155,
      "end_page": 155
    },
    {
      "heading": "heading heading  local local adaptation (from previous page)",
      "text": "Row 1:\nPlatinum-Row 2:\nbasedRow 3:\ncombinationRow 4:\ntherapy,Row 5:\ntargetedRow 6:\nRowRow 7:\nboth",
      "start_page": 155,
      "end_page": 155
    },
    {
      "heading": "heading heading  local local adaptation (from previous page)",
      "text": "Row 1:\nJanne,Row 2:\n2017",
      "start_page": 155,
      "end_page": 155
    },
    {
      "heading": "heading heading  local local adaptation (from previous page)",
      "text": "Row 1:\nNCT019339Row 2:\n32,Row 3:\nSELECT-1,Row 4:\nInternatioRow 5:\nnal study",
      "start_page": 155,
      "end_page": 155
    },
    {
      "heading": "heading heading  local local adaptation (from previous page)",
      "text": "Row 1:\ncondRow 2:\nuctedRow 3:\nbetwRow 4:\noneRow 5:\nOctoRow 6:\nberRow 7:\n2013Row 8:\nandRow 9:\nJanuaRow 10:\nryRow 11:\n2016",
      "start_page": 155,
      "end_page": 155
    },
    {
      "heading": "heading heading  local local adaptation (from previous page)",
      "text": "Row 1:\nRowRow 2:\nselumetinRow 3:\nibRow 4:\n(hydrogeRow 5:\nnRow 6:\nsulphate)Row 7:\ntwiceRow 8:\ndaily + 75Row 9:\nmg/RowRow 10:\ndocetaxelRow 11:\nintravenoRow 12:\nRowRow 13:\nRowRow 14:\nevery 21-Row 15:\nRowRow 16:\n(n=254)Row 17:\n Row 18:\nMatchedRow 19:\nplaceboRow 20:\nplusRow 21:\ndocexoleRow 22:\n(sameRow 23:\nschedule)Row 24:\n(N=256)",
      "start_page": 155,
      "end_page": 155
    },
    {
      "heading": "heading heading  local local adaptation (from previous page)",
      "text": "Row 1:\n1) RowRow 2:\nRowRow 3:\nRowRow 4:\nhistologicallyRow 5:\norRow 6:\ncytologicallyRow 7:\nconfirmedRow 8:\nlocallyRow 9:\nRowRow 10:\nmetastaticRow 11:\nNSCLC (stageRow 12:\nIIIB^IV).Row 13:\n2) PatientsRow 14:\nRowRow 15:\nRowRow 16:\nRowRow 17:\nRowRow 18:\nadvancedRow 19:\nRowRow 20:\ncentrallyRow 21:\nconfirmRow 22:\nKRAS-mutantRow 23:\ntumorRow 24:\n3) RowRow 25:\nperformanceRow 26:\nRowRow 27:\n1",
      "start_page": 155,
      "end_page": 155
    },
    {
      "heading": "heading heading  local local adaptation (from previous page)",
      "text": "Row 1:\n1°: PFSRow 2:\n2°: RowRow 3:\nRowRow 4:\nRowRow 5:\ntolerability,",
      "start_page": 155,
      "end_page": 155
    },
    {
      "heading": "heading heading  local local adaptation (column column 1)",
      "text": "three, three, #2",
      "start_page": 155,
      "end_page": 155
    },
    {
      "heading": "heading heading  local local adaptation (column column 2)",
      "text": "Row 1:\n Row 2:\nAnne,Row 3:\n2017",
      "start_page": 155,
      "end_page": 155
    },
    {
      "heading": "heading heading  local local adaptation (column column 3)",
      "text": "Row 1:\n•Row 2:\n• studio studio • NCT01Row 3:\n• 32,Row 4:\n• SELEFRow 5:\n• InternRow 6:\n■nal stu",
      "start_page": 155,
      "end_page": 155
    },
    {
      "heading": "heading heading  local local adaptation (column column 4)",
      "text": "Row 1:\n•Row 2:\n19339 • 201 201 •conRow 3:\n•uctRow 4:\nCT-1, •betRow 5:\n•eenRow 6:\nouty •OctRow 7:\n■berRow 8:\n▪201Row 9:\n●and",
      "start_page": 155,
      "end_page": 155
    },
    {
      "heading": "heading heading  local local adaptation (column column 5)",
      "text": "Row 1:\n..tumor tumor 3) 1 1 January1) for for ≥ to to screening). (1) Mixed:1°: PF 2° n (and and anti",
      "start_page": 155,
      "end_page": 155
    },
    {
      "heading": "heading heading  local local adaptation (column column 6)",
      "text": "Row 1:\n Row 2:\nFSRow 3:\nRowRow 4:\n, TTP,Row 5:\nRowRow 6:\nrability,",
      "start_page": 155,
      "end_page": 155
    },
    {
      "heading": "heading heading Unpublished data (from previous page)",
      "text": "Row 1:\nTrial name: CodeBreak 100°NCT number: NCT03600883",
      "start_page": 157,
      "end_page": 157
    },
    {
      "heading": "heading heading Unpublished data (column column 3)",
      "text": "Row 1:\n00°NCT number: NCT0360088",
      "start_page": 157,
      "end_page": 157
    },
    {
      "heading": "heading heading Unpublished data (from previous page)",
      "text": "Row 1:\nTrial name: CodeBreak 100°NCT number: NCT03600883",
      "start_page": 158,
      "end_page": 158
    },
    {
      "heading": "heading heading Unpublished data (column column 4)",
      "text": "Row 1:\n00°NCT number: NCT03600883",
      "start_page": 158,
      "end_page": 158
    },
    {
      "heading": "Table 40: SELECT-1 • Study Characteristics",
      "text": "Row 1:\nTrial name: CodeBreak 100°NCT number: NCT03600883",
      "start_page": 159,
      "end_page": 159
    },
    {
      "heading": "Table 40: SELECT-1 • Study Characteristics",
      "text": "Row 1:\nTrial name: SELECT-1°NCT number: NCT01933932",
      "start_page": 159,
      "end_page": 159
    },
    {
      "heading": "heading heading Main exclusion:",
      "text": "Row 1:\nTrial name: SELECT-1°NCT number: NCT01933932",
      "start_page": 160,
      "end_page": 160
    },
    {
      "heading": "heading heading Main exclusion: (column 5)",
      "text": "Row 1:\nNCT number: NCT01933932",
      "start_page": 160,
      "end_page": 160
    },
    {
      "heading": "heading heading Exploratory Outcome variables:",
      "text": "Row 1:\nTrial name: SELECT-1°NCT number: NCT01933932",
      "start_page": 161,
      "end_page": 161
    },
    {
      "heading": "heading heading Exploratory Outcome variables: (column 2)",
      "text": "Row 1:\nNCT number: NCT019339",
      "start_page": 161,
      "end_page": 161
    },
    {
      "heading": "heading heading Exploratory Outcome Variables: (from previous page)",
      "text": "Row 1:\nTrial name: SELECT-1°NCT number: NCT01933932",
      "start_page": 162,
      "end_page": 162
    },
    {
      "heading": "heading heading Exploratory Outcome variables: (column column 6)",
      "text": "Row 1:\nNCT number: NCT01933932",
      "start_page": 162,
      "end_page": 162
    },
    {
      "heading": "heading heading information information None",
      "text": "Row 1:\nTrial name: SELECT-1°NCT number: NCT01933932",
      "start_page": 163,
      "end_page": 163
    },
    {
      "heading": "heading heading information information None",
      "text": "Row 1:\nInclusion Criteria... Sotorasib.. ..DocetaxelRow 2:\n•(CodeBreak 100) • (SELECT-1)",
      "start_page": 163,
      "end_page": 163
    },
    {
      "heading": "heading heading outcome outcome measures",
      "text": "right right right!N= 256Row 2:\nAge (mean) RowRow 3:\nGender (% feale) Gender (feale) + 50%Row 4:\nBrain metastases (%) +21%.NRbRow 5:\nECOG (% PS 1 [vs PS 0]) •70%·59%Row 6:\nRace (% white) ^82%c # 95%Row 7:\n% KRAS-G12Cl100%#42%Row 8:\nAnti-PD-(L) line line lines)",
      "start_page": 164,
      "end_page": 164
    },
    {
      "heading": "heading heading outcome outcome measures",
      "text": "Row 1:\nOutcome meansDefinition:Validity:Clinical relevance",
      "start_page": 164,
      "end_page": 164
    },
    {
      "heading": "heading heading outcome outcome measures (column 1)",
      "text": "Row 1:\nBaseline characteristics (CodeBreak 100) N = 126Row 2:\nAge (mean) RowRow 3:\nGender (% female) •50%Row 4:\nBrain metastases (%) •21%Row 5:\nECOG (% PS 1 [vs PS 0]) −70%Row 6:\nRace (% white) ~82%cRow 7:\n% KRAS-G12C·100%Row 8:\nAnti-PD-(L) prior prior line(s) ^91%Row 9:\nlines lines (% with 1/2/3 prior lines) ■43%/35%/22%Row 10:\nbaseline baseline (% IIIB[vs IV]) ‐97%Row 11:\nHistology (% Non-square)",
      "start_page": 164,
      "end_page": 164
    },
    {
      "heading": "heading heading outcome outcome measures (column 1)",
      "text": "Row 1:\nOutcome meansDefinition:Validity:Clinical relevan",
      "start_page": 164,
      "end_page": 164
    },
    {
      "heading": "heading heading outcome outcome measures (from previous page)",
      "text": "Row 1:\nOutcome meansDefinition:Validity:Clinical relevance",
      "start_page": 165,
      "end_page": 165
    },
    {
      "heading": "heading heading outcome outcome measures (column column 4)",
      "text": "Row 1:\n\"Definition·Validity\"",
      "start_page": 165,
      "end_page": 165
    },
    {
      "heading": "heading heading outcome outcome measures (column column 5)",
      "text": "Row 1:\nClinical Relevance",
      "start_page": 165,
      "end_page": 165
    },
    {
      "heading": "heading heading Results per study",
      "text": "Row 1:\nOutcome meansDefinition:Validity:Clinical relevance",
      "start_page": 166,
      "end_page": 166
    },
    {
      "heading": "heading heading Results per study (column 1)",
      "text": "Row 1:\nOutcome meansDefinition:Validity:Clinical relevan",
      "start_page": 166,
      "end_page": 166
    },
    {
      "heading": "heading heading X",
      "text": "Row 1:\nXX •Row 2:\n• XRow 3:\n■Row 4:\n~ X ~Row 5:\n~X ~ Raw 6: ▪ X ^ XRow 7:\n· Row",
      "start_page": 167,
      "end_page": 167
    },
    {
      "heading": "heading heading X (column 1)",
      "text": "Row 1:\nXX •Row 2:\n■Row 3:\n▪Row 4:\n• XRow 5:\n· XRow 6:\n~ XRow 7:\n^ XRow 8:\n● XRow 9:\n♫ X",
      "start_page": 167,
      "end_page": 167
    },
    {
      "heading": "heading heading X (column 2)",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\n Row 6:",
      "start_page": 167,
      "end_page": 167
    },
    {
      "heading": "heading heading X (column 6)",
      "text": "Row 1:\n•Row 2:\n■Row 3:\n▪Row 4:\n~Row 5:\n−Row 6:\n●Row 7:\n·",
      "start_page": 167,
      "end_page": 167
    },
    {
      "heading": "heading heading X (column 7)",
      "text": "Row 1:\nXRow 2:\n Row 3:\nXRow 4:\nXRow 5:\nXRow 6:\nX row 7: X",
      "start_page": 167,
      "end_page": 167
    },
    {
      "heading": "heading heading X (from previous page)",
      "text": "Row 1:\nXRow 2:\nX°XRow 3:\nX°xRow 4:\nX° XRow 5:\nX° xRow 6:\n•Row 7:\nX*XRow 8:\nX·Row 9:\nX~XRow 10:\nX^XRow 11:\nX/*XRow 12:\nX=XRow 13:\nX",
      "start_page": 168,
      "end_page": 168
    },
    {
      "heading": "heading heading X (column column 1)",
      "text": "Row 1:\n Row 2:\nXRow 3:\nXRow 4:\nXRow 5:\nXRow 6:\n Row 7:\nX Ruw 8: X Raw 9: X Bow 10: X Rock 11: X Roll 12: XRow 13:\nX-Row 14:\nX -Row 15:\nX,Row 16:\nX",
      "start_page": 168,
      "end_page": 168
    },
    {
      "heading": "heading heading X (column column 2)",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\n Row 6:\n Row 7:\n Row 8:\n Row 9:\n Row 10:\n Row 11:\n Row 12:\n Row 13:\n Row 14:",
      "start_page": 168,
      "end_page": 168
    },
    {
      "heading": "heading heading X (column column 7)",
      "text": "Row",
      "start_page": 168,
      "end_page": 168
    },
    {
      "heading": "heading heading X (column column 9)",
      "text": "Row 1:\nXRow 2:\nXRow 3:\nXRow 4:\nXRow 5:\nXRow 6:\n Row 7:\nX Ruw 8: X Raw 9: X Bow 10: XRow 11:\nX Rock 12: X Roll 13: X-Row 14:\nX -Row 15:\nX",
      "start_page": 168,
      "end_page": 168
    },
    {
      "heading": "heading heading Page 166/237 (from previous page)",
      "text": "Row 1:\nadverse adverse events: Sotorasib (CodeBreak-100)*·Docetaxel + placebo (SELECT-1)**",
      "start_page": 175,
      "end_page": 175
    },
    {
      "heading": "heading heading Page 166/237 (column column 1)",
      "text": "Row 1:\nRow",
      "start_page": 175,
      "end_page": 175
    },
    {
      "heading": "heading heading Page 166/237 (column column 2)",
      "text": "Row 1:\nRow",
      "start_page": 175,
      "end_page": 175
    },
    {
      "heading": "heading heading Page 166/237 (column column 3)",
      "text": "Row 1:\nasib (CRow 2:\nn",
      "start_page": 175,
      "end_page": 175
    },
    {
      "heading": "heading heading Page 166/237 (column column 4)",
      "text": "Row 1:\nCodeBreak-100)*Row 2:\nn=126",
      "start_page": 175,
      "end_page": 175
    },
    {
      "heading": "heading heading Page 166/237 (column column 5)",
      "text": "two. two...",
      "start_page": 175,
      "end_page": 175
    },
    {
      "heading": "heading heading Page 166/237 (column column 6)",
      "text": "Row 1:\nDocetaxel + pl",
      "start_page": 175,
      "end_page": 175
    },
    {
      "heading": "heading heading Page 166/237 (column column 7)",
      "text": "Row 1:\nplaceboRow 2:\nn=254",
      "start_page": 175,
      "end_page": 175
    },
    {
      "heading": "heading heading Page 166/237 (column column 8)",
      "text": "Row 1:\no (SELECT-1)Row 2:\n4",
      "start_page": 175,
      "end_page": 175
    },
    {
      "heading": "heading heading Page 166/237 (column column 9)",
      "text": "Row 1:\n)**",
      "start_page": 175,
      "end_page": 175
    },
    {
      "heading": "adverse adverse events",
      "text": "Row 1:\nevent. event...Sotorasib (CodeBreak-100)*·Docetaxel + placebo (SELECT-1)**",
      "start_page": 176,
      "end_page": 176
    },
    {
      "heading": "adverse adverse events",
      "text": "Row 1:\nevent. event...Sotorasib (CodeBreak-100)*·DocetaxRow 2:\n\"n=126\" (%)•Row 3:\n\"Row 3:\n\"\"",
      "start_page": 176,
      "end_page": 176
    },
    {
      "heading": "adverse adverse events",
      "text": "Row 1:\nxel + placebo (SELECT-1)**Row 2:\nn=254 (%)",
      "start_page": 176,
      "end_page": 176
    },
    {
      "heading": "heading heading adverse adverse events (from previous page)",
      "text": "17, (2, 9 9), 9 9 9: Arthralaa ) (21.4);3.4 (24.4) and (2.9) Row 7 (22.8) 7 7 (31.0) ow 7 7: 39 39 (99.2);77 (61.1))235 (92.2)) ceRow 4:\nAnew gradeGrade 3++.8)2 2 +Row 5:\nAny AE/125 (99.2)) 177 (61.21.1)235 (92.5)) •115 (45) (45)Row 6:\nDiarrhoea64 (5.8),7 (50.8) •7 (54.4) ^7 (55.4)",
      "start_page": 177,
      "end_page": 177
    },
    {
      "heading": "heading heading adverse adverse events (column column 1)",
      "text": "Row 1:\nRow",
      "start_page": 177,
      "end_page": 177
    },
    {
      "heading": "heading heading adverse adverse events (column column 2)",
      "text": "Row 1:\nAdvert",
      "start_page": 177,
      "end_page": 177
    },
    {
      "heading": "heading heading adverse adverse events (column column 3)",
      "text": "Row 1:\nRow",
      "start_page": 177,
      "end_page": 177
    },
    {
      "heading": "heading heading adverse adverse events (column column 4)",
      "text": "Row 1:\nEnts",
      "start_page": 177,
      "end_page": 177
    },
    {
      "heading": "heading heading adverse adverse events (column column 5)",
      "text": "Row 1:\nSotorasib (CRow 2:\nn=",
      "start_page": 177,
      "end_page": 177
    },
    {
      "heading": "heading heading adverse adverse events (column column 6)",
      "text": "Row 1:\nCodeBreak-100)*Row 2:\n=126 (%)",
      "start_page": 177,
      "end_page": 177
    },
    {
      "heading": "heading heading adverse adverse events (column column 7)",
      "text": "Row 1:",
      "start_page": 177,
      "end_page": 177
    },
    {
      "heading": "heading heading adverse adverse events (column column 8)",
      "text": "Row 1:\nDocetaxel + pRow 2:\nn=",
      "start_page": 177,
      "end_page": 177
    },
    {
      "heading": "heading heading adverse adverse events (column column 9)",
      "text": "Row 1:\nplaceboRow 2:\n=254 (%",
      "start_page": 177,
      "end_page": 177
    },
    {
      "heading": "heading heading adverse adverse events (column column 10)",
      "text": "Row 1:\no (SELECT-1)Row 2:\n%)",
      "start_page": 177,
      "end_page": 177
    },
    {
      "heading": "heading heading adverse adverse events (column column 11)",
      "text": "Row 1:\n)**",
      "start_page": 177,
      "end_page": 177
    },
    {
      "heading": "heading heading adverse adverse events (from previous page)",
      "text": "Row 1:\nRash •8 (6.3) •0 (0) •28 (11.0) •1 (0.4)Row 2:\nHeadache •11 (8.7) • 0 (0) ■26 (10.2) •NARow 3:\nMyalger • 8 (6.3)",
      "start_page": 178,
      "end_page": 178
    },
    {
      "heading": "heading heading adverse adverse events (column column 1)",
      "text": "Row 1:\nRash •8 (6.3) •0 (0)Row 2:\nHeadache •11 (8.7) • 0 (0)Row 3:\nMyalga • 8 (6.3) *0 (0)",
      "start_page": 178,
      "end_page": 178
    },
    {
      "heading": "heading heading adverse adverse events (column column 2)",
      "text": "Row 1:\n1 (0.4)Row 2:\nNARow 3:\nNA",
      "start_page": 178,
      "end_page": 178
    },
    {
      "heading": "heading heading X *population population (N =126)",
      "text": "Row 1:\nXX°-Row 2:\nX°-X°-x°-",
      "start_page": 182,
      "end_page": 182
    },
    {
      "heading": "heading heading X *population population (N =126)",
      "text": "Row 1, NA-events events & SELECT-1 45%) Comparon ((61%- 45%)) /45%)Row 12:\n100 100 -5.8% (8.7%-NA 40% NA-na-na",
      "start_page": 182,
      "end_page": 182
    },
    {
      "heading": "heading heading Page 178/237",
      "text": "X-X-l-X: X-SX-X - X-Row* X-JX- ð X-HX-II-X+X-I-XX-TX-WX-x-X^X-OX-VX-AX-MX-ZX-UX-LX-FX-CX-NX-PX-QX-GX-BX-, X-",
      "start_page": 184,
      "end_page": 184
    },
    {
      "heading": "heading heading Page 178/237",
      "text": "Row 1:\nX",
      "start_page": 184,
      "end_page": 184
    },
    {
      "heading": "heading heading Page 178/237",
      "text": "",
      "start_page": 184,
      "end_page": 184
    },
    {
      "heading": "heading heading Page 178/237",
      "text": "",
      "start_page": 184,
      "end_page": 184
    },
    {
      "heading": "heading heading Page 178/237",
      "text": "",
      "start_page": 184,
      "end_page": 184
    },
    {
      "heading": "heading heading Page 178/237",
      "text": "",
      "start_page": 184,
      "end_page": 184
    },
    {
      "heading": "heading heading Page 178/237 (column 1)",
      "text": "Row 1:\nX· X* X* ■ X*Row 2:\n^ X*",
      "start_page": 184,
      "end_page": 184
    },
    {
      "heading": "heading heading Page 178/237 (column 1)",
      "text": "Row 1:\nX· X* X * X * ~ X *Row 2:\nX^ X * x * X ~ *Row 3:\nX■ X * * X = X *",
      "start_page": 184,
      "end_page": 184
    },
    {
      "heading": "heading heading Page 178/237 (column 1)",
      "text": "Row 1:\nX· X* X * X * * X \"Row 2:\nX ■ X * x * X ~ X *",
      "start_page": 184,
      "end_page": 184
    },
    {
      "heading": "heading heading Page 178/237 (column 1)",
      "text": "Row 1:\n• x • X • * X ■ X X ~ XRow 2:\nX \\ X ^ X − X __ ~ ~Row 3:\nX } ~ x ~x ~X ~",
      "start_page": 184,
      "end_page": 184
    },
    {
      "heading": "heading heading Page 178/237 (column 1)",
      "text": "Row 1:\nX· X* X* x* X * X*Row 2:\nX*X* X > X*",
      "start_page": 184,
      "end_page": 184
    },
    {
      "heading": "heading heading Page 178/237 (column 2)",
      "text": "Row 1:",
      "start_page": 184,
      "end_page": 184
    },
    {
      "heading": "heading heading X X",
      "text": "Court Court Court",
      "start_page": 185,
      "end_page": 185
    },
    {
      "heading": "heading heading XX (column 1)",
      "text": "Row 1:\n• X",
      "start_page": 185,
      "end_page": 185
    },
    {
      "heading": "heading heading X X (column 5)",
      "text": "Row 1:\nX",
      "start_page": 185,
      "end_page": 185
    },
    {
      "heading": "heading heading X X (column 10)",
      "text": "Row 1:\nX°X",
      "start_page": 185,
      "end_page": 185
    },
    {
      "heading": "heading heading X X",
      "text": "Court Court Court",
      "start_page": 186,
      "end_page": 186
    },
    {
      "heading": "heading heading XX (column 1)",
      "text": "Row 1:\n• X",
      "start_page": 186,
      "end_page": 186
    },
    {
      "heading": "heading heading X X (column 5)",
      "text": "Row 1:\nX",
      "start_page": 186,
      "end_page": 186
    },
    {
      "heading": "heading heading X X (column 10)",
      "text": "Row 1:\nX°X",
      "start_page": 186,
      "end_page": 186
    },
    {
      "heading": "heading heading Side 181/237",
      "text": "Row 1:\nX",
      "start_page": 187,
      "end_page": 187
    },
    {
      "heading": "heading heading Side 181/237 (column 5)",
      "text": "Row 1:\nX·X^X-X-Row 2:\nX*X-~X-Row 3:\nX· X-~x-X -Row 4:\nX■ X- * X- ~ X-°-X ~- X ~ ~ - ~",
      "start_page": 187,
      "end_page": 187
    },
    {
      "heading": "heading heading data data sources",
      "text": "Row 1:\nStudy characteristics: Sotorasib (CodeBreak 100) (87)·docetaxel docetaxel (SELECT-1) (72)Row 2:\nBlinding•RowRow 3:\nInclusion criteria: patients patients (> 18 years) Status Status 0",
      "start_page": 188,
      "end_page": 188
    },
    {
      "heading": "heading heading investigators investigators in",
      "text": "Row_Right_S$-T2; M_M2_BAR_RIGHT;Row 1:\nRow; R right; Rright; ROW 1 Row: Row, Rowh_Row-1 1 •Received Received >regime regime (is is acceptable)Row 3:\ninvestigation-assesed investigation-assesed __FORMEDMM1___MEDARM1_",
      "start_page": 189,
      "end_page": 189
    },
    {
      "heading": "heading heading investigators investigators in",
      "text": "Row 1:\nBaseline characteristics a· Sotorasib (CodeBreak 100) n=126(87) ■docetaxel docetaxel (SELECT-1) (n=256) (130)Row 2:\nAge",
      "start_page": 189,
      "end_page": 189
    },
    {
      "heading": "heading heading indirect indirect comparisons",
      "text": "holder holder (% female) four four 3%Row 2:\nBrain metastases (%) of21%#NRcRow 3:\nPerformance status (ECOG or WHO; % PS 1 [vs PS 0]) •70%=59%Row 4:\nRace (% white) 82%d^95%Row 5:\n% KRAS G12C_-muted",
      "start_page": 190,
      "end_page": 190
    },
    {
      "heading": "heading heading X X X",
      "text": "Row 1:\nX",
      "start_page": 192,
      "end_page": 192
    },
    {
      "heading": "heading heading SET SET 2",
      "text": "Row 1:\nN N = 256°N N = 98°sotorasib sotorasib N= 98Row 2:\nCovariatesSELECT-1·CodeBreaK 100•RowRow 3:\nECOG (% PS 1 [vs PS 0])",
      "start_page": 193,
      "end_page": 193
    },
    {
      "heading": "heading heading SET SET 2 (column 1)",
      "text": "Row 1:\nN N = 256Row 2:\nCovariatesSELECT-1Row 3:\nECOG (% PS 1 [vs PS 0]) •xRow 4:\nAge (mean) ■xRow 5:\nbaseline baseline (%) • xRow 6:\nSmoking status (% ever smoker) \\xRow 7:\nlevel level (<5% vs ≥ 5%) ~xRow 8:\nGender (% female) }xRow 9:\nHistology (% Non-squamous) ^x",
      "start_page": 193,
      "end_page": 193
    },
    {
      "heading": "heading heading Overall Overall survival",
      "text": "Row 1:\nRace (% white)",
      "start_page": 194,
      "end_page": 194
    },
    {
      "heading": "heading heading Overall Overall survival",
      "text": "19. 19.",
      "start_page": 194,
      "end_page": 194
    },
    {
      "heading": "heading heading Progression-free Progression-free survival",
      "text": "16normal 16normal Gamma:326.7",
      "start_page": 197,
      "end_page": 197
    },
    {
      "heading": "heading heading score score analysis",
      "text": "21.73% cohortRow cohortRow 2:\n•n=% copyrightRow copyrightRow 3:\nRowRow 4:\n~N = 206) ^N = 120.57) •Row 5:\nPlatinum-based chemotherapy",
      "start_page": 201,
      "end_page": 201
    },
    {
      "heading": "to to Forecasts",
      "text": "(N) baseline baseline (Y; N) expression expression (<1%, 1-49%, expression expression (< 1%, 1- 19%, 1-19%, < 100%), No PD-P-base base (Y); N) expression expression = 1%, (1) - 1-9%,< 50%), No P-L1, 50%). the the Commission'107 107 (3) (c) Union Union (\"TFEU') 108 108 (3) TFEU. TFEU.",
      "start_page": 204,
      "end_page": 204
    },
    {
      "heading": "heading heading  X X X",
      "text": "Row 1:\nXX",
      "start_page": 205,
      "end_page": 205
    },
    {
      "heading": "heading heading  X X X",
      "text": "Row 1:\nXX •Row 2:\nX • XRow 3:\n■ X ~Row 4:\n• x ~ X ^ XRow 5:\nX − X \\ X } XRow 6:\nX",
      "start_page": 205,
      "end_page": 205
    },
    {
      "heading": "heading heading X",
      "text": "X-X-S-X-2X-X-4X-Row-XX-O-X-1 X-x-X-3 X-Z-X-5 X-J-X-7 X-N-X-8 X-Q-X-0 X-ax-X-9 X-M-X-6 X-",
      "start_page": 206,
      "end_page": 206
    },
    {
      "heading": "heading heading X",
      "text": "Row 1:\nX·Row 2:\nX· X ■ X ~Row 3:\nX * X X ^ X •Row 4:\nX \\ RowRow 5:\nX",
      "start_page": 207,
      "end_page": 207
    },
    {
      "heading": "heading heading X",
      "text": "Row 1:\nXX°-Row 2:\nX°-X-X",
      "start_page": 207,
      "end_page": 207
    },
    {
      "heading": "heading heading X",
      "text": "X-X-ax-X: X-x-row-XX-X ðX-Row-ZX-SX-JX-TX-WX-MX-HX-OX-YX-KX-UX-QX-AX-CX-GX-FX-PX-VX-BX-, X-*X-+X-",
      "start_page": 208,
      "end_page": 208
    },
    {
      "heading": "heading heading X X",
      "text": "Row 1:\nX° X° x° X'Row 2:\nX°Row 3:\nX°X° X 'X'Row 4:\nX* X' X' # X'sRow 5:\nX°x' X \"XRow 6:\nX· X'X' X 'Row 7:\nX^",
      "start_page": 209,
      "end_page": 209
    },
    {
      "heading": "heading heading XX (column 1)",
      "text": "Row 1:\nX°X",
      "start_page": 209,
      "end_page": 209
    },
    {
      "heading": "heading heading XX (column 1)",
      "text": "Row 1:\nX-XRow 2:\nX-xRow 3:\nX-axRow 4:\nX-Z-X",
      "start_page": 209,
      "end_page": 209
    },
    {
      "heading": "heading heading Missing values",
      "text": "Row+right right (0.8)Row 5:\nALT (U/L) n (%); #12 (5.3) .1 (0.8)Row 6:\nAlbumin (g/L), n (%) 071 (l/min/1.73m2) n (%)85 (37.8) •1 (0.8)Row 4:\nALT [U/ L) ~ n (%) 12 (U) •11 (5.9) 1 (0.0)Row 7:\nAlbumin (g / L) ] n (%)7 (kg/m2) •7 (3.1) •3 (2.4)Row 9:\nSmoking history",
      "start_page": 215,
      "end_page": 215
    },
    {
      "heading": "heading heading Missing values (column 2)",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\n Row 6:\n Row 7:\n Row 8:\n Row 9:\n Row 10:\n Row 11:\n Row 12:\n Row 13:\n Row 14:\n Row 15:\n Row 16:\n Row 17:\n Row 18:\ndRow 19:\neRow 20:",
      "start_page": 215,
      "end_page": 215
    },
    {
      "heading": "heading heading <for for __",
      "text": "Row 1:\n•Control • SotorasibRow 2:\nKRAS mutant •Row 3:\nUnadjusted • 206 • 119Row 4:\nAdjusted (ATT) • 104.8 •119Row 5:\nG12C~Row 6:\nUnadjusted • 85·119Row 7:\nAdjusted (ATT) ■ 17.8 •119Row 8:\nKey: treated treated •",
      "start_page": 219,
      "end_page": 219
    },
    {
      "heading": "heading heading <mutation. mutation.",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\n Row 6:\n Row 7:",
      "start_page": 219,
      "end_page": 219
    },
    {
      "heading": "heading heading ECOG: 1 74.27% 70.59% 70.46%",
      "text": "Row 1:\nBaseline characteristics:Row",
      "start_page": 224,
      "end_page": 224
    },
    {
      "heading": "heading heading ECOG: 1 74.27% 70.59% 70.46% (from previous page)",
      "text": "Row 1:\n240.028%Row 3:\nPrior PD-(L)1 immunotherapy: Yes·73.30% •90.76% •90.64%Row 4:\nPrior Platinum-based chemotherapy: Ye*84.47% •89.39%Row 5:\nAlbumin (g/L) 00 00 •RowRow 6:\nKey: AST, aspartate transaminase; mass mass index; filtration filtration rate; protein protein 1; 1 1 Note: variables variables (albumin)",
      "start_page": 225,
      "end_page": 225
    },
    {
      "heading": "heading heading ECOG: 1 74.27% 70.59% 70.46% (from previous page)",
      "text": "21.75% Rows: 74 74 years•35.29%·57%Row 6:\nPresence of __MEDTERM0_/_MEDTERM1_/BRAF/ROS-1 mutation8.24%",
      "start_page": 225,
      "end_page": 225
    },
    {
      "heading": "heading heading ECOG: 1 74.27% 70.59% 70.46% (column column 1)",
      "text": "Row 1:\n24.40.29%Row 2:\n3·23.30%Row 3:\nPrior PD-(L)1 immunotherapy: Yes•73.30%Row 4:\nPrior Platinum-based chemotherapy: Yes*84.47%Row 5:\nAlbumin (g/L) *37.26",
      "start_page": 225,
      "end_page": 225
    },
    {
      "heading": "heading heading ECOG: 1 74.27% 70.59% 70.46% (column column 1)",
      "text": "Row 1:\nRowRow 2:\n•ControlRow 3:\nECOG: 1.70.59%Row 4:\nBrain metastasis: Yes·30.59% Raw 5: Metastatic: Yes^90.59%Row 6:\nPresence of EGFR/ALK/BRAF/ROS-1 mutation8.24%",
      "start_page": 225,
      "end_page": 225
    },
    {
      "heading": "heading heading ECOG: 1 74.27% 70.59% 70.46% (column column 1)",
      "text": "Row 1:\n41. 41.18%Row 2:\n35. 35.29%Row 3:\n≥ 23. 23.53%Row 4:\nBMI (kg/m2) 26.25",
      "start_page": 225,
      "end_page": 225
    },
    {
      "heading": "heading heading ECOG: 1 74.27% 70.59% 70.46% (column column 1)",
      "text": "Row 1:\n1°34.12%Row 2:\n2°40.00%Row 3:\n3°25.88%Row 4:\nLiver metastasis: Yes·11.4.12%Row 5:\nPrior PD-(L)1 immunotherapy: Yes^65.88% Raw 6: Prior platinum-based chemotherapy: Ye*87.06%Row 7:\nAlbumin (g/L) 37.57",
      "start_page": 225,
      "end_page": 225
    },
    {
      "heading": "heading heading (N = 85) (N = 133.11)",
      "text": "21.73% cohortRow cohortRow 2:\n•n=% copyrightRow copyrightRow 3:\nRowRow 4:\n~N = 206) ^N = 120.57) •Row 5:\nPlatinum-based chemotherapy",
      "start_page": 226,
      "end_page": 226
    },
    {
      "heading": "heading heading (N = 85) (N = 133.11) (column 1)",
      "text": "Row 1:\nRegimen... Unweighted coder.. ..Row 2:\n\"n\" % of coder.\"",
      "start_page": 226,
      "end_page": 226
    },
    {
      "heading": "heading heading (N = 85) (N = 133.11) (column 1)",
      "text": "Row 1:\n•(N = 206) •Row 2:\nPlatinum-based chemotherapy • 64.07% • RowRow 3:\nChemotheragy monotherapy (excludes the clerks) ■61 • 29.61% • RowRow 4:\nramucirumab_45 ramucirumab_45 • 21.84% • RowRow 5:\nDocetekler monotherapy •21°10.19% • RowRow 6:\nregimenns regimenns • 15·7.28% • RowRow 7:\n▪",
      "start_page": 226,
      "end_page": 226
    },
    {
      "heading": "heading heading (N = 85) (N = 133.11) (column 1)",
      "text": "Row 1:\n•(N = 85) •Row 2:\nPlatinum-based chemotherapy • 25.41% • RowRow 3:\nChemotheragy monotherapy (excludes the attendants) − 24.24% • RowRow 4:\nDocetaxel plus __MEDTERM0_·18°21.18% • RowRow 5:\nDocetables monotherapy ■ 11.94% ~ RowRow 6:\nOther chemotherapy-based regimenns",
      "start_page": 226,
      "end_page": 226
    },
    {
      "heading": "heading heading Overall Overall survival",
      "text": "Row 1:\nXRow 2:\nX",
      "start_page": 227,
      "end_page": 227
    },
    {
      "heading": "heading heading Overall Overall survival",
      "text": "Row 1:\nX°-Row 2:\n...X°-x°-row 3: . . . X°, X° X° -Row 4:\nX°/X°,Row 5:\nX°X° andRow 6:\nX′ X°",
      "start_page": 227,
      "end_page": 227
    },
    {
      "heading": "heading heading X",
      "text": "4 4 (1) of Regulation (EU) No 182/the the Commission'powers powers (p. p. 13).",
      "start_page": 228,
      "end_page": 228
    },
    {
      "heading": "heading heading X",
      "text": "Row 1:\nXRow 2:\nX",
      "start_page": 228,
      "end_page": 228
    },
    {
      "heading": "heading heading X",
      "text": "Row 1:\nXRow 2:\nX",
      "start_page": 228,
      "end_page": 228
    },
    {
      "heading": "heading heading X (column 1)",
      "text": "Row 1:\nModel/Unrestricted",
      "start_page": 228,
      "end_page": 228
    },
    {
      "heading": "heading heading Progression-free Progression-free survival",
      "text": "4 4 (1) of Regulation (EU) No 182/2011.",
      "start_page": 230,
      "end_page": 230
    },
    {
      "heading": "heading heading Progression-free Progression-free survival (column 1)",
      "text": "Row 1:\nDistribution·Independent fit \"sotorasib\" Independent fit - chemo-Joint fit (unrestricted)",
      "start_page": 230,
      "end_page": 230
    },
    {
      "heading": "heading heading X",
      "text": "Row 1:\nXRow 2:\nX",
      "start_page": 231,
      "end_page": 231
    },
    {
      "heading": "heading heading X",
      "text": "Row 1:\nXRow 2:\nX",
      "start_page": 231,
      "end_page": 231
    },
    {
      "heading": "Table 69. EQ-time time points",
      "text": "21,2+right right stock!Orighthose1 -2nd 2nd 2:Row 2:\nREUN=124)Row 3:\n•Row 4:\n~% RowRow 5:\nceNumber;number;numbber;0 0 6: Assessment Time scoreCcompleted·Expected*set#% RowRow 7:\nBaseline",
      "start_page": 243,
      "end_page": 243
    }
  ]
}